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   INTRODUCTION 
 
1.1. Herbal Drugs 
1.1.1 Introduction to Medicinal Plant:  
 Along with the disease nature has created their cure in the form of 
vegetables, minerals and animals. According to Ecclesiates ―The Lord has 
created medicines out of the earth and a wise man will not abhor them.‖ 
(Siddiqui et al., 1985) 
 As disease, decay and death have always co-existed with life the 
remedial measures for them have been one of the important needs of the man 
since the time immemorial. The earliest remedial measures were Plants 
(Gupta et al., 1981). 
 The relationship between man and plants has been close throughout 
the development of human culture. With the increase in the understanding of 
human diseases there has been continued interest in the drugs from the plant 
kingdom (Modi et al., 1984). Men’s existence on this earth has been made 
possible only because of vital role played by the plant kingdom is sustaining 
life (Sundaresh et al., 1978). 
 Medicinal plants were existing even before human being made their 
appearance on the earth (Shastri, 1993). So the story or history of drugs is as 
old as mankind (Shah et al., 1989).  
 This history of medicines and surgery dates back in the remote past. In 
India the earliest records referring to curative properties of certain herbs are 
continued in Rig-Veda (3500-1800 B.C.). Then came two important works of 
Indian system of medicine, the works of Charaka and Susruta (Kapur, 1991). 
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A new herbal 1551 by William Turner was the earliest English book, which 
gave a truly scientific account of plants (Wallis, 1982).  
 It has been estimated that from 25000 to 75000 species of higher plant 
exist on the earth. A reasonable estimate of about 10% has been used in 
traditional medicine. However perhaps only about 1% of these (250-750 
species) are acknowledged through scientific studies to have real therapeutic 
value when used in extract form by human beings.(Farmworth, 1985).  
 Several approaches have been taken in the past to obtain as much 
biological activity data as possible following the administration of plant extract 
to rodent as a primary screen (Naik, 1989).  
Natural products have been derived from higher plants, microbes or 
animals and those can be of either terrestrial or marine or aquatic origin. The 
medicinal preparations based on these raw materials were in the form of 
crude drug such as dried herbs, or an extract there of and are invariably 
derived from a mixture of several materials. With the advent of European 
scientific methods, many of these reputed medicinal plants came under 
chemical investigation leading to the isolations of active principles. Beginning 
with 1800 AD there was continuous activity in this area and many of the well 
known medicinal plants were chemically analyzed and their active principles 
characterized. Soon after their isolation and characterization these 
compounds, either in pure state or in the form of well characterized extracts, 
became part of Pharmacopoeias of several countries. This is where herbal 
medicine and modern medicine have a common link (Handa, 1991). 
 In modern medicine also, plants occupy a very significant place as raw 
materials for some important drugs, although synthetic drugs brought about a 
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revolution in controlling different diseases. But these synthetic drugs are out 
of reach to millions of people those who live in remote places depends on 
traditional healers, whom they know and trust. Judicious use of medicinal 
herbs can even cure deadly disease (Bhatacharjee, 1989). 
1.1.2. The Indian System of Medicine (ISM) 
 These are traditional systems of medicine which encompasses 3 
systems namely Ayurveda, Siddha and Unani, practiced by Vaidyas, Siddhars 
and Hakkims respectively. The medicines or formulations that come under 
Ayurveda, Siddha and Unani system of treatment are called as Indian System 
of Medicines. The Drug and Cosmetic Act defines the ISM as "Ayurvedic, 
Siddha and Unani drug includes all medicines, intended for internal or 
external use in the diagnosis, treatment, mitigation or prevention of disease or 
disorder in human beings or animals"(Sampath, 2001). 
1.1.3. Modern Drugs from Ayurveda 
 Ayurveda the traditional Indian system of medicine is as old as the 
Indian culture and civilization. Ayurveda has important classical texts of 
Charaka Samhita which deals with clinical diagnosis and Susruta Samhita 
which deals with surgery. Indian Ayurvedic system certainly has given birth to 
number of important modern drugs, viz. ajmalicine, reserpine, leurocristine, L-
dopa, cardiac glycosides, sennosides etc (Naik, 1989). 
 The importance of plants as a source of useful antihypertensive drugs 
was supported by the isolation of reserpine from Rauwolfia serpertina by 
Muller et al., 1952.  Veratrum alkaloids were other antihypertensive agents 
from plant sources (Srimal and Shukla, 1987).  Recently number of medicinal 
plants have been reported to have anti-platelet activity, notable among these 
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are Allium cepa, Allium sativum, Coleus forskohli, Commiphora mukul, 
Cuminum cyminum, Curcuma longa, Zingiber officinale etc. Many of these are 
also mentioned to be useful in cardiovascular ailments in classical text books 
of ancient medicine (Dvivedi and Amrita, 1993). 
1.1.4. Herbal Wealth of India 
 Now a days natural products are an integral part of human health care 
system, because there is now popular concern over toxicity and side effects of 
modern drugs. There is also a realization that natural medicines are safer and 
allopathic drugs are often ineffective. India is one of the 12 leading bio-
diversity centers with presence of over 45,000 different plant species, 15000 – 
18000 flowering plants, 23,000 fungi, 16,000 lichens, 18000 bryophytes and 
13 million marine organisms.  From this flora 15,000 to 20,000 have good 
medicinal value.  Among those only about 7,00 plants are used in Ayurveda, 
600 in Siddha, 700 in Unani and 30 in modern medicines. (Wealth of India, 
1952 ) 
1.1.5. Herbal Drug Market   
 The global herbal products market is worth US $32 billion (Rs.1, 
000,000 crores) and is growing at a rate of about 9-15%.  The average 
turnover of Indian herbal medicine industry is about 2,300 crores against the 
pharmaceutical industry is about Rs.14,500 crores with a growth rate of 15%.  
However to achieve the goal of major exporter of herbal remedies several 
steps need to be taken: 
A. Systematic study of world market demand and short listing of medicinal 
herbs with good potential.  
B. Systematic cultivation of medicinal herbs on a large scale.  
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C. Encouragement for agro-based phytochemicals and pharmaceutical 
industries to manufacture value added herbal products.  
D. Strict legislation to control quality and purity.  
E. Upgradation of cultivation and collection process. 
F. Documentation of research work and standardization for quality  
The increasing demand for herbal medicines inevitably led to the 
issue of obtaining and maintaining their quality and purity based on 
internationally recognized guidelines. (Mukherjee et al., 1998).  
1.1.6. A Brief Look into the History of Herbal Medicine: 
 We can certainly assume, however that the healing properties of 
some plants were discovered by primeval humans fairly early and they 
learned to use them.  By collecting and using medicinal plants, people 
gained valuable experience good as well as bad and handed down 
their knowledge to future generations. 
 One of the first written records concerning curative drugs and 
narcotic substances was found on a clay tablet in Assyrian cuneiform 
script dating back to 2,700 BC.  The tablet mentions a brown drug, 
daughter of the poppy, meaning opium.  In ancient Egypt, medicinal 
science and the use of medicinal substances have an age-old tradition.  
The Egyptian Pharmacopoeia always had a supply of medications of 
plant and animal, as well as mineral origins.  There were 25 types of 
medicinal plants, as basic nutritional and medicinal plants, onion, 
garlic, lettuce, lentils, olives and caraway were used (Gupta et al., 
2000)  The knowledge of Indian physicians is documented by the so-
called Bower manuscript found in 1889 in the ruins of MINGSI in 
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central Asia.  The document and its author praise the garlic as a 
panacea claiming it to prolong life to 100 years.  In ancient Chinese 
pharmacology and herbal medicine the most extensive fields of 
medicine, they contained 8160 prescriptions for the use of various 
drugs, with instructions on how to use, how to collect and prepare 
various drugs from medicinal plants.  
 Ayurveda has well known treaties known as Charak Samhita and 
Susrut Sanhita, the oldest and very first written document of Ayurveda 
(900 BC).  It describes 341 plants and plant products for use in 
medicine and more importantly classify these in terms of physiological 
activity. The traditional medicine used in India known popularly as the 
Indian system of medicine includes Ayurveda, Siddha, Unani and 
Naturopathy. 
 Herbal therapy provides rational means for the treatment of 
many internal diseases which are considered to be obstinate and 
incurable in other system of medicine.  It lays a great deal of emphasis 
upon the maintenance of positive health of an individual.  It thus aims 
at both the prevention and cure of diseases.  Natural therapy also 
studies the basic human nature and natural things like hunger, thirst, 
sleep, sex etc. and provides measures for a disciplined, disease free 
life and will give a holistic approach to the therapy (Thaibinh, 1998). 
1.1.7. What is a Herbal Medicine: 
 Herb has various meanings, but in the context of this it refers to 
"crude drugs of vegetable origin utilized for the treatment of disease 
states, often a chronic nature, or to attain or maintain a condition of 
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improved health".  Herbal preparations called "phytopharmaceuticals", 
or "phytomedicine" are preparations made from different parts of 
plants. They come in different formulations and dosage forms including 
tablet, capsule, elixir, powder, extract, tincture, cream and parenteral 
preparations.  Herbal products in the crude state are also used.  A 
single isolated active principle derived from plants such as digoxin or 
reserpine tablets is not considered as Herbal medicine. Herbal 
remedies are not to be confused with homeopathic preparations.  
Homeopathic medicine, found in the 18th century by the German 
physician Samuel Hanemann also uses herbs and other natural 
products, but it is based upon the "Law of similar" and the "Law of 
dilution". 
 There is a wealth of non scientific herbal medicine information 
readily available to the health consumer.  Access to scientific literature 
is crucial to the pharmacist for his or her role as a drug information 
provider. The pharmacist among all health care practitioners is in the 
best position to provide information about drug safety and 
effectiveness.  If a herb is used as therapeutic agent it should be 
considered as a drug (Thaibinh, 1998). 
1.1.8. Traditional Medicines: 
There are several definitions and interpretations of this term, 
'traditional medicine'.  The most comprehensive is the one where the 
WHO has defined it as "The sum total of all the knowledge and 
practices, whether explicable or not, used in diagnosis, prevention and 
elimination of physical, mental or social imbalance relying exclusively 
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on practical experience and observations handed down from 
generation to generation, whether verbally or in writing (Thaibinh, 
1998). 
1.1.9. Popularity of Herbal Medicine: 
 The traditional medicine is largely gaining popularity over 
allopathic medicine because of the following reasons: 
1. Rising costs of medical care. 
2. As these are from natural origin, they are free from side effects. 
3. Goes to root cause and removes it, so that the disease does not 
occur again. 
4. Cure from many obstinate diseases. 
5. Easy availability of drugs from natural sources. 
1.1.10. Need and Scope of Herbal Therapy: 
 Today we are more concerned with life style diseases like 
depression, cancer and heart troubles caused by faulty nutrition and 
stress. Because these diseases have a mental or emotional 
component, there is a growing conviction that allopathy is largely 
unable to cure them, all of it offers is temporary relief from symptoms. 
There is a need of alternative therapy, to cover a good health for all.  
Herbal therapy will be one of the best practices to overcome the 
illness. 
 Traditional Indian practice held that certain drugs should be 
formulated through the addition of chosen substance that enhances 
bioavailability of the drug.  Recent work, particularly in two Indian 
modern biology labs, has confirmed this bioavailability enhancer ability 
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of pepper and point to the active component as the molecule piperine.  
An anti-TB drug RIFAMPICIN has to be given at a higher dose than 
required, in order to compensate for losses on the way to the target 
site. Formulation of piperine with rifampicin will save the drug and 
counter effects. 
 Herbal oriented pharmaceutical companies like Dabur and the 
Himalaya Drug company are investing crores of rupees on research, 
development, and popularization of OTC remedies. Most of these 
address modern maladies such as stress, premenstrual syndrome, 
depression and obesity, based on adapted version of ancient vedic 
formulas (Thaibinh, 1998). 
1.1.11. Side Effects of Herbs: 
 Little is known about safety of phytomedicine. There has been 
an increase in the number of side effects reported in the literature. 
Many cases, however, could have gone unreported because herbal 
medicine is usually self-prescribed and often ignored by health 
practitioners during the patients care.  Identifying adverse effects is 
further hindered because it is not always possible to assess the quality 
of certain herbal medicinal products. (Calloway, 1997). 
1.1.12. Herbal Medicine-Drug Interactions: 
 The potential risk of an herbal medicine interacting with a 
prescribed drug is also concern with the increased use of 
phytomedicine. Recently, several interactions have drawn the attention 
of the medical community. 
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 A clinically significant interaction between warfarin and a herbal 
medicine containing Salvia miltiorrhiza roots causing clotting 
abnormalities was reported. A randomized, cross over study performed 
on eight healthy subjects reported no significant pharmacokinetic 
interactions between Levofloxacin and three  selected traditional herbal 
medicines.  No differences were found in Levofloxacin plasma 
concentration, area under the curve, terminal elimination half-life or 
renal clearance (Yu, 1987). 
1.1.13. Adulteration in Herbal Medicine: 
 Standardized herbal preparations are becoming increasingly 
available.  In some parts of the world where no government standards 
and quality control are enforced adulteration and contamination pose 
safety as well as efficacy problems. The presence of adulterants such 
as arsenic, mercury, lead in prescription drugs in herbal medications 
can cause significant toxicity.  Having addressed this "public health 
concern" after finding that 23.70% of traditional Chinese medicines 
(total of 2.609 samples) collected over a year among eight hospitals in 
Taiwan were spiked with adulterants such as Caffeine, 
Acetaminophen, Indomethacin, Hydrochlorthiazide and other 
drugs.(Gupta et al., 2000) 
1.1.14. Herbal Research: 
 The effectiveness, easy availability, low cost and comparatively 
being devoid of serious toxic effects (time tested) popularized, herbal 
remedies. 
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 Natural products (crude drug extracts and pure compounds) 
have been derived from higher plants, microbes or animals and these 
can be of either terestrial or marine origin.  Many of the reputed 
medicinal plants came under chemical scrutiny leading to the isolation 
of active principles. Beginning with 1800 A.D., the plants isolates and 
characterized extracts, became part of Pharmacopoeias of several 
countries. This is where herbal medicine and modern medicine have a 
common link. 
 Garlic (Allium sativum), sometimes referred to as Nectar of the 
God is one of the most versatile medicinal plants.  Numerous scientific 
studies have been conducted to evaluate its various potential 
therapeutic effects.  Garlic’s beneficial effect in hypercholesteroemic 
and coronary heart disease subjects is shown in a randomized study 
by Adler and double-blind, randomized cross over study by Steiner. A 
meta-analysis of five randomized, placebo-controlled trials reported a 
"significant reduction in total cholesterol levels" in persons with 
cholesterol level greater than 200mg/dl. Another meta-analysis of 
eighteen trials conducted that there is "inadequate justification for 
garlic and related allium" use to reduce cardiovascular risk.  Its effect 
on platelet aggregation is well documented. Garlic’s antibacterial, 
antifungal and antiviral properties have been studied in vitro (Dalaha 
and Garagusi, 1985) and in vivo (Davis et al., 1990). 
 Maindenhair tree products are among the most popular herbal 
dietary supplements in the U.S., and in Germany, the extract from 
Ginkgo biloba leaves has been prescribed for circulatory system 
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disorders and its retail sales run around 719 million U.S dollars a year. 
A review (Kleijnen and Knispchiled, 1992) summarizes the possible 
mechanisms of action, clinical pharmacokinetics, side effects and 
efficacy of Ginkgo biloba extracts in the treatment of intermittent 
claudification and cerebral insufficiency, substantial scientific data 
about Ginkgo biloba is available in the German literature. Recently a 
placebo-controlled, double-blind, randomized trial, conducted in the 
United States found that Ginkgo biloba extract is "safe and appears 
capable of stabilizing and improving the cognitive performance and the 
social function" in Alzheimer's and multiinfarct dementia patients. (Le 
Bars, 1997) Alzheimer's disease is characterized by a subtle onset and 
progressive loss of immediate memory and other cognitive functions 
due to a degenerative process of the cerebral cortex nerve cells  
1.1.15. Indian Herbal Market: 
 India can be a major player in the global market for herbal based 
medicines. Exports of herbal materials and medicines can jump from 
just Rs.456 crores now to Rs.3,000 crores by 2005 and exports can 
shoot to Rs.10,000 crores by 2010. 
 A 13 member task force on the conservation and sustainable 
use of medicinal plants has reported that there is a growing demand 
for plant based medicines, health products, pharmaceuticals, food 
supplements and cosmetics. The international market for such plants is 
more than 60 billion $ a year and growing at a rate of seven percent 
within the country, these could well provide affordable health care and 
conserve biodiversity. 
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 According to the members of task force, India already has the 
expertise, medicinal plants are used in homes, there are 1.5 million 
practitioners of traditional medicine systems, and about 4.6 lakh 
registered pharmacies of Indian system of medicine and homeopathy.  
Nine tenths of the plants are collected from the wild, generating about 
40 million man days of employment. (Tiwari, 2000) 
Table 1.1. List of some of the Useful Medicinal Plants: (Tiwari, 
2000) 
Sr. 
no 
Latin Name 
Sanskrit 
Name 
Main indications in 
Ayurveda 
1. Acorous calamus Vacha Nervine, antispasmodic, 
sedative, stomachic, 
laxative, diuretic. 
2. Azadirachta indica Neem Blood disease, antibacterial. 
3. Bacopa monnieri  Brahmi  Nervine tonic, diuretic, 
sedative. 
4. Centella asiatica Mandukparn
i 
Sedative, anxiolytic. 
5. Curcuma longa Haridra Arthritic pain, skin disease, 
antibacterial, anti-
inflammatory. 
6. Eclipta alba Bhringraj Liver disease, tonic, emetic, 
purgative, antiviral. 
7. Emblica officinalis  Amalaki Fruit: cooling, laxative, 
stomachic, tonic, diuretic. 
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8. Ocimum sanctum  Tulsi Demulcent, expectorant, 
anthelmintic, antispasmodic. 
9. Picrorhiza kurroa Katuki Hepatitis, asthma, anorexia. 
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1.2. Hepatotoxicity. (Rege et al., 1984; Doreswamy et al., 1995) 
 Liver plays a vital role in the metabolism and elimination of various 
exogenous and endogenous compounds.  As a result of its continuous 
involvement, it is susceptible to toxic injuries caused by certain agents and 
any damage to hepatic cells disturbs body metabolism.  In recent times lots of 
interest has been generated to find out a natural remedy for hepatic disorders 
caused by toxins like alcohol and hepatitis virus (Patel et al., 1998).  The 
agent should protect against such damage, especially of one which facilitates 
regeneration by proliferation of parenchymal cells after damage and arrest 
growth of fibrous tissue  
 There is no remedy for liver diseases which are so prevalent in the 
population.  The treatment is mainly symptomatic. (Rege et al., 1984)  
Scientists and some industrialists deliberated on various prospective plant 
remedies for ailments of liver disorder management.  In the decade 70s, the 
world scientific community concentrated on a herbal plant Vinca rosea.  Then 
in 80s the attention was focused on Panax ginseng.  Now, the news of 
multifarious activities of the Neem tree indicates that it may become centre for 
research in 90s.  Indian Council of Medical Research, New Delhi, in its 
revived research on traditional medicine, had adopted liver diseases as one 
among six thrust areas and for multidisciplinary study.  Screening of active 
constituents from Kutki (Picrorhiza kurroa), Bhoomyamalaki (Phyllanthus 
niruri) have shown marked protection against jaundice.  Hepatitis continues to 
be a major health problem in urban areas in India, and several studies in viral 
hepatitis were under investigation by the ICMR.  For example, extracts of milk 
thistle (Silybum marianum) fruits under investigation for the treatment of 
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alcoholic hepatitis.  According to Indian Society of Gastroenterology, Mulethi 
(Glycyrrhiza glabra) prevents multiplication of viruses inside liver cells.  The 
disorder of liver may be acute or chronic hepatitis (inflammatory liver 
diseases), hepatosis (non-inflammatory liver diseases) and liver cirrhosis 
(fibrosis of the liver).  Liver enzymes act as an index of sub-clinical hepatic 
damage.  Serum glutamic pyruvic transaminase (SGPT), serum 
glutamicoxaloacetic pyruvic transaminase (SGOT), Serum lactic 
dehydrogenase (LDH) and Serum alkaline phosphatase are reported as an 
index of hepatic injury and cholestasis(Doreswamy et al., 1995).  
1.2.1. Anatomy and histology of liver: 
Anatomy: (Tortora and Grabouski, 2006) 
 The liver is a large, solid, gland situated in the right upper quadrant of 
the abdominal cavity. Liver is reddish brown in color, soft in consistency and 
very friable.  It weighs about 1600 gm in males and about 1300 gm in 
females. The liver occupies the whole of the right hypochondrium, the greater 
part of the epigastrium and extends into the left hypochondrium reaching up to 
the left lateral line. 
 The liver is the largest gland in the body.  It secretes bile and performs 
various other metabolic functions.  The liver is also called the 'heaper' from 
which we have the adjective hepatic.  
Histology of the Liver: (Tortora and Grabouski, 2006) 
 The liver is divided into two principle lobes – a large right lobe and 
smaller is left lobe.  The lobes of the liver are made up of many functional 
units called lobules.  A lobule is typically six sided structure (hexagon) that 
consists of specialized epithelial cells called hepatocytes (hepat=liver, 
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cytes=cells), arranged in irregular, branching interconnected plates around a 
central vein.  Instead of capillaries, the liver has larger, endothelium-lined 
spaces called Sinusoids, through which blood passes.  Also present in the 
sinusoids are fixed phagocyte called Stellate reticuloendothelial (Kupffer) 
cells, which destroy, worn-out white blood cells and red blood cells, bacteria 
and other foreign matter in the venous blood draining from the gastrointestinal 
tract.  
Blood supply of the liver: 
 The liver receives blood from two sources, from hepatic artery it 
receives oxygenated blood and from the hepatic portal vein it receive 
deoxygenated blood containing newly absorbed nutrients, drugs and possibly 
microbes and toxins from gastrointestinal tract.  Branches of both the hepatic 
artery and the hepatic portal vein carry blood into liver sinusoids, where 
oxygen, most of nutrients and certain toxic substances are taken up by the 
hepatocytes. 
Functions of Liver: 
 Carbohydrate metabolism:  
The liver is especially important in maintaining a normal blood glucose 
level.  When blood glucose is low, the liver can break down glycogen to 
glucose and release glucose into the bloodstream, when blood glucose is high 
it converts glucose to glycogen and triglycerides for storage.  Liver can also 
convert certain amino acids and lactic acid to glucose.  
 Lipid Metabolism: 
Hepatocytes store some triglycerides, breakdown fatty acids to 
generate ATP, synthesize cholesterol and use cholesterol to make bile salts. 
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 Protein Metabolism: 
Hepatocyte deaminate amino acids so that the amino acids can be 
used for ATP production or converted to carbohydrates or fats, resulting toxic 
ammonia is converted to less toxic urea, which is excreted in urine.  
Hepatocyte synthesizes most plasma proteins, such as alpha and beta 
globulin, albumin, prothrombin and fibrinogen. 
 Processing of drugs and hormones:  
The liver can detoxify substances such as alcohol or excrete drugs 
such as penicillin, erythromycin and sulfonamides into bile. 
 Storage:  
In addition to glycogen, the liver is a prime storage site of certain 
vitamins (A, B12, D, E and K) and minerals (iron and copper), which are 
released from liver. 
1.2.2. Basic hepatic histsopathology (Kissane, 1990): 
Hepatocellular changes: 
 Hydropic change is a descriptive term applied to the hepatocyte with 
pale, watery cytoplasm and a normal nucleus. A wide variety of conditions 
produce this relative lack of cytoplasmic staining.  Increased eosinophilia may 
occur with drug-related hydroperplasia of the smooth endoplasmic reticulum.  
Active regeneration of hepatocytes after necrosis as in several viral hepatitis 
or recovery phase of fatty liver, produces a widespread hepatocellular 
hydropic change as well as a cobblestone pattern of the liver cords.  Hydropic 
change is also an indicator of hepatocellular damage and is noted in acute 
viral hepatitis and drug induced hepatic injury including alcohol injury.  
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 Hepatocellular fat accumulation may be either large cytoplasmic bodies 
of foamy fat.  Fatty liver occurs because of 1) Sudden increase in mobilization 
of fat from the periphery to the liver, 2) Relative lack of protein necessary for 
hepatocellular fat release, 3) Increased hepatocellular fat formation by 
metabolic changes and 4) Decrease hepatocellular fat degradation.  Fatty 
liver is common in alcohol ingestion, parenteral nutrition, tuberculosis, 
starvation, certain drugs, diabetes mellitus and obesity.  Electron microscopy 
shows that the cytoplasmic fat is not membrane bound and lysosomes are 
greatly increased. 
Hepatocellular Necrosis: 
 Necrosis may be classified in many ways, including location (zonal, 
periportal, perivenular and so on), mechanism (lytic, coagulative), amount 
(submassive versus focal), cellular type (lymphocytotoxic veruses hyline 
necrosis) and various patterns are associated with different etiologic factors.  
Zonal necrosis is a common pattern of injury after an acute hepatic injury.  
Sharply demarcated perivenular (zone 3) coagulation necrosis is typical of 
several anoxic injury or acetaminophen injury and may be explained by 
differences in oxygenation and activity of drug-metabolizing enzyme.  
Periportal necrosis (Zone 1) is not common and is noted in eclampsia.  
Midzonal injury is reported for yellow fever. 
 Hepatocellular necrosis (hepatocytolysis) of the lytic type, with the 
associated macrophage activity that is so complete and rapid that dead 
hepatocytes are rarely noted, such necrosis is common in viral hepatitis, 
alcoholic liver disease and many hepatotoxic reactions, and the type of 
inflammatory reactions varies in these conditions.  Coagulative necrosis in the 
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liver is characterized by dying hepatocytes that retain some staining of the 
cytoplasm and the nuclei lose basophilia and gradually disappear.  The cells 
become shrunken and slowly disappears because of the action of 
inflammatory cells.   
 Acidophilic injury usually occurs in an isolated hepatocyte and is similar 
to coagulative necrosis except that the cytoplasm becomes more eosinophilic 
and waxy and the nucleus may be retained and be a dark.  These bodies are 
common in acute viral hepatitis, chronic active hepatitis, severe burns and 
other liver disorders.  Confluent necrosis is attributable to fusion of focal or 
zonal necrosis and may result from intensive necrosis that bridge between 
different zones.  Submassive hepatic necrosis is recognized by confluent 
necrosis that usually involves many perivenular areas and occur most 
commonly in severe acute viral hepatitis, drug injury etc.  Massive hepatic 
necrosis is distinguished from submassive hepatic necrosis by the presence 
of a thin rim of viable-appearing hepatocytes around each portal tract. 
Regeneration: 
 The liver has a remarkable capacity for regeneration and during 
recovery from submassive hepatic necrosis.  In normal adult rat liver, the 
hepatocytes have an annual turnover of one mitosis per year; weight doubles 
48 hours and has returned to normal weight at 3 to 6 days after partial 
hepatectomy.  In man liver, regeneration also occurs rapidly and even in 
cirrhotic liver.  After major hepatic resection for tumor, regeneration of normal 
hepatic volume occurs by 3 to 6 months, and liver function appears normal at 
2 to 3 weeks after surgery. 
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Fibrosis: 
 Hepatic fibrosis is the most important feature of chronic liver disease 
and leads to cirrhosis and irreversible physiologic changes in the liver that 
account for many clinical manifestations of fatal liver disease.  Fibrosis of the 
liver is a common response to chronic inflammatory conditions.  Experimental 
cirrhosis in the carbon tetrachloride treated rat and mouse have served as 
models, but the adequacy of the morphological and biochemical lesions has 
been doubled compared to human cirrhosis. 
Patterns of fibrosis:  
Simple hepatocellular necrosis does not result in collagen formation, 
but in severe hepatic necrosis a collapsed stroma may form a framework for 
collagen retention.  Repeated or continuous necrosis is associated with 
fibrosis, and the most striking fibrosis within the lobule is noted in chronic 
alcoholic liver disease.  This fibrosis occurs even with a very mild 
inflammatory response. Another common pattern of fibrosis occurs in the 
portal areas in chronic active hepatitis, which tends to be more confirmed to 
the portal tracts and does not extend into the lobule as much as portal fibrosis 
does in alcoholic.  Non-collagen matrix components have been investigated 
for a possible role in fibrosis.  Fibronectin is a plasma protein and may 
produce a cellular form in injury. 
Cirrhosis: 
 The currently accepted definition of cirrhosis may be applied to a liver 
with a diffuse fibrosis (that is the entire liver and not focal) and contain 
regenerative nodules, which are masses of hepatocytes lacking the normal 
blood flow because of the lack of terminal hepatic venules.  Regenerative or 
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hyperplastic nodules are required for the identification of cirrhosis because 
altered blood flow and portal hypertension. In contrast hepatic fibrosis, which 
is usually a precursor to cirrhosis, is not associated as frequently with portal 
hypertension.  The development of hepatocellular carcinoma is relatively 
common in cirrhosis with the required regenerative nodules and is not as 
frequent as it is in fibrosis.  
 Cirrhosis is classified as micronodular cirrhosis applies to the liver in 
which nearly all the nodules are less than 3 mm diameter though some have 
used 1.5 mm as the minimum diameter because that is the diameter of a 
normal lobule.  Examples include – alcoholic cirrhosis, biliary tract obstruction 
and hepatic venous obstruction. 
 Macronodular cirrhosis applies if most of the nodules are greater than 
3mm diameter, and it occur in two forms.  The more common form has 
nodules divided by thin septa that are often incomplete and have linking to 
portal tracts. This pattern is common in so-called post-hepatitic cirrhosis. The 
median time interval for conversion of micronodular cirrhosis to macronodular 
type is 2.25 years and majority of patients have such progression.  Alcoholic 
cirrhosis often contains fats within the hepatocytes and the parenchyma is 
increased in weight. Etiological factors related to cirrhosis include alcoholism, 
hepatitis B virus, various metabolic diseases such as hemochromatosis, 
Wilson's disease etc. Cirrhosis without recognizable cause is called as 
"Cryptogenic cirrhosis". The irreversibility of cirrhosis has been emphasized in 
several experimental and clinical studies. If cirrhosis is reversible, it must be 
very rare, though in the most convincing patients having biliary obstruction 
has been corrected surgically.  Functionally more important than nodular size 
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in cirrhosis is the size of the entire hepatic mass, which can be estimated with 
radioisotope scans. 
Steatosis (Derck et al, 1994):  
 Steatosis may be produced by a wide variety of drugs and toxins, by 
far the commonest cause being alcohol.  In most instances drug produce 
steatosis through inhibition of lipoprotein synthesis or secretion, or through 
interference with fatty acid oxidation. 
 Types of steatosis are, macrovesicular steatosis that takes the form of 
large vesicles due to coalescence of small lipid droplets within the cytosol and 
the eventual displacement and indentation of the nucleus.  Corticosteroids 
may cause this type of steatosis. Agents which produce zonal liver necrosis, 
in particular industrial solvents such as carbon tetrachloride, phosphorous, 
toxins also show significant macrovesicular fatty infiltration. Chronic 
occupational exposure to organic solvents has been associated with 
steatosis. 
 Microvesicular steatosis, in contrast mimics acute fatty liver of 
pregnancy and Reye's syndrome.  In case of liver damage by tetracycline, 
hepatocytes are filled with finely divided fat droplets that do not displace the 
nuclei, initially the fat is confined to zone 3 but progressively become 
panacinar in distribution.  There is no significant necrosis and little 
cholestasis.  The liver damage probably results from inhibition of lipoprotein 
production, increased uptake of fatty acids, increased formation of 
triglycerides and/or impaired mitochondrial oxidation of fatty acids leading to 
severe intra hepatocytic lipid retention. 
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1.2. 3.  Environmental injury – drug and toxins (Derck et al., 1994): 
 Water soluble drugs and chemical substances are polar molecules, 
they can be excreted by the kidneys, whereas those which are not water-
soluble i.e. non-polar molecules are handled mainly by the liver.  The main 
drug metabolizing enzymes increase the polarity of the molecule in one of the 
three ways :- a) oxido-reductase, of which the enzyme cytochrome P450 is 
important, b) hydrolase and transferase and c) conjugation reaction. 
 
 
 Traditionally, drug injury to the liver was classified into direct, where 
injury is predictable and dose-dependent, and indirect, where it is not dose-
dependent and is unpredictable.  It is now clear that this was a great 
oversimplification, and most drugs undergo metabolism within the liver cell 
before causing injury.  Substances such as tannic acid, ethionine, ferrous 
sulphate, white phosphorus all cause liver damage, directly causing cell injury.  
In contrast, most of the traditional liver poisons such as carbon tetrachloride 
are in fact harmless in an animal such as Chicken which cannot metabolise 
them.  Paracetamol in overdose and halothane probably operate generally in 
a similar way. 
Drug
Metabolite
Elimination
Conjugation
Glutathione
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 Alcoholic liver injury too may be the result of a reactive metabolite.  
Although both zonal necrosis and viral hepatitis-like liver cell necrosis caused 
by drugs and toxins usually have a mechanism similar to that outlined above, 
very occasionally reactive metabolite may create new cellular antigens which 
elicit an immunological response-free drug hypersensitivity e.g. Methyldopa.  
Cell injury by CCl4 (Zimmerman H.J., 1978): 
 Toxic injury of liver induced by carbon tetrachloride (CCl4) is a model 
system of toxic injury.  Toxic injury of liver by CCl4 is the result of their 
metabolic conversion by a complex of enzymes bound to membranes of the 
smooth-surfaced endoplasmic reticulum.  Action of these enzymes is a major 
mechanism by which toxic compounds are converted to less toxic ones.  In 
some instance non-toxic substances are metabolized to toxic ones such as in 
case of CCl4. 
 Carbon tetrachloride is converted by hemolytic cleavage to a highly 
reactive haloalkane free radical and a chlorine free radical in the following 
reaction:- 
Drug
Metabolite
Elimination
Conjugation
Glutathione
Covalent Binding
To Macromolecules
Cell injury 
e.g. CCl4, Paracetamol
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 CCl4 ---------------> CCl3
+ + Cl-. 
 These in turn reacts with a variety of intracellular molecules, notably 
the unsaturated fatty acids.  
 Polyenolic fatty acids for example are converted to organic free 
radicals which in turn react with molecular oxygen to form organic peroxides.  
These compounds are highly unstable and decompose spontaneously to form 
aldehydes, ketones and other products.  
 CCl4 reacts with sulfydryl groups which mediate the function of the 
many cell proteins including a number of important enzymes and this reaction 
leads to their alkylation and subsequent loss of function. The free radicals 
formed react rapidly with other molecules to form additional free radicals; such 
reactions are autocatalytic and tend to spread from a small focus to involve 
large areas of cytoplasm. The earliest change that has been detected in rat 
liver cells is a functional one that occurs 30 min after the I. P. administration of 
a single dose of 0.25 ml of CCl4.  It consists of rapid decrease in synthesis of 
protein albumin as well as the cytochromic.  The diminution of protein 
synthesis after intoxication appears to be linked to disaggregation of the 
polysomes and probably represents a physical disruption of their association 
with messenger RNA. 
 Significantly in this early phase of carbon tetrachloride induced injury, 
mitochondria appear morphologically intact and are capable of normal 
oxidative phosphorylation and fatty acid oxidation among their many 
functions. 
 Within few hours after administration of CCl4 neutral lipids 
(triglycerides) begin to accumulate in the cytoplasm making their first 
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appearance as osmiophilic droplets ultimately fill the entire cytoplasm.  
Approximately 10 to 12 hours after CCl4 administration the liver is grossly 
enlarged and becomes pale because of accumulated fat.  Lipid can also 
accumulate in the liver by mechanisms such as by increased mobilization of 
free fatty acids from depot fat. 
 Shortly after the ingestion of as little as 5 ml to as much as 100 ml of 
carbon tetrachloride, swelling and hydropic degeneration of the centrilobular 
hepatic cells develop.  These changes progress to a diffuse fatty degeneration 
and necrosis in the centrilobular parenchyma with collapse of the reticulum 
network, followed shortly by haemorrhage and leukocytic infiltration. 
 Autoradiographic studies have shown a rapid uptake of carbon 
tetrachloride by the cytoplasm and nuclei of the cells of centrilobular areas. 
Autoradiographic avoidance shows that radioactive 14C and carbon 
tetrachloride remain in the centrilobular areas as long as 2 days after 
ingestion. 
 Endoplasmic reticulum is damaged within 30 minutes of the 
administration of carbon tetrachloride, whereas the mitochondria survive 
unaltered for several hours.  Protein synthesis is reduced within 2 hours of 
poisoning.  Fatty acids are mobilized from peripheral fat depots to the liver.  In 
the liver cell they are oxidized to triglycerides. 
 Experimentally, CCl4 has been widely used to study toxic hepatic 
necrosis and it is still a favoured model of cirrhosis, which regularly develops 
after repeated injection of CCl4 into rats. (Kissane, 1990) 
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1.2.4. Enzyme that detect hepatocellular necrosis (Schiff et al., 1993): 
 The liver contains thousands of enzymes, some of which are also 
present in serum in very low concentrations.  These enzymes have no known 
function in serum and behave like other serum proteins. They are distributed 
in plasma and intestinal fluid and have characteristic half-lives of 
disappearance, usually measured in days.  The elevation of a given enzyme 
activity in serum is thought to primarily reflect its increased rate of entrance 
into serum from damaged liver cells.  Serum enzyme tests can be grouped 
into two categories:- 1) enzymes whose elevation in serum reflects 
generalized damage to hepatocytes and, 2) enzymes whose elevation in 
serum primarily reflects cholestasis. 
Aminotransferase: 
 The serum aminotransferases (formerly called transaminases) are 
sensitive indicator of liver cell injury, and most helpful in recognizing acute 
hepatocellular diseases such as hepatitis.  Alanine aminotransferase [(ALT, 
serum glutamic-pyruvic traqnsaminase (SGPT)] and Aspartate 
aminotransferase [(AST, serum glutamic-oxaloacetic transaminase (SGOT)], 
activities in serum are the most frequently measured indicator of liver disease.  
These enzymes catalyze the transfer of the -amino groups of alanine and 
aspartic acid respectively to the -keto group of ketoglutaric acid.  This results 
in the formation of pyruvic acid and oxaloacetic acid.  Of the numerous 
methods developed for measuring ALT and AST activity in serum, the most 
specific method couples the formation of pyruvate and oxaloacetate, the 
products of the aminotransferase reactions. The reduced form of 
nicotinamide-adenine dinucleotide (NADH), the cofactor in this reduction is 
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oxidized to NAD. Because NADH, but not NAD, absorbs light at 340 nm, the 
event can be followed spectrophotometrically by the loss of absorptivity at 
340nm. Both aminotransferase normally are present in serum in low 
concentrations, less than 30 to 40 IU/ml. 
 AST is found in the liver, cardiac muscle, skeletal muscle, the kidneys, 
the brain, the pancreas, the lungs, leucocytes and erythrocytes, in decreasing 
order of concentration, whereas ALT is present in highest concentration in the 
liver.  The increase in ALT and AST serum values is related to damage to or 
destruction of tissue rich in the aminotransferases or to changes in cell 
membrane permeability that allow ALT and AST to leak into serum. 
 
 Aminotransferases are typically elevated in all liver disorders.  These 
include all types of acute and chronic hepatitis, cirrhosis, infectious 
mononucleosis, alcoholic liver diseases etc.  Elevations up to eight times the 
upper limit of normal are non-specific and may be found in any of the 
mentioned disorders.  The highest elevations occur in disorders associated 
L-Aspartic
acid
-Ketoglutaric
acid
- AST1
SGOT
L-Glutamic 
acid
Oxaloacetic
acid
+ +
MDH
NADH + H+
NAD
L-Aspartic
acid
-Ketoglutaric
acid
- AST1
SGOT
L-Glutamic 
acid
Oxaloacetic
acid
+ +
LDH
NADH + H+
NAD
Chapter 1  INTRODUCTION  
30 
 
with extensive hepatocellular injury, such as drug and viral hepatitis, exposure 
to hepatotoxins such as carbon tetrachloride and phalloidi.  ALT is somewhat 
higher than AST. 
 The aminotransferases may be falsely elevated or diminished under 
certain circumstances. Aminotransferase values falsely increase, if older 
colorimetric tests are used. Conversely low values of AST may be seen in 
uremia. These values increase after dialysis. 
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1.3 Clinical trials. 
1.3.1. What is a clinical trial? (http://www.biotechmedia.com/definitions-
c.html) 
A clinical trial is a research study in which a treatment or therapy is tested in 
people to see whether it is safe and effective. The information learned from 
clinical trials helps to improve health care and to keep people healthier. 
Researchers also conduct clinical trials to find out which treatments are more 
effective than others. The results from trials can also contribute to our 
understanding of diseases and conditions—for example, how a disease 
progresses or how it affects different systems in the body. Clinical trials are 
also called medical research, research studies, or clinical studies. Each trial 
follows a protocol—a written, detailed plan that explains why there is a need 
for the study, what it is intended to do, and how it will be conducted. The 
protocol is written by the trial’s principal investigator (the person who is in 
charge of the trial). 
1.3.2. What are the major types of clinical trials?  
(http://www.biotechmedia.com/definitions-c.html) 
Clinical trials are used to study many aspects of medical care: 
 Treatment trials tests for a specific disease or condition. 
  Supportive care trials, also called quality-of-life trials, study ways of 
making sick people more comfortable and giving them a better quality 
of life. 
 Prevention trials study ways, to reduce the chance of the disease to 
people who are healthy, but may be at the risk for a disease, will 
develop the disease. 
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 Early detection or screening trials, study new ways of finding diseases 
or conditions in people who are at risk, before they have any signs or 
symptoms. 
 Diagnostic trials, test new ways to identify, more accurately and earlier, 
whether people have diseases and conditions. 
Clinical trials have sometimes been thought of as a last resort for those who 
have a disease and have tried all other treatment options. This is not true. 
There are trials for healthy people (for example, to study disease prevention) 
and trials for all different types and stages of diseases. 
1.3.3. What are the different phases of Clinical trials? 
(http://www.biotechmedia.com/definitions-c.html) 
Because the therapy will be tested in people, before a clinical trial can start, 
there needs to be some evidence that it is likely to work. This evidence can 
come either from previous research studies in animals or from reported 
information on its use by people. Clinical trials take place in phases. In each 
phase, different research questions are answered. 
Phase 1:  (http://www.nccam.nih.gov) 
Initial safety trials on a new medicine in which investigators attempt to 
establish the dose range tolerated by about 20-30 healthy volunteers for 
single or multiple doses. Although usually conducted with healthy volunteers, 
Phase 1 trials are sometimes conducted with severely ill patients, for example 
those with cancer or AIDS. When pharmacokinetic issues are being 
addressed (for example, metabolism of a new antiepileptic medicine on stable 
epileptic patients whose microsomal liver enzymes have been induced by 
other antiepileptic medicines), trials may be conducted in less ill patients. 
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Pharmacokinetic trials are usually considered Phase 1 trials regardless of 
when they are conducted during a medicine's development.  
Phase 2a:  (http://www.nccam.nih.gov) 
Pilot clinical trials to evaluate efficacy and safety in selected populations of 
about 100 to 300 patients who have the disease or condition to be treated, 
diagnosed or prevented. Often involve hospitalized patients who can be 
closely monitored. Objectives may focus on dose-response, type of patient, 
frequency of dosing, or any of a number of other issues involved in safety and 
efficacy. 
Phase 2b: (http://www.nccam.nih.gov) 
Well controlled trials to evaluate safety and efficacy in patients who have the 
disease or condition to be treated, diagnosed or prevented. These trials 
usually represent the most rigorous demonstration of efficacy of the medicine. 
Synonym: pivotal trials.  
Phase 3a: (http://www.nccam.nih.gov) 
Multicenter studies in populations of 1000 to 3000 patients (or more)  
for whom the medicine is eventually intended. Phase 3 trials generate 
additional safety and efficacy data from relatively large numbers of patients in 
both controlled and uncontrolled designs and are used to support a PLA 
(Product License Application). Trials are also conducted in special groups of 
patients or under special conditions dictated by the nature of the particular 
medicine and/or disease. Phase 3 trials are often providing much of the 
information needed for package insert and labeling of the medicine.  
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Phase 3b:  (http://www.nccam.nih.gov) 
Trials are conducted after submission of a new drug application (NDA), but 
before the product's approval for market launch. Phase 3b trials may 
supplement or complete earlier trials, or they may seek different kinds of 
information (for example, quality of life or marketing). Phase 3b is the period 
between submission for approval and receipt of marketing authorization.  
Phase 4:  (http://www.nccam.nih.gov) 
After a medicine is marketed, Phase 4 trials provide additional details about 
the product's safety and efficacy. They may be used to evaluate formulations, 
dosages, and duration of treatment, medicine interactions, and other factors. 
Patients from various demographic groups may be studied. An important part 
of many Phase 4 studies is detecting and defining previously unknown or 
inadequately quantified adverse reactions and related risk factors. Phase 4 
studies that are primarily observational or non experimental are frequently 
called post marketing surveillance.  
1.3.4. What are some common elements of Clinical trials? 
(http://www.biotechmedia.com/definitions-c.html) 
Trials can be randomized. Each participant in a randomized trial is assigned 
by chance (through a computer or a table of random numbers) to one of two 
groups: 
 The investigational group, made up of people who will receive the 
therapy, also called the active treatment 
  The control group, made up of people who will receive either the 
standard treatment (if there is one) for their disease or condition, or a 
placebo 
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Each participant has an equal chance of being assigned to either group. In 
some complex trials, there are more than two groups. Randomization is used 
in all phase III studies and in some phase II studies. It gives the best chance 
of knowing that the study results are caused by the treatment and not some 
other factor, such as people’s choices or beliefs. Trials can be double-blind. 
This means that neither the researchers nor the participants know who has 
been assigned to which group. Blinding is another way to help minimize the 
chance of bias influencing the trial results. The information is kept on file at a 
central office, so if there is an urgent need for the research team to find out 
who was assigned the active treatment, they can.  
Researchers design clinical trials to have one or more endpoints. An 
endpoint is a measure that determines whether the treatment under study has 
an effect. An example of an endpoint is whether a person’s tumor shrinks after 
receiving chemotherapy. 
1.3.5. What is a placebo? (http://www.biotechmedia.com/definitions-c.html) 
A placebo is designed to resemble as much as possible the treatment 
being studied in a clinical trial, except that the placebo is inactive. An example 
of a placebo is a pill containing sugar instead of the drug being studied. By 
giving one group of participants a placebo and the other group the active 
treatment, the researchers can compare how the two groups respond and get 
a true picture of the effect of active treatment.  
Another type of placebo is called a ―sham‖ procedure. When the 
treatment under study is a procedure (not a drug or other substance), a sham 
procedure may be designed that resembles the active treatment but does not 
have any active treatment qualities. For example, in a clinical trial of 
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acupuncture, the sham procedure might consist of placing acupuncture 
needles in areas of the body that are not expected (from previous knowledge) 
to have any therapeutic response. 
In recent years, the definition of placebo has been expanded to include 
other things that could have an effect on the results of health care. Examples 
include how a patient and a health care provider interact, how a patient feels 
about receiving the care, and what he or she expects to happen from the 
care. Therefore, when a treatment is compared to a placebo in clinical trials, 
the patients should differ only in whether they receive treatment, and not in 
other aspects. Not all clinical trials compare an active treatment to a placebo. 
No patient is denied treatment in a clinical trial if there is a standard therapy 
available that could improve the comfort and survival of the patient. 
1.3.6 Who can participate in a clinical trial?  
(http://www.biotechmedia.com/definitions-c.html) 
Clinical trials include people of various ages and ethnic groups and 
both genders as much as possible, so that the results can apply to the general 
population. Each clinical trial, however, is unique in its eligibility criteria (rules 
for who can and cannot participate). Examples of criteria include sex, age, 
type of disease, severity of disease, and history of prior treatment. If a disease 
is being studied in a trial, participants must have a similar degree of illness, so 
that there is a good chance they will respond in similar ways to the treatment 
being studied. 
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1.3.7. Are there protections for people who participate in clinical trials? 
(http://www.biotechmedia.com/definitions-c.html) 
Yes, the Federal Government requires many protections for people 
who participate in federally funded clinical trials. Before a clinical trial can 
start, the written protocol must be approved and monitored by an Institutional 
Review Board (IRB). An IRB is an independent group of health care providers, 
other experts, and lay people from the community who make sure that the 
study is set up and run safely and fairly. IRBs review protocols and the 
consent documents that people must sign in order to participate in a clinical 
trial. 
Participants are also protected by a process called informed consent. If you 
are considering taking part in a clinical trial, during this process you will meet 
with a member of the research team. He or she will provide you with key facts 
about the study, such as: 
  Who is sponsoring and conducting the research? 
 Who has reviewed and approved the study? 
  What the researchers want to learn? 
  How the research team will monitor your health and safety? 
 What participants will be required to do during the trial, and for how 
long? 
 Possible benefits and risks of participating. 
  Other treatments that are available for your disease or condition. 
  How the privacy of your medical records will be protected? 
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You have a right to have all your questions answered. If you do not 
understand an answer you receive, ask again. It can be helpful to make a list 
of questions and concerns before you talk to the study team. 
The staff will also give you a consent form, an agreement that you will sign if 
you decide to join the trial. Consent forms can be long, and they contain a lot 
of information. It is a good idea to take the consent form home, so that you 
can think about it and review it with family members or friends. If you have an 
interest in joining a study, it is also very helpful to discuss it with your health 
care practitioner and others whose advice you trust. 
Participating in a clinical trial is completely voluntary. You can leave the trial at 
any time, for any reason even after you have signed the consent form. 
1.3.8. What happens once a clinical trial starts?  
(http://www.biotechmedia.com/definitions-c.html) 
The research team will check the participant’s health at the beginning of the 
trial, give specific instructions for participating, and monitor their health 
carefully during the trial. Participants may be required to do some things 
between appointments, such as take medication according to a schedule or 
make a phone call to report their experiences. 
Clinical trials take place in a variety of settings, depending on the type of trial 
and what is being studied. For example, participants in a trial of an herb might 
follow the protocol at home, while a trial that involves specialized equipment 
(such as acupuncture) might be carried out in a clinic or other health care 
setting. Still other trials may require participants to be in a hospital, clinic, or 
research center while the therapy is given. 
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1.3.9. What happens after a clinical trial ends? 
(http://www.biotechmedia.com/definitions-c.html) 
The researchers carefully analyze the data from the trial. Then they conclude 
about their findings and decide whether further testing is required or not. If the 
trial is completed, the results have medical importance, they usually report the 
results first in a peer-reviewed medical journal (―peer reviewed‖ means that 
each report is reviewed before publication by a group of experts in the same 
field). A new treatment which is found safe and effective in a carefully 
conducted clinical trial become new standard practice. The results of clinical 
trials are given to the participants after its completion.  
1.3.10. What are the possible benefits of being in a clinical trial?  
(http://www.biotechmedia.com/definitions-c.html) 
 You will receive expert medical care. 
 Your health will be closely watched throughout the study. 
 Clinical trials can be one treatment or prevention option for a disease 
or condition. 
  In some types of trials, you may be among the first to get benefit from 
a new treatment or get new knowledge about a current treatment. 
 You can motivate others to take part in the clinical trial or to be treated 
in the clinical trial.  
1.3.11. What are the possible risks in a clinical trial? 
(http://www.biotechmedia.com/definitions-c.html) 
There are some risks for being in a clinical trial, as they are treatment with any 
other illness in a clinical trial: 
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  The treatment under study does not always turn out to be better than, 
or even as good as, standard treatment.  
  The treatment may have side effects which are not known to the 
researchers. 
  If you are in a randomized trial, you may be assigned to the control 
group, where you may not receive the drug but you may receive 
placebo treatment. 
 Participation may require more tests and more visits or treatments than 
regular care. 
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OBJECTIVE 
2.1 Aim of the present work: 
 To study different effects of Eclipta prostrata in the patients of jaundice. 
The plant is described in Ayurveda and is proven pharmacologically for 
the hepatoprotective activity. 
 To study different effects of treatment of the marketed polyherbal 
formulation containing Eclipta prostrata in patients with jaundice.  
 Compare the effects of Eclipta prostrata and its market formulation in 
the patients of jaundice.       
2.2 Plan of the work: 
 Collect the plant Eclipta prostrata. Confirmation of its identity by the 
government authority and comparing its morphological and 
microscopical characters with the published literature.  
 Drying, powdering and storage of the collected drug.  
 Determination of quality of the powder drug by determining its water 
soluble extractive value, alcohol soluble extractive value, ash value, 
acid insoluble ash value and water soluble ash value. 
 TLC study of the powdered drug and comparison with the published 
literature to determine the quality.     
 To form ethical committee to surprise protocol and condition of patients 
etc. To explain importance of this medicine, regarding different tests 
and importance of this study to the patients.   
 Confirming the hepatoprotective activity (Ayurvedic claim) of the 
powder of Eclipta prostrata by giving it to the patients with jaundice and 
determining their biochemical markers like SGPT, bilirubin at different 
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time interval. Also to study effect of this herb on other biochemical 
parameters like Haemoglobin, Hair growth, Urine sugar, Creatinine, 
etc.  
 To study effects of different marketed polyherbal formulations 
containing Eclipta prostrata on the patients having jaundice by 
determining different biochemical markers like SGPT, bilirubin, 
haemoglobin etc. 
 Comparison of the activity of Eclipta prostrata and its marketed 
formulations.  
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REVIEW OF LITERATURE 
3. 1. Eclipta prostrata (L.) L 
Introduction to the herb and review of literature: - 
Drug consistes of whole plant of Eclipta prostrata (L.)L (Kirtikar and Basu, 
1933: Thakur et al., 1989; Indian Herbal Pharmacopoeia, 2002) 
Synonyms:   Eclipta alba Linn. Hassk, Eclipta erecta Linn., E. appressa 
Moerich, Cotula alba Linn, Micrelium asteroides Forsk, Verbensina prostrata 
Linn, Verbensina alba Linn. 
 
   Fig. 3.1 Plant of Eclipta prostrata 
3. 1. 1. Introduction 
Common Name (Ayur. Pharm., 1999) 
Sanskrit : Kesaraja, Tekaraja, Bhringa, Markava, Bhrngaja 
Assam  : Bhrngaraja 
Gujarati : Bhangro, Bhangaro 
Hindi  : Babri, Bhangra, Mochkand. 
Kannad : Garagadasoppu 
Malayalam : Kayyonni, Knnunni 
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Tamil  : Kayanthakoru, Kaikeshi 
Telugu  : Guntagalagara. 
Urdu  : Bhangra 
Uriya  : Kesarda 
Biological Source: (Ayur. Pharm., 1999) Drug consists of whole plants of 
Eclipta alba Hassk (Fam. Asteraceae). 
Scientific Classification: (Chopra et al., 1965) 
Kingdom : Plantae 
Division : Magnoliophyta 
Class  : Magnoliopsida 
Family : Asteraceae (Compositae) 
Order  : Asterales 
Genus : Eclipta  
Part Used : Leaves, Flowers, Whole plants 
Geographical Source: It is one of the common herbs found in Bengal, 
Central India, Rajasthan, Gujarat, South India, Burma, Srilanka etc. 
3.2. Macroscopic: - (Ayur. Pharm., 1999; Indian Herbal Pharmacopoeia, 
2002) 
It is an erect or prostrate annual herb with rooted nodes. Stem 
cylindrical, with longitudinal ridges, 2-5 mm in diameter, dark green in color. 
Leaves opposite, sessile, usually oblong lanceolate with appressed hairs on 
both sides; flowers white in heads, ray compressed. 
Root: Well developed, a number of secondary branches arise from main root, 
upto about 7mm in diameter, cylindrical, grayish. 
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Stem: Herbaceous branched, occasionally rooting at nodes, cylindrical or flat, 
rough due to appressed white hairs, node distinct, greenish, and occasionally 
brownish. 
Leaf: Opposite, sessile to sub sessile, 2.2-8.5 cm long, 1.2-2.3 cm wide, 
usually oblong, lanceolate, sub-entire, sub-acute, strigose with appressed 
hairs on both surfaces. 
Flower: Solitary or together on unequal axillaries peduncles; involucres bracts 
about 8 ovate, obtuse or acute, herbaceous, strigose with appressed hairs; 
ray flowers ligulate, ligule small spreading, scarcely as long as bracts, not 
toothed white; disc flowers tubular, corolla often 4 toothed; Pappus absent 
except occasionally very minute teeth on the top of achene; stamen 5, 
filaments epipetalous free, anthers united into a tube with base obtuse; pistil 
bicarpellary; ovary inferior, unicellular with one basal ovule. 
Fruits: Achenial cypsela, one seeded, cuneate, with a narrow wing, covered 
with warty excrescences and brown in colour. 
Seed: 0.2-0.25 cm long, 0.1 cm wide, dark brown, hairy and non 
endospermic. 
3.3. Microscopy (Ayur. Pharm., 1999; Indian Herbal Pharmacopoeia, 2002; 
Patel 2000) 
3.3.1. Lamina in surface view (Lower surface) 
Cells of both upper and lower epidermis are polygonal and wavy in 
outline and are traversed by anisocytic and anomocytic types of stomata-
which are more in number on lower side. The cells of lower epidermis are 
more wavy in outline. The epidermal trichomes of both the surfaces are very 
characteristic. They are simple, covering, thick-walled, wavy, conical, 
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tricellular with very long central cell and contain the cystoliths. In the middle 
cell it is spindle shaped and in lower and apical cell they are oval to conical in 
shape. There are also few covering multicellular trichomes which are smaller 
than the previously described trichomes. It also shows small glandular 
trichomes with uni or bicellular head and uni to multicellular small stalk.  
Prisms of Ca-oxalate crystals are seen in the mesophyll cells. The average 
stomatal index of the lower surface is 30, palisade ratio is 4 and vein islet 
number is 3. 
 
Fig: 3.2 Lamina of E. prostrata in surface view (Lower surface) 
3.3.2. Transverse section of the leaf passing through midrib (Patel 2000) 
The leaf is dorsiventral with single layer of palisade cells below the 
upper epidermis; it is discontinuous in the midrib region. Both the epidermis 
are covered with thin cuticle and the trichomes. 
The spongy parenchyma contains Ca-oxalate prisms and few cystoliths 
and is traversed by obliquely cut vascular bundles. Mesophyll cells also 
contain oil globule. In center of the midrib lie 3-5 collateral vascular bundles 
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and collenchymatous cells below the epidermis. Trichomes are covering as 
well as glandular on both the surfaces. 
The characters of the leaf tallies with the microscopical characters 
reported earlier (Indian Herbal Pharmacopoeia, 1998: Gopalkrishnan et al., 
1992), except presence of prisms of Ca-oxalate crystals and few cystoliths in 
parenchymatous cells of the mesophyll and midrib region; presence of spindle 
shaped cystoliths in the middle cells of the covering trichomes and oval and 
triangular shapes in the lower and apical cells respectively. It also shows 
glandular trichomes with either unicellular head without stalk or unicellular or 
bicellular head with multicellular stalk. Occasionally, unicellular covering 
trichomes are also found. 
 
Fig: 3.3 T. S. of E. prostrata leaf through midrib 
3.3.3. Transverse section of stem (Patel 2000) 
The transverse section of the stem is circular in outline with a narrow 
ring of collateral vascular bundles surrounding the central parenchymatous 
pith containing prisms of Ca-oxalate crystals. Groups of pericyclic fibers are 
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seen at the periphery of the vascular ring. Endodermis is distinct. The 
trichomes of the epidermis are similar to that of the leaf. Hypodermis is 
composed of 2-3 layers of collenchymatous tissue; cortex is parenchymatous 
and is transversed by many small air chambers. 
Some of the reports do not mention anything about the presence or 
absence of Ca-oxalate crystals (Indian Herbal Pharmacopoeia, 2002) while 
some other has mentioned the presence of acicular crystals (Gopalkrishnan et 
al., 1992). These findings differ from the one which is noticed here. 
 
Fig: 3.4 Diagrammatic T.S. of stem of E. prostrata 
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Fig: 3.5 Detail T. S. of stem of E. prostrata 
3.3.4. Transverse section of the root: (Patel 2000) 
It is circular in outline with a central narrow xylem surrounded by a 
layer of cambium, phloem and a wide zone of cortex interspersed by the 
circles of giant air spaces. The outermost tissue is composed of ill developed 
1-2 layered brownish cork cells, which often gets exfoliated leaving behind the 
inner secondary cortical zone. Cortex is parenchymatous transversed by large 
air spaces in the outer zone. The inner cortical parenchyma contains Ca-
oxalate prisms and scattered isolated pitted stone cells. Xylem is composed of 
radially arranged annular and reticulated xylem vessels associated with xylem 
parenchyma and fibers. 
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Fig: 3.6 Diagrammatic T. S. of root of E. prostrata 
 
 
Fig: 3.7. Detail T. S. of root of E. prostrata 
3.3.5. Powder study of E. prostrata herb: (Patel 2000) 
It shows the characters of the leaf, stem, root and flower. The 
diagnostically important characters are as mentioned in fig 3.2 to fig 3.7. 
Leaf: Many greenish pieces of lamina in surface view are seen as shown in fig 
3.2. The tricellular covering trichomes are characteristic of E. prostrata, they 
are described in 3.3.1. along with other characters of the lamina like polygonal 
wavy walled epidermal cells with anisocytic and anomocytic stomata, prisms 
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of Ca-oxalate, crystals etc. Transversely cut lamina (3.8a) along with single 
layer of palisade cells, oil globules and prisms of Ca-oxalate crystals are 
seen. 
Stem: It shows group of pericyclic fibres along with phloem parenchyma 
(3.8b). It also shows bifurcate xylem fibres (3.8c). 
Root: It shows brownish polygonal cork cells in surface view (3.8d); oval to 
elongated, pitted stone cells (3.8e) and annular to reticulate thickened xylem 
vessels (3.8f). 
Flower: It shows round pollen grains with spines (3.8g).  
 
Fig: 3.8. Powder of E. prostrata herb. 
3.4. Medicinal value: (Kirtikar and Basu, 1933; Thakur et al., 1989).  
The herb popularly known as Bhringraj or Bhangra is reputed in many 
indigenous systems of medicine. The plant has a bitter, hot and sharp taste 
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and is used in Ayurveda for the treatment of „Kapha‟ and „Vata‟. It is found to 
possess antihepatotoxic (Wagner et al., 1986: Chandra et al., 1987: Singh et 
al., 1985: Dixit et al., 1981:  Dule et al., 1982: Sankarm et al., 1984), anti-
inflammatory (Singh et al., 1985), antiulcerogenic (Dhar et al., 1967: Reddy et 
al., 1990), antibiotic (Al-Sharma et al., 1979: Phadke et al., 1989: Farouk et 
al., 1983: Sushil et al., 1985) properties. In traditional medicine the decoction 
of the herb is much valued as a tonic and is also used in liver and spleen 
enlargement (Kirtikar and Basu, 1933). An Ayurveda alcoholic preparation 
“Bhringraj Asawa” is highly reputed for general itching, elephantiasis and for 
curing sores on shoulders caused by carrying heavy loads (Kirtikar and Basu, 
1933). An Ayurvedic herbomineral preparation „Gandhak Rasayanis‟ is highly 
valued in all types of skin diseases.  
It is astringent and is used in cases of stomatitis, toothache and for 
strengthening the gums. In China the plant is rubbed on gums for toothache 
and pounded leaves are prescribed in cases of haemorrhages and fluxes 
(Kirtikar and Basu, 1933). 
It is used as anthelmintic, antiseptic, alexipharmic, expectorant, 
antipyretic, stomachic, and antiabortificient, uterine pain reliever after delivery, 
antiasthmatic and antibronchitis (Kirtikar and Basu, 1933). 
The root is emetic and purgative. It is used in veternary practice. It is 
applied externally as an antiseptic to ulcer and wounds of the cattles. The root 
is applied in conjunctivitis and galled necks of the cattle. In Chota Nagpur, the 
roots are merely tied to the belly of the cattle to remove its diseased condition. 
The root is also used for relieving scalding urine (Kirtikar and Basu, 1933). 
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It is highly valued in cosmetics. The paste of the herb is rubbed on the 
discolored skin for improving its complexion. The extract of the herb is used 
internally and externally to give the natural black color to the hair. The fresh 
juice or the “Bhringaraj hair oil” is rubbed on the shaven scalp to promote the 
growth of the hair. Due to these properties the herb is commonly named as 
hair promoting herb or “Keshraj “.  
3.5. Ethnomedical uses 
As per the disease its ethno medical uses are listed below, along with 
name of the country and part of plant used in the bracket. 
3.5.1. Antiasthamatic: Dry (Ar- Thailand) powder is taken (Gupta et al., 
1977). 
3.5.2. Anticancer: Decoction (Lf-Indonesia) is used orally in stomach and 
matrix cancer (Lin et al., 1986). 
3.5.3. Antidiarrhoeal: Decoction (Ar-India; Srivastava et al., 1990); Lf-Nigeria 
(Gopalkrishanan et al., 1992) are used orally 
3.5.4. Antidiabetic: Decoction (Hb-Taiwan) is used orally (Linn et al., 1992). 
3.5.5. Antiepileptic: Leaf pounded with garlic and pepper is taken orally 
(Anantapur, A.P., and India) in conscious epileptic patient. Its extract is 
dropped in the nostrils of the unconscious patient (Reddy et al., 1989). 
3.5.6. Anti-inflammatory: Decoction (Hb-Bihar, India) along with black 
pepper and raw sugar is taken orally as an anti-inflammatory drug (Jain et al., 
1994). 
3.5.7. Antileprotic: Decoction (Hb-India) is used alone orally as antileprotic 
(Kosuge et al., 1981) while in other parts (Bundelkhand, India) hot water 
extract with other four herbs is used orally (Saxena et al., 1981). In Somalia 
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they crush the entire plant, mix it with oil and apply externally (Samuelsson et 
al., 1992). 
3.5.8. Antileucodermal: In Bundelkhand (A.P, India) they use the plant along 
with four other herbs orally (Saxena et al., 1981). 
3.5.9. Antimalarial: Chenchu tribal people (A.P, India) use plant with pepper 
orally (Reddy et al., 1988). 
3.5.10. Antioedemic: Leaf paste along with salt is applied externally by the 
people of Anantpur (A.P, India) on edema of the legs (Reddy et al., 1989). 
3.5.11. Antipyretic: Decoction (Hb- India; Sahu et al., 1984) and paste (Lf – 
Chittoor, India; Reddy et al., 1989) are used orally. 
3.5.12. Antirabbies: Tribal people of Bihar (India) use 2-3 pills of root paste 
with sugar candy orally in dog bite (Jain et al., 1994). 
3.5. 13. Antitubercular: Decoction (Hb-China) is taken orally (Duke et al., 
1985). 
3.5.14. Antivenin: Decoction (Hb-China) is taken orally in snake bite (Mors et 
al., 1989) while they use fresh herb in Brazil (Martz, 1992). Yanadi tribal 
people (S. India) use leaf juice with butter milk orally (Sudarshanam et al., 
1995), while in N. Gujarat they use orally, leaf juice as an antidote for snake 
bite (Shah et al., 1985). 
3.5.15. Bronchitis: Decoction (Hb-India) is used orally by tribal people of 
Ujjain (Singh et al., 1980). 
3.5.16. Cholagogue: Decoction (Ar-Arab countries) is used orally 
(Schmucker et al., 1969). 
3.5.17. Emetic: Decoction (Ar-Arab countries; Schmucker et al., 1969); Lf-
Nigeria (Akah et al., 1995) is used orally. 
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3.5.18. Eye disease: Decoction (Hb-Ujjain, India) is used externally in eye 
diseases (Singh et al., 1980). Leaf juice with honey is used orally by tribal 
people of Katra (J& K, India) in catarrhal disorders (Kapur et al., 1984). 
3.5.19. Haemostatic: Decoction (Hb-China) is used orally (Kosuge et al., 
1981). 
3.5.20. Headache: Tribal people of Rayalseema (Nagarajun et al., 1990) 
(A.P., India) and others (Sahu et al., 1984) apply extract of the bud and the 
herb respectively in sesame oil externally on forehead. 
3.5.21. Hair care: Tribal people of Katra (J & K India) apply leaf juice with 
Neem oil for the growth of hair (Sahu et al., 1984) while people (Japan) apply 
water extract of the herb externally for this purpose (Tanaka et al., 1980). 
Chenchu tribe (AP., India) uses juice of plant with coconuts oil externally as 
hair tonic (Reddy et al., 1988). People in Tamilnadu (India) use fresh unripe 
fruit juice with other herbs in olive oil externally to prevent premature graying 
of hair (Kumar et al., 1987). Kani tribal people (Kerala, India) use leaf extract 
boiled with coconut oil to deepen black color of the hair and to promote their 
growth (John, 1984). 
3.5.22. Heart diseases: Hot water extract of the herb with other herbs and 
minerals is used orally in India (Kumar et al., 1987). 
3.5.23. Hepatitis: Decoction (Hb-Bangladesh; Atahara et al., 1990) and 
Taiwan (Linn et al., 1990)) is used orally. Hot water extract with other three 
herbs is used orally in Tirupati (AP., India), 4g thrice a day in divided doses for 
infective hepatitis in children (Vedavathyk et al., 1995). 
3.5.24. Insanity: People in Bihar (India) use pills prepared from the root paste 
in insanity (orally), 4 to 5 pills twice a day for 7 days (Jain et al., 1994). 
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3.5.25. Jaundice: In Arab countries leaf juice is used orally as hepatic tonic 
(Schmucker et al., 1969). In Tamilnadu people use fresh leaves, in 
Dandakaranya (Saxena et al., 1981) (India) they use herb orally in case of 
Jaundice. People in India also apply paste of root and seeds of Ricinus 
communis near eyes in case of jaundice (Hemadri et al., 1984). They use root 
juice orally in liver complains in N. Gujarat (Shah et al., 1985) (India). People 
in Cannanore (Kerala, India) use leaf with other herbs orally in case of 
jaundice (Ramachandran, 1987). Tribal people of Chittoor (AP., India) use dry 
powder of the herb orally, 4gm for a week to cure jaundice along with P. 
amarus to rejuvenate the liver (Reddy, 1988). In Rayalseema (AP., India) they 
use juice of the herb with butter milk and curd twice a day orally, but no salt in 
case of jaundice (Nagaraju et al., 1990). 
3.5.26. Male sterility: Tribal people of Gorakpur (UP., India) use juice of the 
plant with Terminalia chebula fruit powder to treat male sterility. 
3.5.27. Purgative: Decoction (Ar-Arab countries, Schmucker et al., 1969) and 
Lf-Nigeria (Akah et al., 1995) are used orally as purgative and laxative 
respectively. 
3.5.28. Safe delivery (Prevention of miscarriage):10 to 15 ml juice of herb 
with cow‟s milk per day are taken orally from early days of pregnancy to 
prevent miscarriage and to have safe delivery (Bhattarai, 1994). 
3.5.29. Skin diseases: The roots of the plant with other herbs are used 
externally for cow as an antiseptic in Ujjain (MP. India) (Singh et al., 1980). 
Decoction (Hb-India) in combination with other plants is taken orally in 
elephantiasis (Upadyay et al., 1988). A paste of the herb (India) with other 
plants in sesame oil is applied externally in case of ringworm lesions (Girach, 
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1994). People of Rayalseema (AP., India) use fresh juice of the plant 
externally in skin diseases (Jain et al., 1981). People use decoction (Hb-
Somalia) externally in skin infection and vesicles in the skin (Samuelsson et 
al., 1992). They use juice (Lf-Nepal) externally in wound healing (Bhattari et 
al, 1997). 
3.5.30. Spleen disorder: People in Katra (J & K., India) use leaf juice with 
honey orally (Nagaraju et al., 1990). 
3.5.31. Tonic: Decoction (Hb-Arab countries (Schmucker et al., 1969)) is 
taken orally. 
3.5.32. Toothache: Paste of the plant (India) in sesame oil is applied 
externally (Sahu et al., 1984). 
Abbreviations: Ar = aerial parts; Hb = Herb; Lf = Leaf; Rt = Root. 
3.6 Pharmacognostical review: 
Satyavati et al., (1976) have mentioned morphological and 
microscopical characters of E. alba. 
 Mehra et al., (1968) have compared the morphological and 
microscopical character of Eclipta alba with its Ayurvedic substitute, Wedelia 
calendulacea, commonly known as peeta (yellow flowered) Bhringraj. 
Gupta, (1977) has reported two forms of E. prostrata, erect and 
prostrate. Erect forms grow luxuriantly in shady and moist habitat where as 
prostrate forms flourish in open sunlight, dry and disturbed areas irrespective 
of seasons. There is difference in size of roots, internodes, flower head etc. 
but no major difference in extractive values. 
Linn et al. (1986) have described the Pharmacognostical characters of 
a Chinese drug „Han-lian-cao‟ i.e. E. alba. 
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Patel, (1989) has described diagnostic microscopic characters of the 
powder of E. alba. 
Indian Herbal Pharmacopoeia, (1998) has mentioned the 
morphological and microscopical characters of leaf, stem and root of E. alba 
and it‟s certain constants like foreign matter, ash values and extractive values. 
Shrivastava et al., (1990) have discussed the morphological characters 
of three commercial adulterants of Bhringraja namely, Ageratum conyzoids 
(Asteraceae), Caesulia axillaris (Asteraceae) and Alternantera sessilis 
(Amaranthaceae) and compared the diagnostic microscopical characters of 
their powdered drugs of leaf, stem and root with that of E. alba. 
Gopalkrishnan & Johnson et al., (1992) have compared the 
microscopical characters of leaves & stems of E. alba with its substitute W. 
calendulacea. Their certain physical constants (ash value, extractive values, 
loss of wt on drying etc.) and other observations (fluorescence and chemical 
analysis) are also compared. 
Shrotiya et al., (1986) have reported growth performance study of E. 
alba in relation to Cadmium treatment. Cadmium, a heavy metal was found to 
be toxic to the growth of the plant at all the concentration tested. Tolerance of 
the plant to some degree was also noticed. 
Saeed et al., (1996) have carried out comparative cytomorphological 
studies of T.S of fresh herb and dried powder of various parts of Conyza 
ambigua, Eclipta alba & Sonchus asper. Chloroform &Menthol extracts of the 
leaves, roots and flowers of all the herbs exhibited prominent erythema on 
mice‟s skin. Extracts of Sonchus as per flowers were more potent than the 
other extracts of the same species and also the other herbs. The possible 
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relationship of anatomical structures with photochemistry and irritancy of 
these species has been discussed. 
Subha Rao et al., (1983) have studied the effect of heavy oil effluent on 
morphological characters and pigment concentration of E. alba. Decrease in 
pigment concentration and increase  in the number of branches, leaves, 
flower buds, fruits and leaf area of E. alba growing in polluted places have 
been reported. 
Siddiqui et al., (1987) have studied the salinity effect of sodium 
sulphate (S.S) on seed germination of E. alba. Seeds of two population 
(saline & non saline) of E. alba were germinated in various concentrations of 
sodium sulphate containing ethrel. Exogenous application of ethrel inhibited 
the seed germination in both population and germination continued up to 6 
atm. Only in saline population. Increasing concentration of S. S. also lowered 
% germination of seeds in both the population. Higher concentration of ethrel 
reduced % of germination of seed in non saline population. 
3.7 Chemical constituents: 
Different types of chemical constituent like alkaloids, alkenynes, 
cardiac glycosides, coumarins, flavonoids, lipids, polyacetylene compounds, 
triterpenes, steroids, saponins, steroidal alkaloids etc. have been reported by 
various workers in different parts of E. prostrata from different countries. 
Genetic environment or other factors like geographical sources, season and 
time of collection may also cause the variability in these constituents where by 
contradictory reports regarding presence or absence of certain constituents 
are found to exist. The reported compounds are mentioned below. The place 
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from where these reports are published and parts of plant are mentioned in 
the bracket. 
 
 
Entire plant (India) is reported to contain an alkaloid nicotine (Pal et al., 
1943) but other reports (Gopalkrishanan et al., 1992, : Debelmas et al., 1973,: 
Al-Sharma et al., 1979,: Aynehchi et al., 1985,: Abu-Mustafa et al., 1977,: 
Sinha et al., 1985) have shown its absence in the different parts of the plant .It 
is also reported to contain Alkanes-hentriacontan-1-ol (Sikroria et al., 1982) 
(Rt-India), heptacosan-14-ol (Sikroria et al., 1982) (Rt-India) and 
heptacosane-n (Ali et al., 1997) (Ar-India); Alkyne-tetradeca-4-6-diene-8-10-
12 triyne (Rt),trideca-1-ene-3-5-7-9-11-pentayne (Rt), trideca-cis-1-7-diene-3-
5-9-11-tetrayne-8-methyl sulfonate (Rt), trideca-trans-1-7-diene-3-5-9-11-
tetrayne-5-methyl sulfonate (Bohlmann et al., 1990) (Rt) and cardiac 
glycosides (Debelmas et al., 1973) (Ent-Nepal). Coumarins- Wedelolactone 
(Wagner et al., 1986: Govindachari et al, 1956,: Mors et al., 1991: Franca et 
al, 1995: Wagner et al., 1987: Melo et al, 1994: Mors et al., 1989:  Zou et al., 
1993: Sarg et al., 1981) and demethylwadelolactone (Wagner et al., 1986). 
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Flavonoids- cynaroside (Sarg et al., 1981) (Ar-Egypt), apigenin (Wagner et 
al., 1986) (Ar-India) and unspecified (Aynehchi et al., 1985) type (Ar-Iran) 
Lipids-heptacosan-5-one-1-ol-myristate (Ali et al., 1997) (Ar-India) and 
pentadeca-1ol-palmitate-11-hydroxy (Ali et al., 1997) (Ar-India) are also 
reported to be present. Roots and aerial parts are reported to contain various 
types of number of (more than 26 number) Polyacetylene Sulphur 
compounds like bithienyl derivatives (Bohlmann et al., 1990), dithiophene 
derivatives (Singh, 1988,: Sihgh et al., 1985,: Singh et al., 1992), terthienyl 
derivatives (Bohlmann et al., 1990,: Jain et al., 1988), thiophene derivatives 
(Bohlmann et al., 1990,: Singh, 1988,: Jain et al., 1988). Triterpenes-B-
amyrin (Sarg et al., 1981) (Ar-Egypt), Enchinocystic acid (Zhang et al., 1996) 
(Ent-China), Eclalbasaponins (Yahara et al., 1994,: Yahara et al., 1997) 
triterpene acid glycoside (Sarg et al., 1981), Ecliptasaponin A (Zhang et al., 
1996), Ecliptasaponin B (Zhang et al., 1996) and Ecliptasaponin D (Zhang et 
al., 1997); oleanolic acid (Zhang et al., 1996); Steroids-B-sitosterol (Mors et 
al., 1989) (Ar-Brazil) and stigmasterol (Mors. et al., 1991) (Ar -India (Singh, 
1988), Ar-Brazil (Melo et al, 1994), Ent-China (Zou et al.,1993), Rt-India 
(Sikroria et al., 1982); haemolytic saponins (Debelmas et al., 1973,: 
Aynehchi et al., 1985,:Abu-Mustafa et al., 1977,: Sinha et al., 1985), Steroidal 
alkaloids-Ecliptalbine (Abdel- Kader et al., 1998) (Lf-Suriname), Verazine and 
its derivatives (Abdel- Kader et al., 1998) (Lf-Suriname) are reported to be 
present in E. prostrata. 
3.8. Pharmacological Review: 
Eclipta prostrata is reported to have different types of biological 
activities on different animals and tissues at different dose levels. These 
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activities are produced by various types of extracts obtained from different 
parts of the plant and are reported by different countries. It has antibacterial, 
antifungal, antiviral, antiyeast, mollucidal, nematocidal, ovicidal, 
antidiarrhoeal, antihepatotoxic, antihepatitisB, analgesic(weak), 
anticonvulsant(weak), anti-inflammatory, antipyretic, antispasmodic, 
antihistaminic, antivenin, hypolipidemic, hypotensive, cytotoxic, weak uterine 
stimulant (pregnant rat) etc. activities. Clinical trials have proved its 
antihepatotoxic activities. All these activities have been elaborated below. The 
name of the country where these activities have been reported and part of 
plant used are mentioned in the bracket. 
3.8.1. Antibacterial; 
 80% alcohol extract (Ar-Iraq) is active against Mycobacterium 
smegmatis at 1mg/ml (Al-Shamma et al., 1979). 
 Chloroform and methanolic extracts of the plant (Sudan) are active 
against Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa 
and Staphylococcus aureus at 1.0 gm/ml (Farouk et al., 1983). 
 The ethanol extract (Hb-Suriname) is inactive at 50mg/ml, versus B. 
subtilis, E. coli, P. aeruginosa and S. aureus (Verpoorte et al., 1987). 
 Ethanol extract (Hb-India) is active against Staphylococcus albus, E 
.coli, Shigella flexheri, Staphylococcus aureus but it is inactive against 
Proteus vulgaris and other bacteria, Klebsiella pneumonia, Proteus 
mirabilis, Pseudomonas aeruginosa, Salmonella parathyphi A, S. 
paratyphi B, S. paratyphi C, S. typhi, Staphylococcus citreus at 500 
mcg/disc concentration. It has weak activity on Shigella boydii, Sh. 
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dysenterica, Sh. schmitzi and Sh. sonnei at 500 mcg/disc concentration 
(Phadke et al., 1989). 
 Ethanol extract (Lf-India) is inactive at 10 mg/ml against 
Corynobacterium diphtheriae, Diplococcus pneumonia, S. aureus, 
Streptococcus pyogens, Streptococcus viridans (Naovi et al., 1991). 
 Seeds of the herb when placed on nutrient media have activity against 
B. subtilis, E. coli, Pseudomonas cichorri, but inactive against 
Salmonella typhimurium (Sushil et al., 1985). 
3.8.2. Antifungal activities 
 Ethanol extract (Ar-India) is active against Helminthosporium turcicum 
(Nene et al., 1968). 
 Ethanol extract (Hb-Suriname) is inactive against Aspergillus niger at 
50 mg/ml concentration (Verpoorte et al., 1987). 
 Ethanol extract (Hb-India) is inactive against Microsporium canis, 
Phylophora jeanselmei, Piedaria hortae, Trichophyton mentagrophytes 
and Microsporus gypseum at 10 mg/ml concentration (Naovi et al., 
1991). 
3.8.3. Antiviral activities: 
 Ethanol: water (1:1) extract (Hb-India) has antiviral activities against 
Ranikhet virus at 50 mcg/ml concentration (Dhar et al., 1967). 
 Juice (undiluted) of the leaf (India) has activities against Bean 
mosaic virus (Tripathi et al., 1982). 
 Decoction (Hb-China) has weak activities against Herpes simplex 
type 1 at conc. of 100 mg/ml by cell culture method (Zheng, 1988). 
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 Alcohol extract (Hb-China) has weak activities against Herpes 
simplex at 10 mg/ml concentration (Minshi, 1989). 
 Ethyl acetate extract of the plant is inactive at 100 mcg/ml while 
water extract has weak activities against Herpes simplex virus-1 at 
the same concentration (Hattori et al., 1995). 
 Water extract of the plant is inactive against HIV type 1 (Protease 
inhibition) at 200 mcg/ml concentration (Kusumoto et al., 1995). 
3.8.4. Antiyeast activities: 
 80% ethanol extract (Ar-Iraq) is inactive against Candida albicans at 
1 mg/ml)  
 Ethanol extract (Hb- Surinam) is also inactive even at higher 
concentration (50 mg/ ml) against Candida albicans (Verpoorte et 
al., 1987). 
 Ethanol, water and hexane extracts (Hb-India) are inactive against 
Candida albicans and Candida tropicalis at 10 mg/ml concentration 
(Naovi et al., 1991). 
 Methanol extract (Hb-Surinam) is active against Saccharomyces 
cervisiae strain 1138, S. cervisiae strain 1140 and S. cervisiae 
strain 1353 at the conc. 16 mcg, 26 mcg and 9 mcg per ml 
respectively (Abdel- Kader et al., 1998) 
3.8.5. Mollucidal activities: 
 Ethanol extracts (Lf & St, Brazil) are active against Biomphalaria 
glabrata at 100 ppm conc. but the hexane extract is inactive at 100 ppm 
concentration (Mendes et al., 1984). 
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3.8.6. Anthelmintic activities: 
 Ethanol, water and n-hexane extracts (Lf-India) have no anthelmintic 
activity at 10 mg/kg (Naovi et al., 1991). 
3.8.7. Antinematodal (Nematocidal) activity: 
 Water extract (Hb-India) has strong activity against Meloidogyne 
incognita (Vijayalakshmi et al., 1979). 
3.8.8. Ovicidal activity: 
 Water extract (St & Rt-India) is active against ova of Sitostroga 
cerealella, ED50 is 25% extract (Prakash et al., 1979). 
3.8.9. Antidiarrhoeal activities: 
 Hot and cold water extracts (Hb-India) are active against E. coli 
enterotoxin induced secretion at 300 mg dose ,on rabbit and guinea pig 
ileal loop (Gupta et al., 1993)  
 3.8.10. Antihepatotoxic activity: 
 Leaf juice (Burma) is hepatoprotective to female guinea pig by oral 
route if given four days prior to CCl4 treatment (Khin Ma-Ma, et al., 
1978). 
 Chloroform and water extracts (Hb-India) are active against Hepatitis B 
surface antigen at 2% concentration (Thyagarajan et al., 1982). 
 Ethyl acetate fraction of the methanol extract (Hb-India) is active at 0.1 
mg/ml conc. against rat hepatocytes intoxicated with CCl4 and 
galactosamine; P < 0.01 and P < 0.001 respectively (Wagner et al., 
1986). 
 Aerial powder of the herb 500 mg/kg for 9 days, by gastric incubation 
has hepatoprotective activity in male rats intoxicated with CCl4; inhibit 
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AAT, GTP, and AP. Ethanol extracts 1mg/ml stabilized human RBC 
membrane (Chandra et al 1987). 
 Ethanol extract (Hb-India) 50 mg/kg oral, increase the bile flow and 
liver weight in the rats (Kumar et al., 1987). 
 Extracts of aerial parts and roots are reported to have antihepatitis B 
surface antigen activity in vitro studies. Red pigment was the active 
constituent (Khin Ma-Ma, et al., 1978). 
 Red pigment of the herb inactivates hepatitis B surface antigen in vitro 
(Jayaram et al., 1989). 
 Total aqueous and successive aqueous extracts (Hb-India) have 
hepatoprotective activity (20% and 12 % activity respectively) versus 
CCl4 toxicity in rats at 500 mg/kg/i.p.; chloroform, methanol and petrol 
extracts are inactive (Sharma et al., 1991). Ethanol extract (Ar-India) 
62.5 mg/kg/intragastric to mouse inhibit zoxazolamine induced 
paralysis.ED50, 175.9 mg/kg/intragastric to mouse decrease 
bromosulphalein clearance time, ED50, 156.7 mg/kg/intragastric to 
mouse reduces barbiturate sleeping time in CCl4 treated animals 
(Chandra et al., 1987). 
 Ethanol extract (Hb-India) is hepatoprotective to rat and mouse 
(Pandey et al., 1993). 
 Ethanol extract (Hb-India) is active against CCl4 toxicity in rabbit at 100 
mg/kg/intragastric dose (Murthy et al., 1993). 
 60% ethanol extract is active against Hepatitis B-virus (DNA 
polymerase inhibitor) at 10 mg/ml in the cell culture (Ghisalberti et al., 
1995). 
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3.8.11. Polyherbal formulations: 
 Eclinol-a polyherbal formulation (PHF-India) reduces liver and 
serum lipids in rats by oral route, which are induced by CCl4 
(Vaishwanar et al., 1967).  
 PHF (four herbs - India) is active versus CCl4 toxicity in rats 
(Chandra et al., 1987). 
 A herbomineral preparation is also active in rats versus 
hepatocellular Jaundice (Patki et al., 1990). 
 Hepatogard, a PHF (India) is active versus CCl4 toxicity in rats 
(Saraf et al., 1981). 
 Hepatomed, a PHF (India) 3ml/100gm for 15 days is active versus 
cumene hydroperoxide toxicity (Sharma et al., 1995). 
3.8.12. Analgesic activity: 
 Hot water extract (Hb-Nepal) at 500 mg/kg/intragastrically has a 
weak analgesic activity in mouse versus acetic acid injury but was 
inactive against hot plate (Debelmas et al., 1976). 
3.8.13. Anticonvulsant activity: 
 Hot water extract (Hb-Nepal) at 500 mg/kg/intragastric has a weak 
anticonvulsant activity versus superamaxial electroshock induced 
convulsions in male mouse but inactive versus strychnine induced 
convulsions (Debelmas et al., 1976). 
3.8.14. Anti-inflammatory activity; 
 Powder of aerial parts, 1.5 g/kg/intragastric, is active against 
carrageenin induced pedal edema in male rats (Chandra et al., 
1987). 
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 Decoction (Hb-India), 1.0 g/kg/intragastric is active versus chronic 
inflammation in rats but weak activity versus carrageenin induced 
pedal edema and adjuvant induced arthritis (Reddy et al., 1990). 
3.8.15. Antimalarial activity: 
 Ethanol: water (1:1) extract (Hb-India) is inactive against 
Plasmodium berghei at 100 mcg/ml concentration in vitro and 1 
g/kg/intragastric in mouse (Jayaram et al., 1987). 
3.8.16. Antioxidant activity: 
 Herb (India), (EC50 2.28 mg/ml) inhibit lipid peroxide formation and 
scavenges hydroxyl radical (Joy et al., 1995). 
3.8.17. Antipyretic activity; 
 Hot water extract (Hb-Nepal) has antipyretic activity at 500 
mg/kg/gastric incubation in male mouse (Debelmas et al., 1976). 
3.8.18. Antispasmodic activity: 
 Alcohol: water (1:1) extract (Hb-India) has antispasmodic activity 
versus acetylcholine and histamine induced spasms on guinea pig 
ileum (Dhar et al., 1967). 
 Hot water extract (Hb-Nepal) has no anticholinergic activity in male 
mouse at 500 mg/kg/gastric incubation (Debelmas et al., 1976). 
 Decoction (Hb-India) has antihistaminic activity at 1.0 g/kg/gastric 
incubation in rats (Reddy et al., 1990). 
3.8.19. Antiulcerogenic activity: 
 Cauvery 100, PHF (India) has antiulcerogenic activity in rats 
through oral route versus indomethacin induced ulcer (Manonmani 
et al., 1994). 
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3.8.20. Antivenin (Antisnake venom) activity: 
 Ether, ethanol (40%) and ethanol (95%) extracts (Brazil) have 
antivenin activity at 0.5 mg, 2.5 mg and 1.8 mg per animal 
respectively. Hexane extract is inactive (2-3mg/animal) 
 Water extract has kinase inhibition (skeletal muscle of mouse) and 
creatinine kinase inhibition (in mouse) activity at 8.5 mcg/ml and 
250 mcg/kg respectively (Mors et al., 1989). 
 The plant (Brazil) extract through i.v route to mouse, protect against 
snake venom injection (Mors et al., 1991). 
3.8.21. Activity on blood: 
 Water extracts of the plant, 1.0 g/kg/i.p. has a haemostatic activity 
in mouse (Kosuge et al., 1981). 
 Methanol extract (IC50 2.0 mcg/ml) and Wedelolactone (IC50 2.5 
µmol) have lipoxygenase-5-inhibitory activity on leucocytes of pig 
(Wagner et al., 1986). 
 Hexane extracts (Lf & St-Thailand) has no coagulant, fibrinolytic or 
platelet aggregation stimulation activity (Triratana et al., 1988). 
 PHF, Abana (India), 50mg/kg/intragastric has hypolipidemic activity 
in rat (Khanna et al., 1991). 
3.8.22. Blood pressure: 
 Ethanol: water (1:1) extract (Hb-India) has hypotensive activity on 
dog at 50mg/kg/i.v. (Dhar et al., 1967). 
 Ethanol extract and columbin (the active compound) have 
hypotensive activity on anaesthetized cat (Rashid et al., 1992). 
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3.8.23. Cytotoxic activity: 
 Methanol extract of the herb is active against CA-Ehrlich Ascites 
cell culture at 1.25 mg/ml (Koshuget et al., 1985). 
 Water extract (Ar-China) is inactive at 500 mcg/ml versus CA-
mammary micro alveolar cell culture (Sato et al., 1989). 
 Ethanol: water (1:1) extract (Hb-India) is inactive at ED50 > 20.0 
mcg/ml versus CA-9KB cell culture (Dhar et al., 1967). 
 Water and ethyl acetate extracts of the herb are inactive at 100 
mcg/ml in cellvero (Hattori et al., 1995).  
3.8.24. Tranquilizing activity: 
 Hot water extract (Hb-Nepal) is neither having tranquilizing activity 
nor spontaneous activity at 500 mg/kg/gastric intubation to male 
mouse (Debelmas et al., 1976). 
3.8.25. Uterine activity: 
 Water extract (Lf-India) has no stimulant activity on the uterus of 
non pregnant guinea pig (Kapur, 1948). 
 Water extract (Rt-India) is having no simulative activity on the 
uterus of rat (Dhawan et al., 1958). 
 Hot water extract of the herb has no stimulant activity on the uterus 
of non pregnant rat but has a weak activity on the uterus of 
pregnant rat (Gupta et al., 1993). 
 Ethanol: water (1:1) extract (Ar), 100mg/kg/oral has no anti-
implantation activity on the female rat (Mishra et al., 1979,: Kamboj, 
1988). 
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3.9. Clinical trials- E. prostrata alone: 
3.9.1. Antihepatotoxic activity: 
 Powder (Hb-India), 50 mg/kg/oral has antihepatotoxicity activity, 40 
children recovered from jaundice out of 50 (Dixit et al., 1981). 
 Powder (Hb-India), 500 mg/person, three times a day for 3-4 weeks 
cured 55% of hepatic patients and for 8 weeks treatment cured 75 % 
patients (Dule et al., 1982).  
3.9.2. Dyspepsia: 
 20gm powder (Hb-India) in a syrup base in three divided doses (oral) 
for six weeks, cured 90 % of patients (out of 30) from non ulcerative 
and peptic ulcer dyspepsia by reducing the gastric activity (Singh et al., 
1990). 
3.9.3. Gastritis: 
 12 gm of the herb powder (India) in three divided doses (oral) for 45 
days has excellent response in 52% patients (out of 25) of gastritis by 
reducing the gastric acidity (Das, 1992). 
3.10. Clinical Trials with polyherbal formulations (PHF) 
 Shen Mari Yin (China) has well anti Aids activity if taken for 8 months 
orally (Yu, 1987). 
 Tefroli (India) is active against hepatitis virus, orally (Sankarm et al., 
1984). 
 Pilex tablet and ointment (India) orally and externally respectively have 
anti-inflammatory activities (Vijayasarathy et al., 1981: Agrawal et al., 
1982). 
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 A polyherbal capsule (1 cap. twice a day for 3, 6, 9, 12, months, orally) 
and the cream (externally, twice a day) cured 40 to 66 % patients of 
leucoderma out of 40 patients (Karnick et al., 1990). 
 A polyherbal (six herbs) capsule (450 mg/oral) for 15 days was active 
against renal calculi (Karnick, 1992). 
 A polyherbal preparation (including fruit of E .alba) containing vitamins 
is active externally in controlling grey hair (China; Zhang, 1990).  
 3.11. Toxicity: 
 Alcohol extract (India), 2 g/kg/mouse/intragastric has no toxicity in 
mouse (Singh et al., 1993). 
 0.2 mg extract/day/oral in mouse for 90 days has no mortality or weight 
loss (Jayaram et al., 1987). 
 Ethanol: water (1:1) extract (India) 1mg/kg/i.p.in mouse is the 
maximum tolerated dose (Dhar et al., 1967). 
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METHODOLOGY  
4.1. Material and method: 
4.1.1 Plant material 
 The plant of Eclipta prostrata was collected in the month of August 
2006 from the fields of a village Dugarwada in Modasa Taluka in Sabarkatha 
(S.K.) District (Gujarat) where it is growing wild. The herb was authenticated 
by Dr. H.B. Singh, Scientist F & Head, Raw Materials Herbarium & Museum, 
Council of Scientific and Industrial Research (CSIR), NISCAIR, New Delhi. 
(Date: 04-08-08, Ref. 1031/62). After authentication, the herbs were subjected 
to study physicochemical parameters. Livercare Churna manufactured by 
Rajsha pharmaceuticals, Ahmadabad and Hepatogard forte tablet 
manufactured by Surajmani Enterprises, Daman were purchased from local 
market.    
4.1.2 Study protocol 
The ability of whole dried drug powder of Eclipta prostrata was tested at 
Sapan Hospital, Bayad, Dist-S.K., Gujarat, for hepatoprotective activity on 
patients who were suffering from liver disease. Before starting this study on 
the patients an ethical committee was formed (consisting of an ayurvedic 
physician, modern physician MD, social worker, advocate, scientist etc. 
Annexure II). The strategy of work was planned and before starting the work 
with patients. Their written consent was taken, after explaining the details 
regarding the effect of the drug and the analysis of blood sample at different 
time interval. The powder of Eclipta prostrata was given thrice a day (morning, 
noon and night, 3 gm each time) orally with glucose to the first group of liver 
damage 98 patients of different age groups and sex for one, two, three, four 
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and six weeks as per severity of the patients and treatment was continued 
until the recovery. The marketed formulation Livercare Churna was given 
thrice a day (morning, noon and night, 3 gm each time) orally with honey to 
the second group of liver damage 93 patients of different age groups and sex 
for one, two, three, four and six weeks as per severity of the patients and 
treatment was continued until the recovery. Hepatogard forte tablet was given 
thrice a day (morning, noon and night, 1 tablet each time) orally to the third 
group of liver damage 95 patients of different age groups and sex for one, 
two, three, four and six weeks as per severity of the patients and treatment 
was continued until the recovery. Biological parameter like SGPT, Bilirubin, 
Haemoglobin, Creatinine, HBsAg, urine sugar, blood pressure, etc were 
measured and monitored during the treatment.  
The reagents used in clinical investigations were collected from Span 
Diagnostic Ltd, Shivam Surgical, Ahmadabad, for estimation of SGPT, 
Bilirubin and Haemoglobin. 
Chapter 4  METHODOLOGY  
75 
 
Table 4.1: Different age of patients who were treated with Eclipta 
prostrata as hepatoprotective drug. 
ECLIPTA PROSTRATA 
Age Male Female 
Total 
Patients 
0-15 8 4 12 
16-30 18 10 28 
31-45 15 16 31 
46-60 18 5 23 
61-Above 4 0 4 
Total 63 35 98 
 
 
 
M = Male, F = Female  
Figure 4.1: Patients v/s Age. Column graph showing patients of Eclipta 
prostrata with different age. 
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Table 4.2:  Different age of patients who were treated with Livercare 
Churna as hepatoprotective drug. 
LIVERCARE CHURNA 
Age Male Female 
Total 
Patients 
0-15 1 1 2 
16-30 15 8 23 
31-45 22 15 37 
46-60 21 9 30 
61-Above 0 1 1 
Total 59 34 93 
 
 
 
M = Male, F = Female  
Figure 4.2: Patients v/s Age. Column graph showing Patients of 
Livercare Churna with different age. 
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Table 4. 3:  Different age of patients who were treated with Hepatogard 
Forte Tablet as hepatoprotective drug. 
HEPATOGARD FORTE TABLET 
Age Male Female 
Total 
Patients 
0-15 1 2 3 
16-30 8 11 19 
31-45 22 14 36 
46-60 21 15 36 
61-Above 1 0 1 
Total 53 42 95 
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M = Male, F = Female  
Figure 4. 3: Patients v/s Age. Column graph showing patients of 
Hepatogard Forte Tablet with different age 
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Table 4.4:  Total number of patients for Eclipta prostrata, Livercare 
Churna, and Hepatogard Forte Tablet. 
 
M = Male, F = Female   
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M = Male, F = Female 
Figure 4.4 : Patients V/S Total number of patients M/F. Column graph 
showing total number of Patients for Eclipta prostrata, Livercare Churna, 
and Hepatogard Forte tablet. 
 
 
M/F 
Eclipta 
prostrata 
Livercare 
Churna 
Hepatogard 
Forte  Tablet 
Total 
M 63 59 53 175 
F 35 34 42 111 
Total 98 93 95 286 
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4.2. TLC studies of the herbs (Patel, 2000) 
TLC studies of the extracts of fresh herb as well as their market formulations 
were carried out to know their TLC finger prints and to compare them and also 
to identify the presence of the active hepatoprotective compound present in 
them. 
Eclipta prostrata 
Extraction: 50 mg of the dry herb Eclipta prostrata (EE) and marketed 
formulations containing 50 mg equivalent amount Eclipta prostrata of 
Livercare Churna (EL) and Hepatogard forte tablet (EH) containing 50 mg 
equivalent amount Eclipta prostrata were separately extracted with 10 ml of 
methanol by heating on water bath for 10 min. To ensure the complete 
extraction the marc was again extracted similarly twice by using 5 ml 
methanol each time. The combined filtrate was concentrated to 0.5 ml and 
used for spotting on the TLC plate. 
TLC: 
Extract of each of the above fresh herb of Eclipta prostrata (EE), and 
marketed formulations Livercare Churna (EL) and tablet Hepatogaurd Forte 
tablet (EH) were spotted on silica gel G plate. It was developed using 
Toluene: Acetone: Formic acid (11: 6: 1) as a mobile phase; dried and 
observed in day light, UV light and after spraying with 5 % aqueous FeCl3 
solution.  
Detection:  
1. 5% aqueous FeCl3 (day light) 
2. UV light(254 nm ) 
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Extracts: Alcoholic extracts of dry fresh herb Eclipta prostrata (EE), and 
marketed formulation containing Livercare Churna (EL) and Hepatogaurd 
Forte tablet (EH). 
4.3. Physicochemical parameter 
4.3.1. Ash values. (Harbone, 1998; WHO/QCMMPM guidelines, 1992) 
Ash content of the crude drug is generally taken to be the residue remaining 
after incineration. It represents the inorganic salts naturally occurring in the 
drug and adhering to it, but it may also include inorganic matter added for the 
purpose of adulteration. 
Total ash is the residue remaining after incineration. Acid insoluble ash is the 
part of the total ash, which is insoluble in dilute hydrochloric acid. Water-
soluble ash is the part of total ash, which is soluble in hot water.  
4.3.1.1. Determination of Total Ash. 
About 2g of the powdered drug was accurately weighed (W) in a tarred silica 
crucible. The powdered drug was spread as a fine layer at the bottom of the 
crucible. The crucible was incinerated at a temperature not exceeding 450°C 
until free from carbon. The crucible was cooled and weighed. 
The procedure was repeated till a constant weight was observed. The 
percentage of the total ash was calculated with reference to the air-dried 
drug. 
4.3.1.2. Determination of Acid Insoluble Ash 
The ash obtained as described in the determination of total ash was boiled 
with 25 ml of hydrochloric acid for 5 min. The insoluble ash was collected on 
an ashless filter paper and washed with hot water. The insoluble ash was 
transferred into a tarred silica crucible along with filter paper, ignited, cooled 
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and weighed. The procedure was repeated till a constant weight was 
observed. The percentage of acid insoluble ash was calculated with 
reference to the air-dried drug. 
4.3.1.3. Determination of Alcohol-Soluble Extractive: 
Macerate 5 gm of the air dried coarsely powdered drug with 100 ml of alcohol 
in a 250 ml volumetric flask for 24 hours, shake frequently during six hours 
and allow to stand for 18 hours.  Filter rapidly taking precaution against loss of 
alcohol, evaporate 25% of the filtrate to dryness in a tarred shallow dish dried 
at 1050C and weighed. Calculate the percentage of alcohol soluble extractive 
with reference to the air dried drug. 
4.3.1.4. Determination of Water-Soluble Extractive: 
Macerate 5 gm of the air dried coarsely powdered drug with 100 ml of 
chloroform water in a 250 ml volumetric flask for 24 hours, shake frequently 
during six hours and allow to stand for 18 hours.  Filter rapidly, evaporate 25% 
of the filtrate to dryness in a tarred shallow dish dried at 105 0C and weighed. 
Calculated the percentage of water soluble extractive with reference to the air 
dried drug. 
4.4. Estimation of SGPT (Reitman et al., 1957: Nobert, 1970, Godkar et al, 
2006) 
4.4.1. Intended Use: 
 This reagent kit is intended for in-vitro quantitative determination of 
SGPT (ALT) activity in serum/plasma.  
4.4.2. Principle:  
Glutamate pyruvate transaminase (GPT) or Alanine aminotransferase (ALT) 
catalyses alphaketoglutarate and L-Alanine. Pyruvate formed by this catalysis 
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reacts with 2, 4 dinitrophenylhydrazine (2, 4 DNPH) to give a brown-red 
colored hydrazone complex in an alkaline medium.  The concentration of 
brown red colored complex is directly proportional to the activity of SGPT 
present in sample and it is measured colorimetrically at 505nm or with green 
filter. 
4.4.3. Reaction: 
i. Alpha-ketoglutarate + L-Alanine       
GPT
          L-Glutamate + 
Pyruvate. 
ii. Pyruvate + 2, 4 DNPH   
.
 
Alk medium
         Brown-Red Hydrazone Complex 
4.4.4. Clinical Significance: 
Even though glutamate pyruvate transaminase is widely distributed in various 
tissues of the body; it is a useful parameter in evaluating liver function.  The 
elevated serum levels are found in case of hepatitis, obstructive jaundice, 
metastatic carcinoma, hepatic congestion and myocardial infarction or in 
kidney diseases. 
4.4.5. Reagent Preparation:  
Reagent 1: Buffered alanine -KG substrate. 
Reagent 2: DNPH color reagent. 
Reagent 3: sodium hydroxide, 4N. 
Reagent 4: Working pyruvate standard, 2mM. 
Solution 1: One ml of Reagent No.3 was diluted to 10 ml with distilled water.  
Reagent 1, 2 & 4 are ready for use as such.  
4.4.6. Test Procedure: 
Reagent 1(Buffered alanine -KG substrate) 0.5 ml is taken in a test tube. It is 
incubated at 37oC for 5 min, fasted serum 0.1 ml is added to the test tube. It is 
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mixed well and incubate at 37oC for 30 min. Reagent 2, (DNPH color reagent) 
0.5 ml is added to the above test tube. It is allowed to stand at room 
temperature for 20 min. Solution 1; 5 ml is added to the solution of the test 
tube. It is mixed well and allow to stand for 10 min. The absorbance of the 
solution is measured 505 nm using water as blank.   
4.4.7. Test Results: 
The calibration graph is used to obtain test results in U/ml. 
4.4.8. Linearity:  
This method is linear up to 150 U/ml of SGPT in serum.  Samples having 
higher values are diluted with 0.9% saline and assay results were multiplied 
with dilution factor. 
4.5. Estimation of Bilirubin (Malloy et al., 1937, Godkar and Godkar, 2006) 
4.5.1. Intended Use: 
This diagnostic reagent kit is intended for in-vitro quantitative estimation of 
direct and indirect bilirubin from serum/plasma. 
4.5.2. Principle: 
The direct or conjugated bilirubin reacts with diazotized sulphanilic acid to 
form purple colored complex, whereas indirect or unconjugated Bilirubin 
reacts only in presence of DMSO reagent to give purple colored complex.  
The intensity of the purple color developed is proportional to the amount of 
either total or direct bilirubin present in sample and it is measured 
colorimetrically at 540 nm or with yellow-green filter. 
4.5.3. Reaction: 
Direct/ conjugated Bilirubin + Diazotized Sulphanilic acid  Purple colored 
azo bilirubin complex  
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Indirect / unconjugated bilirubin + Diazotized sulphanilic acid    
DMSO
 
 Purple colored azo bilirubin complex. 
4.5.4. Clinical Significance: 
Bilirubin is produced from haemoglobin in reticulo endothelial system and 
circulates in normal concentration in blood.  It is conjugated with glucuronic 
acid in liver and excreted through bile.  The estimation of total and direct 
bilirubin is of importance for diagnosis, differentiation and follows up of 
jaundice.  The serum levels of unconjugated Bilirubin rises in the cases of 
hemolytic jaundice.  Whereas conjugated serum bilirubin levels rises in the 
cases of obstructive jaundice.  Hepatic jaundice is characterized by 
simultaneous rise in both, conjugated and unconjugated serum bilirubin 
levels.  
4.5.5. Reagent Preparation: 
Reagent A: Total bilirubin reagent. 
Reagent B: Direct bilirubin reagent. 
Reagent C: Sodium nitrite reagent. 
Reagent D: standard bilirubin = 10mg% bilirubin.  
All reagents in the kit are ready to use as such. 
4.5.6. Procedure for Colorimetric estimation of Bilirubin: 
For total bilirubin estimation 3 ml of reagent A and 0.1 ml of reagent C are 
mixed by inversion of test tube No T and waited for 30 seconds. For total 
bilirubin blank 3 ml of reagent A is taken in test tube No TB. Fasted serum 
0.15 ml is added in each test tube No T and TB. The content of both the test 
tubes are mixed well and incubated at 37oC for 5 min and absorbance is read 
at 540 nm using water as blank. 
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For direct bilirubin estimation 3 ml of reagent B and 0.1 ml of reagent C are 
mixed by inversion of test tube No D and waited for 30 seconds. For direct 
bilirubin blank 3 ml of reagent B is taken in test tube No DB. Fasted serum 
0.15 ml is added in each test tube No D and DB. The content of both the test 
tubes are mixed well and incubated for 37oC for 5 min and absorbance is read 
at 540 nm using water as blank. 
The absorbance of the reagent D (standard bilirubin) is read directly against 
distilled water. The standard once used is discarded. Serum Bilirubin in mg% 
calculated as below. 
4.5.7. Test Results: 
 
Where T= Total bilirubin, TB= Total bilirubin blank, D= Direct bilirubin, DB= 
Direct bilirubin blank. 
4.5.8. Linearity: 
This method is linear up to bilirubin concentration of 15 mg%, for sample 
having higher values of bilirubin are diluted with 0.9% normal saline and 
multiplied with dilution factor.  
4.6. Estimation of Creatinine (Tora and Ackermann, 1975: Bonses and 
Taussky, 1945; Godkar and Godkar, 2006) 
4.6.1. Method: Alkaline Picrate Method 
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4.6.2. Principle: Creatinine in a protein free solution reacts, with Alkaline 
Picrates and produces a red colored complex, which is measured 
colorimetrically. 
4.6.3. Advantages: 
 Very popular method 
 Simple, convenient and highly reproducible. 
 One minute deprotenization step with a single deprotenization reagent. 
 Result within half an hour. 
 Economic. 
Sample: 24hrs urine is preferred. Dilute 1ml of urine to 250 ml with purified 
water. 
4.6.4. Reagent: 
Reagent 1: Picric acid 
Reagent 2: Sodium Hydroxide, 0.75N 
Reagent 3: Stock Creatinine Standard, 150 mg% 
Preparation of working solution: Dilute 0.1 ml of reagent 3 to 10 ml with 
purified water and mix well. All other reagents are ready for use. 
Storage and stability: All reagents are stable at room temperature till the 
expiry date mentioned on the individual label. Once opened Reagent 3 is 
stable at 2-8 0C. Working standard has to be prepared fresh everyday.  
4.6.5. Precautions: 
1) Use clean and dry glassware. 
2) Bring all solution to room temperature before use. 
3) Prepare one blank and one standard for each series of estimations. 
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4) Mark the test tube properly as blank (B), standard (S), and test (T) 
before proceeding for the estimation, because markings may come off 
when the tubes are placed in the boiling water bath during 
deprotenization (step A). 
5) Do not fail to dilute the urine during creatinine estimation from urine. 
4.6.6. Procedure 
A. For colorimetry 
Step A. Deprotenization of test sample: 
Dilute urine   0.5 ml  
Purified water   0.5 ml 
Reagent 1: Picric acid  3.0 ml 
Mix well; keep in a boiling water bath exactly for one minute. Cool 
immediately under running tap water and centrifuge or filter 
Step B. Color Development:  Blank   Standard  Test 
Filtrate/Supernant (From Step A.)   -    -  2.0 ml 
Working Standard     -  0.5 ml    - 
Purified water    0.5 ml    -    - 
Reagent 1: Picric acid   1.5 ml  1.5 ml    - 
Reagent 2: NaOH (0.75N)  0.5 ml  0.5 ml  0.5 ml 
Mix well and allow to stand at room temperature exactly for 20 minutes 
and measure immediately the optical density of Blank (B), Standard(S) 
and Test (T) against Purified water on a colorimeter with a green filter. 
B. For Spectrophotometer: All the volumes mentioned under colorimetric 
procedure can be adjusted proportionately depending on flow 
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cell/cuvette capacity. Rest of the procedure remains unchanged. 
Measure the O.D. at 520nm. 
4.6.7. Calculation: 
Urine Creatinine in mg/ 100ml = O.D. test – O.D. blank 
     O.D. std – O.D. blank    
 
Normal values of Urine Creatinine: Men: 1.1- 2.8 g/ 24hrs 
           Women: 0.9- 1.6 g/24 hrs 
4.6.8. Note:  
1) If the O.D. of test exceeds 0.8 repeat the test after diluting the urine 1 
→ 50 or more if necessary and multiply the final result so obtained with 
2.0 or an appropriate factor. 
2) Optical density should be measured exactly after 20 minutes after the 
addition of sodium hydroxide.  
3) The filtrate/ supplement obtained during deprotenization should be 
crystal clear.  
4.6.9. Clinical significance 
In renal disease, creatinine determinations have one advantage over urea 
determinations that they are not affected by a high protein diet as is the case 
for urea determinations. In addition to renal disease, elevated levels of Serum 
Creatinine and Creatinuria may be observed in extensive muscle destruction. 
4.7. Estimation of HBsAg test. (Godkar and Godkar, 2006) 
4.7.1. Intended use: 
The Advanced quality one step HBsAg test is a rapid, one step, 
immunochromatographic assay for the detection of Hepatitis B surface 
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antigen (HBsAg) in human serum or plasma. The presence of 5ng /ml HBsAg 
can be detected within 10 minutes and 1ng/ml HBsAg in 30 minutes. The test 
provides a visual, qualitative result, and is intended for professional use. 
4.7.2. Principle of the assay 
Solid phase “Sandwich” immunoassay for the detection of HBsAg was 
described by Wisdom (Wisdom, 1976, Wolters et al., Wei et al., 1977). The 
production, characterization and application of monoclonal antibodies for the 
detection of HBsAg have previously been reported (David, 1981: Goodall, et 
al., 1981: Kennedy. et al., 1983: Shih, et al., 1980: Wands et al., 1981). 
The advanced quality one step HBsAg test is a colloidal gold enhanced 
immunoassay that detects Hepatitis B surface antigen in human serum or 
plasma. The sample initially reacts with the monoclonal antibody-colloidal 
conjugate on the sample pad. This mixture migrates across the membrane by 
capillary action and reacts with the anti-HBsAg in the test region. If the sample 
contains HBsAg a line will form on the membrane at this point. If the antigen is 
not present in the sample no line is formed, indicating a negative result. The 
mixture continues to flow to the control area of the membrane, where it forms 
a line indicating the test result valid. 
4.7.3. Storage conditions 
The kit must be stored at 2-30C. 
4.7.4. Precautions 
It is recommended that all specimens be handled in accordance with biosafety 
level 2 practices as described in the CDC NIH publication, Biosafety on 
microbiological and biomedical laboratories (USDHHS, 1988) or other 
equivalent guidelines (WHO, 1983: NCCLS, 1989) 
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1. For in vitro diagnostic use only. 
2. Wear gloves to perform this procedure and treat all specimens and 
used devices as potentially infectious. 
3. Clean and disinfect all spills of specimens and reagents using a 
suitable disinfectant, such as 1% sodium hydrochlorite12. 
4. Sterilize all devices used in this assay prior to disposal. 
5. Do not use test beyond the expiration date 
4.7.5. Specimen collection 
1. Serum or plasma may be used in this test .Anticoagulants typically 
used for blood collection do not interfere with this test. 
2. Remove the serum or plasma from the clot or red cells as soon as 
possible to avoid hemolysis. 
3. Haemolyzed extremely thickened or fatty specimens are not suitable 
for this assay. Specimens containing particulate matter may give 
inconsistent results and should be clarified prior to testing. 
4. Serum or plasma specimens should be refrigerated at 2 to 8 oC up to 3 
days and frozen at -20 oC for longer periods. 
5. Shipped specimens should be packed in compliance with federal and 
international regulations covering the transportation of etiologic agents. 
6. Avoid frequent (more than 3 times) thaw- and freeze of specimens. 
7. 0.1% sodium azide can be added to the specimen as a preservative 
without affecting results of the assay. 
4.7.6. Materials provided 
 10 or 40 test cards individually foil pouched with a desiccant. 
 Instruction for use. 
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 Sample dispensing plastic dropper with each test pouch. 
4.7.7. Assay procedure 
Do not open pouch until you are ready to the sample. 
1. Bring all reagents and specimens to room temperature. 
2. Remove the test card from the foil pouch and place on a clean dry 
surface. 
3. Identify the test card for each specimen or control. 
4. Dispense 2-3 drops of the specimen or control into the sample well on 
the card by provided plastic sample dropper. Caution: Use only 
provided sample dropper for every sample to avoid cross- 
contamination. 
5. Read the result between 5 to 10 minutes for 5ng/ml, and 30 minutes for 
1ng/ml. A positive result may be interpreted early, however read any 
negative at 30 minutes to ensure sample is negative and not a low 
concentration of the HBsAg, requiring more time to develop. Do not 
interpret the result after 30 minutes. 
It is recommended to run a known positive and negative control in each 
performance to ensure the assay procedure. 
4.7.8. Interpretation of Results 
Negative: Only one purplish red colored band appears in the control 
region. 
Positive: In addition to the purplish red control band, a distinct purplish 
red colored band also appears in the test region. 
Invalid: Neither test band nor control band appears. The specimen should 
be tested again using a new test card. 
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4.7.9. Limitations:  
Although the association between the presence of HBsAg and infection is 
strong, available methods for HBsAg detection are not sensitive enough to 
detect all potentially infectious units of blood or possible hepatitis 
infections. 
4.7.10. Performance characteristics 
Serum or plasma concentration as low as 1ng/ml is detected by this assay. 
The advanced quality one step HBsAg test has been compared to an 
equivalent EIA system. A result of 99.5% correction to EIA test was 
demonstrated by a clinical study of 1208 patient‟s specimens. 
4.8. Estimation of Urine Sugar (Godkar and Godkar, 2006, Goyal et al., 
2006) 
4.8.1. Principle:  
Benedict‟s quantitative reagent consists of copper sulphate, potassium 
thiocyanate and other chemicals in alkaline media. Copper sulphate is 
reduced to cuprous oxide by glucose. Potassium thiocyanate reacts with 
cuprous oxide and form white precipitates of cuprous thiocyanate instead of 
usual precipitates of cuprous oxide. Disappearance of blue tint from solution, 
indicate complete reaction of copper sulphate. 
4.8.2. Reaction  
 2 Cu (OH) 2  (reduction) → Cu2O + 2 H2O 
4.8.3. Reagents:  
1) Benedict‟s quantitative reagent:   
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(A)  Dissolve with the aid of heat, 100 gm of anhydrous sodium carbonate, 
200 gm of sodium or potassium citrate and 125 gm of dry potassium 
thiocyanate in 800 ml water and filter if necessary. 
(B) Dissolve 18gm of copper sulphate in 100ml of water. Cool the solution. 
Add „B‟ to „A‟ with constant stirring. Add 5 ml of 5% potassium 
ferricyanide solution. Add water to make 1000 ml. 25ml of the reagent 
is reduced by 50 mg of glucose. Check the strength by titrating with 
standard solution of glucose; 1ml of reagent = 2mg of glucose. 
2) Anhydrous sodium carbonate:  
Dilution: The urine is diluted in such a way that the burrate reading is 
between 5 to 15 ml for 10 ml of the reagent. For this, take 5 ml of 
Benedict„s qualitative reagent. Add 8 drops of urine, boil and cool. 
Green ppts: Dilute urine 1 in 2 or 3 
Yellow ppts: Dilute urine 1in 5 or 8 
Brick red ppts: Dilute urine 1 in 10 or more 
End point: Complete disappearance of the blue color. 
4.8.4. Procedure: 
(A) Pipette out 10 ml of Benedict„s qualitative reagent solution in a 100 ml 
conical flask. Add 20 ml of water, 5gm of anhydrous sodium carbonate and 
few pieces of porcelain to prevent bumping. Heat the flask on a flame to 
boiling. Keeping the mixture just boiling, add this urine in a flask rapidly, 
until white precipitates begin to form. After this add urine, drop by drop at 
the interval of 10 seconds until the blue color just disappear. The solution 
must be kept vigorously boiling and be stirred continuously throughout the 
entire titration. 
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(B)  Add 5ml of the Benedict„s qualitative reagent and mix with 0.5 ml of 
urine, Boil for 2 minute and cool 
Green precipitates    Glucose up to 1% 
Yellow precipitates   Glucose up to 2% 
Red precipitates    Greater than 2% 
4.8.5. Calculation: 
If n ml of urine, dilution 1 in D (if not diluted D=1) required, then the 
glucose contents of urine are, 
0.02 x 100     x D        =     2D gm% 
N                                 n 
Note: In Benedict„s qualitative reagent, small amount of potassium 
ferricyanide assists in maintaining the cuprous oxide in solution. The use of 
sodium carbonate as alkali instead of sodium hydroxide, prevent the 
destruction of the small amount of sugar. 
4.8.6. Interpretation; Normal value of glucose excretion is 2 to 10 mg 
glucose/100 ml or 78.5 mg/day, which is not detected by common qualitative 
test. Determination of sugar concentration in urine is important for the 
management of diabetics. Presence of sugar in urine is known as glucosuria 
and the persistent presence indicate diabetes mellitus. 
4.9. Determination of Haemoglobin. (Godkar and Godkar, 2006, Goyal et 
al., 2006) 
4.9.1. Reagent and Glassware: 
Sahil haemoglobinometer or hemometer which consists of two sealed 
comparison tubes fixed in rack, a specially graduated diluting tube,  a thin 
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glass rod and micropipette of 20 cubic millimeter capacity, pricking needle, 
N/10 HCl, distilled water, 70% alcohol and absorbent cotton. 
4.9.2. Principle: 
When blood is mixed with N/10 HCl, RBCs are haemolyzed and Hb is librated. 
This Hb is converted into acid hematin which is reddish brown in color. The 
solution is diluted with distilled water till it matches with the standard glass 
(Comparison) tubes. The Hb% can directly be read from the graduated tube. 
4.9.3. Procedure: The graduated diluting tube and the micropipette are 
cleaned thoroughly and dried. The graduated diluting tube is filled with N/10 
HCl up to the mark 2 gm or till the micropipette touches the level of acid in the 
tube. The finger is cleaned with 70% alcohol and it is pricked to obtain a drop 
of blood. First drop is wiped out. Second drop is sucked in the micropipette 
upto the mark 20cmm. The blood is immediately deposited at the bottom of 
the graduated tube. The pipette is rinsed two to three times in HCl. The blood 
is mixed with the help of stirrer and then solution is allowed to stand for 10-15 
minutes so that all Hb is converted into acid haematin. Then mixture is diluted 
with distilled water. Distilled water is added drop by drop and every time it is 
stirred till the exact match with standard glass tubes is obtain and the scale is 
read on the side of tube. 
4.9.4. Observation and Calculation 
Observed Hb gm % = --------- gm % 
Observed Hb % = ---------- % 
International value of Hb is 14.5 gm% = 100 % 
Calculation Hb% =   gm %    x 100 
                                 14.5 
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4.9.5. Normal value 
  Normally 14.5 gm of Hb in 100 cc of blood is considered to be 100 % 
Hb according to British Standards. The value may vary according to sex, 
age and altitude. In female adults it may vary from 12 to 15 gm (average 
13.7 gm %) and in adult males it ranges from 13 gm to 16 gm (average 
14.8 gm %). New born child has an average of 23 gm% by the end of third 
month it falls below the normal. After this it gradually recovers within a 
year to 12.5 gm. People at higher altitude have higher value, because 
oxygen of air is less at that level. 
4.9.6. Precautions; 
 While filling the micropipette, entry of air bubbles should be 
avoided. It is advisable to fill up the micropipette more than 20 cmm 
marks. The excess of blood in the micropipette may be removed by 
touching the tip of the pipette on palm. 
 While depositing blood into graduated tube, one should not blow it 
forcibly so that blood sticks to the side of pipette. Rinsing should 
also be done slowly. 
 Never take less quantity of N/10 HCl. 
 While observing for color match, stirrer should be kept out of 
solution, and the calibrated side should not come in view. The 
observation must be done while facing it against uniform intensity of 
light. 
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4.10. Estimation of Blood Pressure (Godkar and Godkar, 2006; Goyal et al., 
2006) 
Blood pressure (B.P.) is defined as the lateral pressure exerted on the 
walls of the vessels by the contained blood. This is due to muscularity and 
elasticity of the walls of blood vessels. The B.P. also depends on the force 
with which heart pumps the blood. The maximum pressure during systole 
is defined as systolic B.P whereas the minimum pressure during diastole is 
defined as the diastolic B.P. The difference between systolic and diastolic 
B.P is described as the pulse pressure. 
4.10.1. Principle: 
The blood flow through a large sized artery is obstructed by means of 
air pressure exerted through a rubber bag wrapped around the limb. The 
pressure is slowly released and the entry of blood through the obstruction 
is studied by  
 Feeling of the pulse(Palpatory method) 
 Observation of oscillation of the mercury level ( oscillatory method) 
 Hearing with the stethoscope the sounds produced in the segment 
of the artery distal to obstruction (Auscultatory method) 
The blood flow stops when the pressure transmitted to the artery through 
the rubber bag is equal to or more than the blood pressure. The first entry 
of blood through an obstruction indicates the blood pressure. Usually the 
arm or thigh is used because there is only one big vessel which runs 
superficially in each of these parts of the extremities. 
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4.10.2. Procedure: 
1. The cuff is tied around the arm. It should be neither too tight to 
cause any discomfort to the subject, nor too loose to allow its 
movement round the arm. 
2. The artery is felt and its course is marked in the cubital fossa. Also 
the radial pulse is felt and marked at the place where it is felt well. 
3. The manometer is placed by the side of the subject, between his 
arm and the body. The screw of the rubber pump is tightened and 
the pump is pressed to inflate the bag. It is inflated to raise the 
mercury to 200 mm level or 20-25 mm hg higher after the 
disappearance of pulse. 
4. Keeping the eyes fixed at mercury level and the finger at the pulse, 
pressure is slowly released by unscrewing the valve of the rubber 
pump. The reading of the level of mercury when the pulse 
reappears gives systolic pressure. This is Palpatory method. This 
method does not give idea of diastolic pressure. The systolic 
pressure recorded by this method is about 5-10 mm lower than the 
actual systolic pressure. 
When the pulse appears, it is also noted that mercury starts oscillation. 
The first oscillation starts increasing in magnitude and then slowly 
diminishes. The level at which the oscillation are maximum is taken as the 
diastolic pressure. This is oscillatory method. In this method the deflation 
has to be carried out slowly the systolic pressure should be read within 
fifteen seconds and the diastolic pressure within thirty second. 
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In the Auscultatory method after as usual the chest piece of stethoscope is 
placed over the brachial artery in the cubital fossa and deflation is started 
by slowly releasing the pressure. The level at which a sudden tap is 
heared is the systolic blood pressure. The sound suddenly gets muffled 
and disappears. The level at which the sinus muffles is the diastolic 
pressure, the sounds heared are korokorr‟s sounds. These are due to 
interrupted flow of blood. 
In many instances when the systolic blood pressure is very high, the first 
sound is a faint tap and is then missed. As the pressure in the bag is 
reduced the sound produced become louder and audible at a much lower 
level. This reading is then erroneously taken as the systolic blood pressure 
reading.  The difference between this reading and the true systolic reading 
is described as the „Auscultatory gap‟. 
4.11 Statistical Analysis 
 Results of biochemical estimation were reported as Mean, S.D, SEM 
and Median for determination of significant inter group difference each 
parameter was analyzed separately and one way analysis of variance P value 
was carried out Graph Pad statistics software. 
 Results of biochemical estimation were reported as Mean, S.D, and 
SEM for determination Student T Test of significant inter group difference 
each parameter was analyzed separately and one way analysis of variance t 
value and P value was carried out by SPSS 12.0 statistics software. 
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RESULT AND DISCUSSION 
Result and Discussion 
5.1 Physicochemical parameter 
The herb of Eclipta prostrata collected from the field of village Dugarwada in 
Modasa was identified as Eclipta prostrata by scientist of NISCAIR, New Delhi 
(4/8/08; Ref: 1031/62). 
The physicochemical parameters of the powder of the herb were determined 
which are shown in Table no. 5.1     
Table 5.1: Physicochemical parameter for Eclipta prostrata 
Sr. 
no 
Name of 
parameter 
Experimental 
Value 
Indian Herbal 
Pharmacopoeia 
Ayurvedic 
Pharmacopoeia 
of India  
1 Water soluble  
extractive value 
17.0 % NLT 20 % NLT 15 % 
2 Alcoholic soluble 
extractive value 
7.0 % NLT 5 % NLT 5 % 
3 Total ash 14.5 NMT 19 % NMT 22 % 
4 Acid insoluble 
ash value 
8.0 % NMT 8 % NMT 11 % 
 
Water soluble extractive value, Alcoholic soluble extractive value, Total ash 
and Acid insoluble ash value of the Eclipta prostrata herb collected for the use 
comply with the Ayurvedic Pharmacopoeia of India 
as well as Indian Herbal Pharmacopoeia. Only Water soluble extractive value 
is 3% less than the value mentioned by Indian Herbal Pharmacopoeia.  
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5.2 TLC of Eclipta prostrata and its market formulations  
PLATE  1                           PLATE  2                              PLATE  3 
                       
       EE   EL  EH                        EE   EL   EH                         EE    EL   EH 
Figure 5.1: TLC study of Eclipta prostrata and their formulations. 
Where A= Spot of wedelolactone (Rf=0.43, Identified through literature as 
Wedelolactone ), S = Place of spotting, F = Solvent front. 
Stationary phase: Silica gel G. 
Mobile phase:  Toluene: Acetone: Formic acid (11: 6: 1). 
Detection:  Plate 1 – As seen in day light.  
Plate 2 – As seen in U. V. light (254nm) 
Plate 3 - After spraying with 5% aqueous FeCl3 as seen in day 
light 
EH; Alcoholic extract of Hepatogard forte Tablet 
EL; Alcoholic extract of Livercare Churna 
EE; Alcoholic extract of Eclipta prostrata 
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TLC was observed in day light, UV light (254nm) and after spraying with 5% 
aq. FeCl3 solution as seen in day light. 
In day light, UV and after spraying with 5% FeCl3 reagent spot at Rf= 0.43 is 
prominent. It turns dark blue after spraying with FeCl3 reagent. As per the 
literature description this spot at Rf= 0.43 is Wedelolactone which is present in 
the collected herb sample, Livercare Churna and Hepatogard forte Tablet. 
However the intensity of the spot (Rf = 0.43) and diameter was bigger in the 
sample of Livercare Churna than in collected herb and Hepatogard forte 
Tablet.       
Total 7 spots were seen in Eclipta herb in day light, but they were less in 
number in Livercare Churna and Hepatogard forte Tablet.  
About 8 spots were seen in Eclipta herb chromatogram after spraying with 
FeCl3 reagent. All the spots were blue to dark blue in colour. The number of 
spots were less in Livercare Churna and Hepatogard forte Tablet after 
spraying with FeCl3 reagent. 
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5.3 Clinical data 
Table 5.2:  SGPT values of the patients after treatment with Eclipta 
prostrata  
Sr. no of 
patients 
Age 
SGPT values after different weeks treatment 
Initial 
(zero 
week) 
First Second Third Fourth Sixth 
1 65 248 210 35 - - - 
2 30 1500 900 380 - 40 - 
3 38 154 90 35 - - - 
4 38 420 140 45 - - - 
5 35 255 110 55 - - - 
6 40 570 430 310 60 40 - 
7 60 1300 710 430 180 55 - 
8 4.5 621 390 120 39 - - 
9 50 74 60 50 35 - - 
10 50 738 380 110 - - - 
11 25 520 210 60 30 - - 
12 45 840 320 58 - - - 
13 30 318 45 - - - - 
14 24 680 270 45 - - - 
15 40 1200 840 480 55 - - 
16 16 540 370 55 - - - 
17 50 380 110 65 - - - 
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18 41 135 48 - - - - 
19 35 750 520 340 240 65 - 
20 49 1050 530 170 45 - - 
21 9 1100 670 250 65 - - 
22 32 2043 1180 650 90 - - 
23 9 2020 1980 1250 720 450 90 
24 47 160 85 65 - - - 
25 20 2100 1200 950 680 430 85 
26 40 110 80 65 35 - - 
27 29 1890 1340 750 430 250 45 
28 42 680 410 240 65 - - 
29 60 2500 1870 1110 940 450 70 
30 47 2000 1640 1020 450 65 - 
31 9 1520 1080 830 320 45 - 
32 40 330 240 65 - - - 
33 17 116 70 - - - - 
34 27 1740 1090 550 70 - - 
35 50 600 540 380 85 - - 
36 53 920 540 210 90 - - 
37 25 270 60 - - - - 
38 19 1550 1270 650 280 65 - 
39 18 2200 940 430 170 95 - 
40 38 130 47 - - - - 
41 37 110 75 - - - - 
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42 52 3600 2200 1100 620 450 65 
43 50 370 280 140 65 35 - 
44 60 1500 880 320 80 - - 
45 22 1500 1200 650 120 - - 
46 9 1600 1140 740 470 110 - 
47 10 3100 2800 1200 440 220 45 
48 40 540 290 140 45 - - 
49 19 1900 940 530 110 - - 
50 38 2400 1840 1100 325 85 - 
51 50 590 310 230 170 51 - 
52 39 400 150 45 - - - 
53 45 720 430 290 110 - - 
54 47 125 45 - - - - 
55 50 220 95 45 - - - 
56 57 1640 1070 650 290 120 65 
57 32 1420 1210 730 380 90 - 
58 50 4500 2700 1300 820 370 85 
59 53 2220 1480 890 680 380 55 
60 40 450 310 150 70 65 45 
61 48 750 490 270 85 - - 
62 29 2450 1460 650 130 - - 
63 28 1050 780 370 85 - - 
64 42 600 540 430 190 45 - 
65 29 2340 1790 730 290 45 - 
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66 42 55 50 45 - - - 
67 37 1850 720 390 45 - - 
68 21 1100 790 290 55 - - 
69 37 950 640 250 130 65 - 
70 22 262 135 85 - - - 
71 22 880 610 220 75 - - 
72 40 145 75 - - - - 
73 24 1700 1470 525 220 75 - 
74 10 1620 1340 540 320 85 - 
75 48 3250 2800 1800 830 410 65 
76 27 750 390 180 85 - - 
77 16 440 290 75 35 - - 
78 12 1290 780 540 220 65 35 
79 48 258 140 65 - - - 
80 28 190 65 - - - - 
81 46 160 70 - - - - 
82 65 290 120 50 - - - 
83 38 380 190 60 35 - - 
84 12 435 280 180 90 60 - 
85 8 480 310 220 110 55 - 
86 56 300 160 85 - - - 
87 42 2190 1790 730 490 230 60 
88 38 230 120 90 50 - - 
89 42 1100 670 390 110 35 - 
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90 28 850 480 210 85 - - 
91 23 380 210 65 - - - 
92 35 280 140 60 - - - 
93 18 580 240 80 - - - 
94 11 460 210 90 - - - 
95 18 910 420 180 60 - - 
96 45 190 85 - - - - 
97 12 430 190 65 - - - 
98 20 50 - - - - - 
Average  987.775 654.639 378.697 222.483 152.823 62.3076 
 
Table 5.3. a: P value of SGPT after treatment with Eclipta prostrata  
Group 
(week)  
Mean  Standard 
Deviation  
Standard 
Error of 
Mean  
Median 
Initial 987.77 869.90 84.894 621.00 
First 654.63 648.86 64.247 390.00 
Second 378.69 367.28 38.715 235.00 
Third 222.48 227.91 28.489 110.00 
Fourth 152.82 145.98 24.675 75.000 
Sixth 62.308 16.596 4.436 63.654 
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Table 5.3.b: Paired samples test of SGPT after treatment with Eclipta 
prostrata 
Pai
r  
Paired Differences 
t test df 
P value 
Significa
nt (2 
tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
313.685 313.245 30.425 253.358 374.013 10.31 105 0.000* 
677.106 577.708 60.230 557.466 796.746 11.24 91 0.000* 
1074.36 761.960 93.790 887.048 1261.67 11.45 65 0.000* 
1459.67 918.343 153.05 1148.95 1770.40 9.537 35 0.000* 
2303.07 1042.80 289.22 1672.91 2933.24 7.963 12 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
Table 5.4: SGPT values of the patients after treatment with Livercare 
Churna  
Sr. no of 
patients 
Ag
e  
SGPT values after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 17 210 130 70 - - - 
2 47 1050 630 290 80 - - 
3 49 490 270 85 - - - 
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4 51 2450 1760 1030 540 230 40 
5 31 610 310 110 - - - 
6 53 890 470 190 45 - - 
7 47 298 170 110 45 - - 
8 40 3200 2350 1430 770 310 35 
9 47 2250 1770 1090 440 130 - 
10 50 1450 730 470 180 90 - 
11 44 790 410 100 - - - 
12 46 3480 2570 1720 1070 645 95 
13 35 780 590 310 80 - - 
14 55 450 195 60 - - - 
15 50 1270 1040 770 490 110  
16 60 3610 2140 1950 1170 640 80 
17 43 270 110 - - - - 
18 45 320 185 65 - - - 
19 40 3200 1530 890 540 360 40 
20 29 492 240 80  - - 
21 44 2015 1310 430 190 28 - 
22 25 2540 1070 610 310 35 - 
23 17 2215 1130 680 210 42 - 
24 40 195 45 - - - - 
25 35 2250 1240 700 240 60 - 
26 25 2600 1330 790 320 75 - 
27 21 1810 1020 570 270 40 - 
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28 52 285 70 25 - - - 
29 45 1420 830 440 180 65 - 
30 62 2470 1820 1180 830 540 90 
31 50 430 110 55 - - - 
32 45 1350 760 320 85 - - 
33 50 1845 1130 680 210 80 - 
34 30 1530 890 570 390 100 - 
35 19 1745 1090 630 210 55 - 
36 45 515 270 65 - - - 
37 25 1420 690 120 60 - - 
38 25 1240 640 210 90 - - 
39 27 1420 890 480 110 75 - 
40 17 945 540 320 90 - - 
41 57 1200 580 270 85 - - 
42 45 260 190 65 - - - 
43 60 380 210 100 - - - 
44 49 360 170 65 - - - 
45 36 200 120 65 - - - 
46 49 2200 1870 1170 775 390 50 
47 50 1240 730 370 85 - - 
48 40 3290 2500 1390 820 380 75 
49 40 2100 1870 1070 390 90 - 
50 39 245 95 - - - - 
51 41 2700 2250 1785 1190 540 95 
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52 45 480 170 80 - - - 
53 29 1210 650 320 65 - - 
54 52 560 270 62 - - - 
55 50 1265 775 390 100 - - 
56 49 1750 1080 680 310 45 - 
57 39 340 110 - - - - 
58 11 680 240 60 - - - 
59 19 715 210 45 - - - 
60 52 550 430 240 90 - - 
61 21 1320 940 690 360 120 - 
62 29 750 580 310 180 55 - 
63 40 140 80 45 - - - 
64 55 180 40 - - - - 
65 50 750 480 370 210 70 - 
66 39 310 110 54 - - - 
67 38 380 160 45 - - - 
68 19 1075 490 210 85 - - 
69 35 2650 1280 630 290 80 - 
70 45 340 190 75 - - - 
71 31 1625 745 320 65 - - 
72 49 190 60 - - - - 
73 45 130 65 - - - - 
74 53 470 190 75 - - - 
75 48 230 40 - - - - 
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76 20 160 45 - - - - 
77 17 750 370 60 - - - 
78 27 3010 1830 1110 830 460 80 
79 31 800 380 45 - - - 
80 50 180 50 - - - - 
81 35 2190 1745 1070 470 90  
82 39 130 50 - - - - 
83 29 380 85 - - - - 
84 41 118 45 - - - - 
85 22 120 85 - - - - 
86 31 1060 470 270 95 - - 
87 47 260 75 - - - - 
88 28 425 190 40 - - - 
89 12 390 90 - - - - 
90 41 140 50 - - - - 
91 36 410 85 - - - - 
92 44 460 180 65 - - - 
93 39 540 280 65 - - - 
Average  1092.344 651.075 446.28 334.893 194.516 68 
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Table 5.5.a: P value of SGPT after treatment with Livercare Churna 
Group 
(week)  
Mean  Standard 
Deviation  
Standard 
Error of Mean  
Median 
Initial 1092.3 933.22 96.254 750.00 
First 651.08 658.63 67.932 420.00 
Second 446.28 463.63 53.182 310.00 
Third 334.89 309.64 44.692 210.00 
Fourth 194.52 192.65 34.056 90.00 
Sixth 68.000 22.935 6.915 75.00 
 
Table 5.5.b: Paired samples test of SGPT after treatment with Livercare 
Churna 
Pai
r  
Paired Differences 
t test df 
P value 
Significan
t (2 
tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
397.374 354.245 34.407 329.151 465.597 11.549 105 0.000* 
779.914 558.323 60.918 658.750 901.077 12.803 83 0.000* 
1342.05 698.744 96.898 1147.52 1536.58 13.850 51 0.000* 
1862.10 777.905 135.415 1586.26 2137.93 13.751 32 0.000* 
2893.00 474.881 150.170 2553.29 3232.70 19.265 9 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.6:  SGPT values of the patients after treatment with Hepatogard 
forte Tablet. 
Sr. no 
of 
patients 
Age 
SGPT values after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 370 190 45 - - - 
2 34 700 390 210 85 - - 
3 50 2250 1890 1200 970 535 110 
4 39 3690 2980 2110 1340 650 210 
5 39 2700 2260 1390 810 390 110 
6 60 3250 2790 1770 1090 435 110 
7 32 1250 810 645 290 85 - 
8 49 780 610 370 230 65 - 
9 55 260 170 90 - - - 
10 60 380 210 85 - - - 
11 35 520 310 140 65 - - 
12 36 290 130 90 - - - 
13 58 680 490 330 290 170 65 
14 40 300 130 60 - - - 
15 50 340 170 65 - - - 
16 29 235 165 90 - - - 
17 38 180 112 65 - - - 
18 42 210 150 75 - - - 
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19 59 205 130 65 - - - 
20 11 340 190 70 - - - 
21 32 1150 740 390 190 45 - 
22 60 1800 845 340 190 65 - 
23 35 470 190 75 - - - 
24 59 1100 590 240 85 - - 
25 49 680 390 110 55 - - 
26 21 1260 740 320 110 - - 
27 60 260 180 80 - - - 
28 45 220 170 110 45 - - 
29 50 1490 970 530 320 110 - 
30 55 250 120 85 45 - - 
31 51 940 430 190 110 - - 
32 23 1110 820 520 310 90 - 
33 20 210 120 50 - - - 
34 22 115 50 - - - - 
35 48 220 130 60 - - - 
36 47 1500 980 590 310 95 - 
37 41 940 470 230 110 - - 
38 32 1040 725 410 210 110 - 
39 21 740 360 95 - - - 
40 21 810 430 220 65 - - 
41 22 140 60 - - - - 
42 50 180 70 - - - - 
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43 42 120 55 - - - - 
44 30 375 110 55 - - - 
45 18 425 340 210 63 - - 
46 30 150 45 - - - - 
47 40 410 180 120 58 - - 
48 35 180 50 - - - - 
49 28 430 370 290 180 70 - 
50 37 895 710 410 310 170 60 
51 49 130 100 45 - - - 
52 30 125 110 65 - - - 
53 29 190 70 - - - - 
54 41 470 310 190 85 - - 
55 42 450 300 95 - - - 
56 37 130 55 - - - - 
57 18 650 430 280 160 60 - 
58 13 145 65 - - - - 
59 23 485 240 180 150 100 45 
60 28 110 53 - - - - 
61 45 635 540 320 120 80 - 
62 15 670 480 370 80 - - 
63 50 1310 840 530 210 80 - 
64 32 380 90 - - - - 
65 43 2100 1400 790 460 320 80 
66 36 2020 970 470 310 70 - 
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67 38 390 90 - - - - 
68 35 648 320 110 - - - 
69 51 290 180 80 - - - 
70 55 550 430 220 110 50 - 
71 43 270 120 60 - - - 
72 46 390 190 70 - - - 
73 59 270 90 - - - - 
74 39 320 280 170 110 70 - 
75 55 1060 630 480 210 90 - 
76 35 1100 620 310 80 - - 
77 51 155 60 - - - - 
78 45 980 610 290 85 - - 
79 40 600 310 90 - - - 
80 17 1920 1010 640 380 200 49 
81 50 825 580 320 75 - - 
82 50 280 95 - - - - 
83 20 700 350 85 - - - 
84 51 430 220 75 - - - 
85 55 320 120 60 - - - 
86 50 1250 570 310 45 - - 
87 39 250 150 55 - - - 
88 47 2190 1540 630 310 45 - 
89 37 538 230 110 - - - 
90 40 280 130 45 - - - 
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91 51 1750 880 320 75 - - 
92 47 2380 1790 1430 910 425 90 
93 49 1390 870 530 290 95 - 
94 39 300 140 55 - - - 
95 35 550 290 130 45 - - 
Average  746.484 470.157 308.812 254.916 170.357 92.9 
 
Table 5.7.a: P value of SGPT after treatment with Hepatogard forte Tablet 
Group 
(week)  
Mean  Standard 
Deviation  
Standard 
Error of 
Mean  
Median 
Initial 746.48 690.95 66.486 430.00 
First 470.15 533.54 52.318 285.00 
Second 308.81 370.96 39.771 180.00 
Third 254.91 280.11 38.477 120.00 
Fourth 170.35 159.93 28.725 90.000 
Sixth 92.900 45.658 13.767 90.000 
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Table 5.7.b: Paired samples test of SGPT after treatment with 
Hepatogard forte Tablet 
Pai
r  
Paired Differences 
t test  df 
P value 
Significan
t (2 
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
271.822 218.012 21.076 230.037 313.607 12.897 106 0.000* 
536.329 395.935 42.206 452.438 620.220 12.707 87 0.000* 
907.944 528.325 71.895 763.739 1052.14 12.629 53 0.000* 
1255.64 728.786 130.893 988.324 1522.96 9.593 30 0.000* 
1804.18 1082.899 326.506 1076.67 2531.68 5.526 10 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.8:  Comparative average SGPT values for different week 
treatment using Eclipta prostrata, Livercare Churna and Hepatogard 
forte Tablet.  
Week 
Eclipta 
prostrata 
Livercare 
Churna 
Hepatogard 
forte Tablet 
Initial 987.7755 1092.344 746.4842 
First 654.6392 651.0753 470.1579 
Second 378.6977 446.28 308.8125 
Third 222.4839 334.8936 254.9167 
Fourth 152.8235 194.5161 170.3571 
Sixth 62.30769 68 92.9 
 
 
 
Figure 5.2: SGPT v/s Week of treatment. Column graph showing 
comparative value of SGPT for different week treatment using Eclipta 
prostrata, Livercare Churna and Hepatogard forte Tablet as 
hepatoprotective drugs. 
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For Eclipta prostrata the mean SGPT value of the group on zero day is 
considered as 100%. In comparison with zero week, SGPT level are 
recovered on first week 33.73%, on second week 61.67%, on third week 
77.48%, on fourth week 84.53% and sixth weeks 93.70% respectively. The P 
value is < 0.0001.  
For Livercare Churna the mean SGPT value of the group on zero day 
is considered as 100%. In comparison with zero week, SGPT level are 
recovered on first week 40.38%, on second week 59.15%, on third week 
69.41%, on fourth week 82.23% and sixth weeks 93.77% respectively. The P 
value is < 0.0001.  
For Hepatogard forte Tablet the mean SGPT value of the group on 
zero day is considered as 100%. In comparison with zero week, SGPT level 
are recovered on first week 36.99%, on second week 58.71%, on third week 
65.95%, on fourth week 77.21% and sixth weeks 87.66% respectively. The P 
value is < 0.0001.  
Table 5. 9: Percentage recovery of SGPT with different formulations 
Treatment %Recovery 
Formulation First week 
Second 
week 
Third week 
Fourth 
week 
Sixth week 
Eclipta 
prostrata 
33.73 61.67 77.48 84.53 93.70 
Livercare 
Churna 
40.38 59.15 69.41 82.23 93.77 
Hepatogard 
forte Tablet 
36.99 58.71 65.95 77.21 87.66 
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Table 5.10:  Bilirubin values of the patients after treatment with Eclipta 
prostrata.   
 Sr. no 
of 
patient
s  
Ag
e  
Bilirubin value mg % after different week treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 65 3 2.1 0.8 - - - 
2 30 4 3.2 1.9 - 0.8 - 
3 38 2.4 1.8 1.1 - - - 
4 38 7.1 4.1 1.2 - - - 
5 35 4.8 2.1 1.3 - - - 
6 40 30 22 14 6.3 2.3 - 
7 60 9 7.2 5.4 3.1 1.2 - 
8 4.5 8 5.1 2.9 1.1 - - 
9 50 17 11.2 5.1 1.3 - - 
10 50 9 5.3 3.2 - - - 
11 25 7 3.2 1.8 0.8 - - 
12 45 4.3 2 0.8 - - - 
13 30 6.9 1.4 - - - - 
14 24 10.2 4.8 1.6 - - - 
15 40 10.8 8.3 6.2 1.8 - - 
16 16 9.1 5.1 2 - - - 
17 50 11.2 6 1.3 - - - 
18 41 1.9 1.1 - - - - 
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19 35 11.3 7.1 5.2 4.9 1.3 - 
20 49 3.2 3 2.1 0.8 - - 
21 9 7.8 5.8 2.2 1 - - 
22 32 8.9 6.2 3.2 0.9 - - 
23 9 6.2 6.8 4.2 3.9 2.2 1 
24 47 2.4 2.2 0.9 - - - 
25 20 3.9 3.9 2.1 1.8 1.8 1.2 
26 40 12 8 4.3 1.8 - - 
27 29 23 17 11.2 7.3 2.8 1.1 
28 42 4.2 3.8 1.8 0.9 - - 
29 60 10.4 8.2 6.2 4.8 3.2 1.1 
30 47 3.9 3.1 2.7 2.1 1.2 - 
31 9 5.9 4.2 3.6 2.2 0.9 - 
32 40 2.2 1.8 0.9 - - - 
33 17 1.8 1.1 - - - - 
34 27 4.2 3.8 2.2 0.9 - - 
35 50 10.5 6.2 3.2 1.3 - - 
36 53 5.1 3.4 2.2 1.2 - - 
37 25 3 1.2 - - - - 
38 19 1.2 1.1 1.1 1 0.9 - 
39 18 1.8 1.1 0.9 0.9 0.9 - 
40 38 1.1 0.9 - - - - 
41 37 2.9 1 - - - - 
42 52 9.2 6.2 4.3 2.2 1.8 1.1 
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43 50 12.9 8.4 4.2 2.2 1 - 
44 60 4.2 3.2 2.2 1.1 - - 
45 22 4.2 2.8 2.1 1.1 - - 
46 9 2.8 2.5 1.7 1.6 1.1 - 
47 10 5.4 4.9 3.2 2.2 2.1 1.3 
48 40 7.4 4.3 2.2 0.9 - - 
49 19 1.8 1.7 1.4 0.8 - - 
50 38 10.6 8.2 7.2 3.2 1.3 - 
51 50 10.8 8.3 5.9 2.9 1.1 - 
52 39 4.3 2.2 1.1 - - - 
53 45 1.8 1.6 1.2 1 - - 
54 47 1.2 0.9 - - - - 
55 50 2.4 1.8 1.2 - - - 
56 57 18 13.8 12.2 6.9 3.1 1 
57 32 2.3 2 1.9 1.5 0.8 - 
58 50 3.4 2.7 2.2 1.8 1.2 0.9 
59 53 11.1 7.9 6.1 5.1 4.2 1.3 
60 40 22.4 16.2 9.4 6.2 4.3 1.2 
61 48 4.6 2.3 1.2 0.9 - - 
62 29 1.8 1.6 1.4 1.2 - - 
63 28 4.9 3.1 2.4 1.2 - - 
64 42 13.1 12.1 6.2 2.8 1.2 - 
65 29 10.9 8.2 3.4 3.4 1.2 - 
66 42 8.2 4.8 2.1 - - - 
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67 37 2 1.6 1.2 0.9 - - 
68 21 1.4 1.1 1 0.9 - - 
69 37 10.2 6.4 3.9 2.3 1.1 - 
70 22 3.2 2.1 1 
 
- - 
71 22 4.3 3.5 2.2 0.9 - - 
72 40 1.3 0.9 - - - - 
73 24 6 4.2 2.2 1.2 0.9 - 
74 10 2.8 2.3 1.8 1.4 1 - 
75 48 11.3 8.4 6.3 4.2 3.2 1.1 
76 27 6.3 4.1 2.2 1.2 - - 
77 16 3.1 2.8 1.7 1 - - 
78 12 12.1 8.3 6.8 4.2 2.2 1.1 
79 48 2.2 1.4 1.1 - - - 
80 28 2.2 1.2 - - - - 
81 46 2.1 1.1 - - - - 
82 65 4.3 2.2 1 - - - 
83 38 3.9 3 1.6 1 - - 
84 12 6.8 4.8 2.7 1.4 1 - 
85 8 11 9.3 6.1 3.6 1.3 - 
86 56 1.1 1 0.9 - - - 
87 42 12.2 10.1 6.2 4.1 3 1 
88 38 3.9 2.8 1.4 1.1 - - 
89 42 6.8 3.2 2.8 1.2 0.9 - 
90 28 3.2 2.9 1.3 1 - - 
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91 23 2.1 1.6 0.9 - - - 
92 35 4.1 2.3 1.1 - - - 
93 18 4.8 2.9 1.2 - - - 
94 11 3.6 1.8 0.9 - - - 
95 18 2.8 1.9 1.1 0.9 - - 
96 45 2.1 1 - - - - 
97 12 3.9 2.1 1 - - - 
98 20 1.8 1 - - - - 
Average  6.3387 4.4071 3.0093 2.1741 1.6787 1.1076 
 
Table 5.11.a : P value of bilirubin after treatment with Eclipta prostrata 
Group 
(week)  
Mean  Standard 
Deviation 
Standard 
Error of Mean 
Median 
Initial 6.3387 3.782 0.3745 4.9 
First 4.4071 2.917 0.2917 2.8 
Second 3.0093 2.112 0.2326 2.05 
Third 2.1741 1.354 0.1934 2.1 
Fourth 1.6787 0.8531 0.1485 1.1 
Sixth 1.1076 0.1020 0.03075 0.9 
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Table 5.11.b: Paired samples test of bilirubin after treatment with Eclipta 
prostrata 
Pai
r  
Paired Differences 
t test  df 
P value 
Significan
t (2 tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
1.931 1.6868 0.170 1.5934 2.269 11.336 97 0.000* 
3.884 3.0642 0.330 3.2279 4.541 11.757 85 0.000* 
5.551 4.4478 0.564 4.4220 6.681 9.828 61 0.000* 
7.554 5.8632 1.020 5.4755 9.633 7.402 32 0.000* 
10.323 6.3816 1.769 6.4666 14.179 5.832 12 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
Table 5.12:  Bilirubin values of the patients after treatment with Livercare 
Churna.  
Sr. no 
of 
patients 
Age  Bilirubin value mg % after different week treatment 
Initial(zer
o week) First Second Third Fourth Sixth 
1 17 4.1 2.2 1 - - - 
2 47 3.9 2.9 1.8 1 - - 
3 49 5.7 2.1 1.2 - - - 
4 51 6.9 4.6 3.1 2.3 1.7 0.8 
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5 31 4.9 2.6 1 - - - 
6 53 8 4.4 2.1 0.9 - - 
7 47 8.9 5.4 3.1 1 - - 
8 40 7.9 6.3 5.3 3.1 2.7 0.9 
9 47 9.7 4.3 3.1 2 1 - 
10 50 6.8 4.2 3.4 2.1 1 - 
11 44 3.2 1.7 0.9 - - - 
12 46 9.9 7.8 5.4 4.3 2.1 0.9 
13 35 5.5 3.3 2 0.9 - - 
14 55 3.7 2.1 0.9 - - - 
15 50 11.5 8.9 6.5 3.1 1 - 
16 60 7.7 4.3 3.2 2.1 1.3 0.9 
17 43 3.9 1.1 - - - - 
18 45 4.5 2.9 0.9 - - - 
19 40 7.6 6.2 4.9 2.4 1.4 1 
20 29 2.4 1.7 0.9 - - - 
21 44 9.5 6.3 4.3 2.1 1 - 
22 25 4.1 3.2 2.5 1.8 0.9 - 
23 17 6.7 4.3 3.2 1.8 1.1 - 
24 40 2.9 1.2 - - - - 
25 35 8 6.1 4.3 3.1 1 - 
26 25 5.3 5.2 4.6 2.8 1.2 - 
27 21 6.5 4.3 3.2 1.8 1 - 
28 52 4 1.8 1 - - - 
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29 45 4.8 3.2 2 1.3 0.9 - 
30 62 30 21.2 12.6 7.3 4.9 1.2 
31 50 2 1.4 1 - - - 
32 45 5.7 4.5 2.2 1 - - 
33 50 7.3 4.3 3.2 1.8 1 - 
34 30 6 4.9 4 2.1 1.1 - 
35 19 6.2 4.8 3.2 2.2 0.9 - 
36 45 4 2.3 1 - - - 
37 25 3.2 1.9 1.4 0.9 - - 
38 25 4 2.4 1.6 1 - - 
39 27 6.6 5.1 3.8 2.1 1.1 - 
40 17 2.4 2 1.5 1 - - 
41 57 5.3 2.9 1.6 1 - - 
42 45 4.7 2.1 1.1 - - - 
43 60 5.1 2.6 1.2 - - - 
44 49 5.5 2.6 1.1 - - - 
45 36 4.7 1.9 0.9 - - - 
46 49 6.9 6.2 4.4 3.2 2.1 0.9 
47 50 4.3 3.2 2.1 1 - - 
48 40 7.4 5.9 3.6 2.2 1.7 0.9 
49 40 6.7 5.8 3.2 1.8 0.9 - 
50 39 3.9 1.2 - - - - 
51 41 13.2 11.2 8.9 6.4 2.8 1 
52 45 5.6 2.8 0.9 - - - 
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53 29 5.3 2.4 1.8 0.9 - - 
54 52 3.5 1.3 0.9 - - - 
55 50 7.8 4.7 3.8 1.1 - - 
56 49 6.8 5.3 4.3 2.1 1 - 
57 39 3.8 1 - - - - 
58 11 7 3.2 1.1 - - - 
59 19 5.5 2.2 1.1 - - - 
60 52 4.5 3.9 2.3 1 - - 
61 21 12.2 8.4 5.9 3.4 1 - 
62 29 10.3 8 4.7 2.1 0.9 - 
63 40 6.9 3.1 1.2 - - - 
64 55 1.9 1.1 - - - - 
65 50 14.9 8.4 5.3 2.9 1.1 - 
66 39 4.3 1.8 0.9 - - - 
67 38 4 2.1 1 - - - 
68 19 3.2 2.3 1.2 0.9 - - 
69 35 6.2 5.4 3.8 2.4 1.1 - 
70 45 5.5 3.2 1.2 - - - 
71 31 5.6 3.1 2.4 1.1 - - 
72 49 2.6 0.9 - - - - 
73 45 2.4 1 - - - - 
74 53 3.4 1.8 0.9 - - - 
75 48 1.9 0.9 - - - - 
76 20 2.1 1 - - - - 
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77 17 3.6 1.9 1 - - - 
78 27 16 10.3 7.6 5 3.1 0.9 
79 31 3.9 1.8 0.9 - - - 
80 50 1.3 1 - - - - 
81 35 12 9.7 6.4 3 1 - 
82 39 3.9 1 - - - - 
83 29 3.4 1 - - - - 
84 41 2.1 1 - - - - 
85 22 2.9 1 - - - - 
86 31 6.7 4.1 2.3 1 - - 
87 47 3.4 1 - - - - 
88 28 5.1 2.3 1 - - - 
89 12 4.4 1 - - - - 
90 41 1.4 1 - - - - 
91 36 3.2 1 - - - - 
92 44 5.2 3.1 0.9 - - - 
93 39 4.9 2.8 1.1 - - - 
Average  5.8516 3.6483 2.7373 2.1659 1.4516 0.94 
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Table 5.13.a : P value of bilirubin after Livercare Churna treatment 
Group 
(week)  
Mean  Standard 
Deviation  
Standard 
Error of 
Mean  
Median 
Initial 5.851 3.758 0.3614 4.85 
First 3.648 2.996 0.2938 2.9 
Second 2.737 2.105 0.2297 2.0 
Third 2.165 1.347 0.1869 2.05 
Fourth 1.451 0.8450 0.1449 1.075 
Sixth 0.940 0.1020 0.03075 0.9 
 
Table 5.13.b: Paired samples test of bilirubin after treatment with 
Livercare Churna 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
Pair 
Paired Differences 
t test df 
P Value 
Significant. 
(2 tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
2.1561 1.3007 .1314 1.8953 2.4169 16.409 97 0.000* 
3.7794 2.1930 .2483 3.2850 4.2739 15.221 77 0.000* 
5.5416 3.4018 .4910 4.5538 6.5294 11.286 47 0.000* 
7.6322 4.2186 .7576 6.0848 9.1796 10.073 30 0.000* 
10.4100 7.1326 2.2555 5.3076 15.5123 4.615 9 0.001* 
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Table5.14: Bilirubin values of the patients after treatment with 
Hepatogard forte Tablet.  
Sr. no 
of 
patients  
Age Bilirubin value mg % after different week treatment  
Initial(zero 
week) First Second Third Fourth Sixth 
1 32 4.2 2.1 1 - - - 
2 34 6.9 4.2 2.2 1.1 - - 
3 50 13.4 8.9 6.3 4.8 3.1 1 
4 39 6.9 5.4 4.9 4 3.1 1.7 
5 39 22.1 18.3 12.2 9.4 6.3 2.1 
6 60 14 12.1 8.3 6.9 3.4 1.2 
7 32 7.4 4.3 3.1 2.7 1 - 
8 49 11 8.4 5.9 3.7 1.2 - 
9 55 6.2 3.9 1.3 - - - 
10 60 4.3 2.4 0.9 - - - 
11 35 6.9 3.6 1.7 0.9 - - 
12 36 4.9 2.4 1 - - - 
13 58 13.7 8.9 6.2 3.4 2.1 0.9 
14 40 7.4 3.2 1.2 - - - 
15 50 2.9 1.4 0.9 - - - 
16 29 3.7 2.1 1 - - - 
17 38 4 1.9 1 - - - 
18 42 5.1 2.9 1 - - - 
19 59 3.4 2.1 0.9 - - - 
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20 11 4.3 2.1 1 - - - 
21 32 6.4 3.2 2.4 1.3 0.9 - 
22 60 7 4.3 2.1 1.7 0.9 - 
23 35 3.9 1.6 1 - - - 
24 59 7 3.2 2.1 1 - - 
25 49 4.4 2.1 1.7 0.9 - - 
26 21 3.9 2.1 1.4 1 - - 
27 60 2.9 1.4 0.9 - - - 
28 45 6.4 3.9 2.1 1 - - 
29 50 8.2 6.8 4.6 2.8 1.2 - 
30 55 6.3 4.2 2.4 1.1 - - 
31 51 6.4 4.2 1.9 1 - - 
32 23 4.2 2.2 1.2 1 0.9 - 
33 20 5.7 2.6 1.2 - - - 
34 22 3.2 1.2 - - - - 
35 48 5.3 2.9 1.1 - - - 
36 47 4.3 3.2 2.8 1.9 1 - 
37 41 5.9 4 2.2 1 - - 
38 32 7.4 5.4 3.2 2.8 1.1 - 
39 21 4.4 2.2 0.9 - - - 
40 21 4.3 2.3 1.4 0.9 - - 
41 22 1.3 0.9 - - - - 
42 50 3.3 1.1 - - - - 
43 42 1.4 1 - - - - 
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44 30 5.6 3.2 1 - - - 
45 18 10 8.3 5.8 1.2 - - 
46 30 1.3 1 - - - - 
47 40 7.1 4.3 2.3 1 - - 
48 35 2.7 1 - - - - 
49 28 8.3 6.3 3.9 2 1 - 
50 37 12.1 9.1 8.4 6.1 2.3 1 
51 49 3 1.8 0.9 - - - 
52 30 5.9 3 1.2 - - - 
53 29 3.8 1.4 - - - - 
54 41 6.1 4.8 1.9 1 - - 
55 42 5.9 3.2 1.1 - - - 
56 37 1.6 0.9 - - - - 
57 18 11.2 9.3 6.1 4.1 1.2 - 
58 13 3.2 1.1 - - - - 
59 23 19 12.7 9.5 6.1 3.1 1 
60 28 2.9 1.1 - - - - 
61 45 13.25 10.8 9.7 3.2 1.2 - 
62 15 5.7 5 3.8 1.2  - 
63 50 7.4 6.2 4.1 1.8 0.9 - 
64 32 2.1 1 - - - - 
65 43 8.3 6.8 4.9 3.2 1.8 0.9 
66 36 10.1 8 5.8 3.2 1.1 - 
67 38 1.2 0.9 - - - - 
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68 35 3.2 2.2 1.1 - - - 
69 51 3.1 2.1 1.1 - - - 
70 55 6.2 4.8 2.9 1.8 0.9 - 
71 43 3.1 1.4 0.9 - - - 
72 46 4.1 2 1 - - - 
73 59 1.6 1 - - - - 
74 39 7.6 6.4 4.3 2.6 1.1 - 
75 55 6.3 4.2 2.9 1.8 0.9 - 
76 35 3.2 1.8 1 0.9 - - 
77 51 1.9 1 - - - - 
78 45 4.8 3.2 1.7 0.9 - - 
79 40 4.8 2.1 1  - - 
80 17 16 12.2 9.3 6.2 4.1 1.1 
81 50 4.9 4.1 2.1 0.9 - - 
82 50 3.7 1 - - - - 
83 20 3.1 2.7 1 - - - 
84 51 5.1 2.3 1 - - - 
85 55 4.1 2.7 1 - - - 
86 50 6.6 4 1.9 0.9 - - 
87 39 4 2.1 1 - - - 
88 47 6.9 4 2.7 1.3 0.9 - 
89 37 5.7 2.9 1 - - - 
90 40 3.7 1.9 0.8 - - - 
91 51 6.7 3.2 2 0.9 - - 
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92 47 8.4 6.2 5 3.9 2.1 0.9 
93 49 10.7 7.4 4.9 2.1 0.9 - 
94 39 3.2 1.9 1 - - - 
95 35 4.9 2.3 1.7 0.9 - - 
Average  6.0163 3.9042 2.7912 2.4062 1.775 1.18 
 
Table 5.15.a : P value of bilirubin after treatment with Hepatogard forte 
Tablet. 
Group 
(week)  
Mean  Standard 
Deviation  
Standard 
Error of 
Mean  
Median 
Initial 6.016 3.702 0.3630 5.1 
First 3.904 3.076 0.3045 2.9 
Second 2.791 2.457 0.2665 1.7 
Third 2.406 1.897 0.2656 1.7 
Fourth 1.775 1.266 0.2351 1.2 
Sixth 1.180 0.3816 0.1150 1.0 
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Table 5.15.b: Paired samples test of bilirubin after treatment with 
Hepatogard forte Tablet 
pai
r 
Paired Differences 
t test  df 
P value 
Significan
t. (2 
tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
2.1630 1.1126 .1075 1.949 2.3763 20.111 106 0.000* 
3.8960 2.2020 .2347 3.429 4.3625 16.597 87 0.000* 
5.9750 2.5549 .3476 5.277 6.6723 17.185 53 0.000* 
8.3209 3.5607 .6395 7.014 9.6270 13.011 30 0.000* 
12.554 4.5926 1.3847 9.469 15.6399 9.066 10 0.000* 
 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
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Table 5.16:  Comparative average bilirubin values for different week 
treatment using Eclipta prostrata, Livercare Churna and Hepatogard 
forte Tablet. 
Week 
Eclipta 
prostrata 
Livercare 
Churna 
Hepatogard forte 
Tablet 
Initial 6.338776 5.851613 6.016316 
First 4.407143 3.648387 3.904211 
Second 3.009302 2.737333 2.79125 
Third 2.174194 2.165957 2.40625 
Fourth 1.678788 1.451613 1.775 
Sixth 1.107692 0.94 1.18 
 
 
Figure 5.3: Bilirubin v/s Week. Column graph showing comparative 
values of bilirubin for different week treatment using Eclipta prostrata, 
Livercare Churna and Hepatogard forte Tablet as hepatoprotective 
drugs. 
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For Eclipta prostrata the mean bilirubin value of the group on zero day 
is considered as 100%. In comparison with zero week, bilirubin level are 
recovered on first week 30.15%, on second week 52.38%, on third week 
65.55%, on fourth week 73.49% and sixth weeks 82.53% respectively. The P 
value is < 0.0001.  
For Livercare Churna the mean bilirubin value of the group on zero day 
is considered as 100%. In comparison with zero week, bilirubin level are 
recovered on first week 37.7%, on second week 53.33%, on third week 
63.07%, on fourth week 75.21% and sixth weeks 83.93% respectively. The P 
value is < 0.0001.  
For Hepatogard forte Tablet the mean bilirubin value of the group on 
zero day is considered as 100%. In comparison with zero week, bilirubin level 
are recovered on first week 35.10%, on second week 55.07%, on third week 
60.06%, on fourth week 70.46% and sixth weeks 80.36% respectively. The P 
value is < 0.0001.  
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Table 5. 17: Percentage recovery of bilirubin with different formulations 
Treatment %Recovery 
Formulation First week 
Second 
week 
Third week 
Fourth 
week 
Sixth week 
Eclipta 
prostrata 
30.15 52.38 65.55 73.49 82.55 
Livercare 
Churna 
37.70 53.33 63.07 75.21 83.93 
Hepatogard 
forte Tablet 
35.10 55.07 66.06 70.46 80.36 
 
Table 5.18: Haemoglobin values of the patients after treatment with 
Eclipta prostrata.  
Sr. no 
of 
patients 
Age  Hb values after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 65 9.3 9.4 9.8 - - - 
2 30 8.1 8.2 8.6 9.0 9.4 - 
3 38 7.2 7.6 8 - - - 
4 38 14.2 14.2 14.3 - - - 
5 35 10.2 10.4 10.8 - - - 
6 40 8.3 8.4 8.4 8.6 8.7 - 
7 60 10.3 10.3 10.3 10.4 10.6 - 
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8 4.5 14.1 14.8 14.1 15.3 - - 
9 50 12.1 12.1 12.2 12.5 - - 
10 50 11.3 11.4 11.6 - - - 
11 25 10.1 10.3 10.5 10.6 - - 
12 45 8.1 8.3 8.8 - - - 
13 30 12.1 12.3 - - - - 
14 24 10.2 11.3 12.2 - - - 
15 40 11.8 11.9 12.1 13.1 - - 
16 16 12.8 12.8 12.8 - - - 
17 50 12.4 13.1 14.6 - - - 
18 41 11.7 12.8 - - - - 
19 35 12 12.7 12.9 13.1 13.3 - 
20 49 12.2 12.3 12.4 12.4 - - 
21 9 13 13 13.6 13.6 - - 
22 32 12.7 12.7 12.8 12.9 - - 
23 9 11.2 10.8 11.1 11.2 11.3 11.3 
24 47 13.2 13.3 13.4 - - - 
25 20 12.1 12.2 12.5 12.5 12.5 12.5 
26 40 11.2 11.2 11.5 11.7 - - 
27 29 9.2 9.4 10.1 10.2 10.4 10.4 
28 42 14.8 14.8 14.8 14.9 - - 
29 60 10.2 10.2 10.4 10.4 10.4 10.5 
30 47 12.2 12.2 12.3 12.4 12.4 - 
31 9 9.7 9.7 9.7 9.9 9.9 - 
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32 40 11.7 11.7 11.9 - - - 
33 17 12.3 12.5 - - - - 
34 27 10.9 11 11 11 - - 
35 50 13.4 13.4 13.4 13.5 - - 
36 53 8.1 8.3 8.6 8.6 - - 
37 25 10.2 10.3 - - - - 
38 19 11.2 11.2 11.3 11.3 11.4 - 
39 18 10.2 10.3 10.3 10.4 10.4 - 
40 38 10.5 10.6 - - - - 
41 37 9.1 9.4 - - - - 
42 52 13.7 13.8 13.8 13.8 13.8 13.8 
43 50 10.2 10.33 10.3 10.3 10.4 - 
44 60 13.6 13.6 13.6 13.6 - - 
45 22 12 12.4 12.4 12.4 - - 
46 9 13.3 13.3 13.4 13.5 13.5 - 
47 10 9 9.1 9.1 9.4 9.4 9.5 
48 40 10.8 10.8 10.9 10.9 - - 
49 19 12.6 12.7 12.7 12.9 - - 
50 38 12.3 12.3 12.4 12.5 12.6 - 
51 50 12.4 12.4 12.4 12.4 12.4 - 
52 39 10.2 10.3 10.3 - - - 
53 45 11.8 11.8 11.9 11.9 - - 
54 47 11.2 11.3 - - - - 
55 50 10.9 10.9 10.9 - - - 
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56 57 11.2 11.2 11.3 11.3 11.4 11.5 
57 32 12.8 12.8 12.9 12.9 13 - 
58 50 12.1 12.2 12.2 12.2 12.3 12.4 
59 53 13.2 13.2 13.3 12.3 12.3 13.4 
60 40 11.1 11.2 11.3 11.3 11.3 11.4 
61 48 7.4 8.1 8.2 8.3 - - 
62 29 11.2 11.4 11.5 11.5 - - 
63 28 9.7 9.9 9.9 10 - - 
64 42 7.2 7.5 7.8 8.1 8.1 - 
65 29 12.1 12.2 12.3 12.3 12.3 - 
66 42 11.2 11.2 11.3 - - - 
67 37 7.4 7.7 8 8.2 - - 
68 21 12.1 12.2 12.2 12.3 - - 
69 37 12.4 12.4 12.5 12.5 12.5 - 
70 22 11.2 11.3 11.5 - - - 
71 22 10.2 10.3 10.4 10.4 - - 
72 40 11.2 11.4 - - - - 
73 24 10.3 10.3 10.5 10.5 10.5 - 
74 10 9.3 9.4 9.7 9.7 9.8 - 
75 48 8.2 8.3 8.4 8.4 8.5 8.7 
76 27 11.2 11.2 11.4 11.5 - - 
77 16 10.2 10.3 10.4 10.5 - - 
78 12 10.3 10.4 10.5 10.6 10.6 10.6 
79 48 11.2 11.3 11.3 - - - 
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80 28 11.2 11.5 - - - - 
81 46 10.3 10.4 - - - - 
82 65 10.3 10.4 10.5 - - - 
83 38 10.8 10.9 10.9 11 - - 
84 12 10.1 10.2 10.3 10.4 10.5 - 
85 8 6.3 6.8 6.9 7.2 7.4 - 
86 56 9.3 9.4 9.5 - - - 
87 42 8.1 8.2 8.3 8.4 8.5 8.7 
88 38 8.3 8.4 8.5 8.5 - - 
89 42 11.2 11.3 11.3 11.4 11.4 - 
90 28 10.2 10.3 10.3 10.4 - - 
91 23 11.1 11.1 11.2 - - - 
92 35 9.1 9.1 9.2 - - - 
93 18 9.1 9.3 9.4 - - - 
94 11 10.2 10.3 10.4 - - - 
95 18 8.3 8.4 8.5 8.6 - - 
96 45 10.2 10.4 - - - - 
97 12 8.1 8.3 8.5 - - - 
98 20 8.3 8.4 - - - - 
Average  10.760 10.861 11.043 11.219 10.976 11.130 
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Table 5.19. a: P value of Hb after treatment with Eclipta prostrata 
Group 
(week) 
Mean  Standard 
Deviation  
Standard Error 
of Mean  
Median 
Initial 10.760 1.755 0.1764 10.900 
First 10.861 1.729 0.1737 11.000 
Second 11.043 1.763 0.1890 11.100 
Third 11.219 1.777 0.2239 11.300 
Fourth 10.976 1.620 0.2739 10.976 
Sixth 11.131 1.561 0.4173 11.215 
 
Table 5.19.b: Paired samples test of Hb after treatment with Eclipta 
prostrata 
Pair  
Paired Differences 
t test Df 
P value 
Significan
t 
 (2 tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
.077 .863 .083 -.089 .2433 .919 105 0.360 
-.053 1.755 .183 -.416 .3102 -.291 91 0.772 
.1384 1.968 .244 -.349 .6261 .567 64 0.573 
.122 2.315 .385 -.661 .9058 .317 35 0.753 
-.392 .284 .078 -.564 -.2205 -4.97 12 0.000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week  
Where * = The P value is < 0.001, considered significant. 
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Table 5.20: Haemoglobin values of the patients after treatment with 
Livercare Churna.  
Sr. no 
of 
patients 
Hb value after different weeks treatment  
Age  
Initial First Second Third Fourth Sixth 
1 17 11.5 11.6 11.7 - - - 
2 47 10.5 10.6 10.7 10.7 - - 
3 49 11.2 11.4 11.5 - - - 
4 51 9.6 9.8 9.9 10 10 10.1 
5 31 11.6 11.7 11.9 - - - 
6 53 12.1 12.3 12.4 12.5 - - 
7 47 9.1 9.4 9.5 9.5 - - 
8 40 12.2 12.4 12.6 12.7 12.8 12.8 
9 47 8.6 8.7 8.8 8.9 9 - 
10 50 11.4 11.6 11.7 11.8 11.9 - 
11 44 11.4 11.6 11.7 - - - 
12 46 10.7 10.9 11 11 11.5 11.6 
13 35 9.6 9.7 9.8 9.8 - - 
14 55 10.9 11 11.1 - - - 
15 50 12.2 12.4 12.5 12.5 12.5 - 
16 60 10.1 10.4 10.7 10.8 10.8 10.8 
17 43 10.3 10.6 - - - - 
18 45 10.2 10.4 10.5 - - - 
19 40 9.4 9.6 9.7 9.7 9.8 9.9 
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20 29 10.7 10.9 11 - - - 
21 44 8.9 9 9.1 9.3 9.4 - 
22 25 12.1 12.3 12.4 12.4 12.5 - 
23 17 10.3 10.4 10.5 10.6 10.6 - 
24 40 10.2 10.7 - - - - 
25 35 11.2 11.4 11.4 11.5 11.6 - 
26 25 11.2 11.3 11.4 11.6 11.6 - 
27 21 10.1 10.4 10.6 10.7 10.9 - 
28 52 10.1 10.4 10.8 - - - 
29 45 8.7 8.8 8.9 9.1 9.2 - 
30 62 8.2 8.6 9 9.2 9.3 9.5 
31 50 9.2 9.4 9.6 - - - 
32 45 11.2 11.3 11.4 11.5 - - 
33 50 10.7 10.8 10.8 10.9 10.9 - 
34 30 9.3 9.5 9.8 10 10.1 - 
35 19 11.2 11.2 11.3 11.4 11.5 - 
36 45 9.3 9.4 9.6 - - - 
37 25 9.3 9.6 9.8 9.9 - - 
38 25 11.4 11.6 11.7 11.8 - - 
39 27 9.3 9.6 9.8 10 10.1 - 
40 17 11.3 11.6 11.7 11.8 - - 
41 57 13 13.2 13.3 13.4 - - 
42 45 13.2 13.3 13.4 - - - 
43 60 12.6 12.8 12.9 - - - 
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44 49 12.1 12.2 12.4 - - - 
45 36 12.7 12.7 12.8 - - - 
46 49 8.7 8.8 9 9.2 9.3 9.5 
47 50 9.3 9.4 9.6 9.9 - - 
48 40 8.2 8.4 8.6 8.7 8.8. 8.9 
49 40 7.9 8.1 8.2 8.3 8.4 - 
50 39 12.4 12.6 - - - - 
51 41 9.4 9.5 9.7 9.8 9.8 9.9 
52 45 12.1 12.3 12.4 - - - 
53 29 8.5 8.6 8.8 8.9 - - 
54 52 11.7 11.9 12 - - - 
55 50 11.3 11.5 11.5 11.6 - - 
56 49 10.2 10.4 10.5 10.6 10.7 - 
57 39 12.2 12.5 - - - - 
58 11 10.2 10.4 10.6 - - - 
59 19 11.2 11.2 11.3 - - - 
60 52 6 6.4 6.7 7.2 - - 
61 21 12.5 12.6 12.8 12.8 12.9 - 
62 29 9.8 9.9 10 10.1 10.2 - 
63 40 13.7 13.8 13.9 - - - 
64 55 12.6 12.7 - - - - 
65 50 13 13.2 13.3 13.3 13.4 - 
66 39 10.1 10.3 10.4 - - - 
67 38 11.4 11.6 11.7 - - - 
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68 19 9.2 9.4 9.5 9.6 - - 
69 35 8.1 8.4 8.5 8.6 8.8 - 
70 45 8.2 8.8 9 - - - 
71 31 10.7 10.9 11 11.1 - - 
72 49 10.3 10.3 - - - - 
73 45 11.6 11.7 - - - - 
74 53 9.7 9.9 10 - - - 
75 48 10.3 10.5 - - - - 
76 20 10.9 11 - - - - 
77 17 11 11.2 11.4 - - - 
78 27 9.2 9.4 9.5 9.5 9.6 9.6 
79 31 11.2 11.4 11.5 - - - 
80 50 10.9 10.9 - - - - 
81 35 9.4 9.6 9.7 9.8 9.8 - 
82 39 10.7 10.9 - - - - 
83 29 10.4 10.9 - - - - 
84 41 11.1 11.6 - - - - 
85 22 10.1 10.7 - - - - 
86 31 8.9 9.2 9.4 9.5 - - 
87 47 11.4 11.6 - - - - 
88 28 9.6 9.9 10 - - - 
89 12 9.4 9.8 - - - - 
90 41 10.3 10.5 - - - - 
91 36 10.8 11.3 - - - - 
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92 44 10.9 11 11.2 - - - 
93 39 10.3 10.5 10.6 - - - 
Average  10.5064 10.7086 10.7386 10.5 10.63 10.26 
 
Table 5.21. a : P value of Hb after treatment with Livercare Churna 
Group 
(week) 
Mean Standard 
Deviation 
Standard 
Error of Mean 
Median 
Initial 10.506 1.395 0.1402 10.4 
First 10.708 1.368 0.1389 10.709 
Second 10.738 1.413 0.1599 10.719 
Third 10.50 1.381 0.1972 10.5 
Fourth 10.63 1.299 0.2296 10.615 
Sixth 10.260 1.107 0.3339 9.9 
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Table 5.21.b : Paired samples test of Hb after treatment with Livercare 
Churna 
Pair  
Paired Differences 
t test Df 
P value 
Significan
t (2 tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
.0234 .856 .0827 -.1407 .1874 .282 106 .778 
-.0761 1.811 .1976 -.4693 .3170 -.385 83 .701 
.1423 2.195 .3045 -.4689 .7536 .467 51 .642 
.0250 2.459 .4348 -.8617 .9117 .057 31 .955 
-.6900 .264 .0836 -.8791 -.500 -8.25 9 .000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week, D=Initial-
Fourth week, E= Initial-Sixth week 
Where * = The P value is < 0.001, considered significant. 
Table 5.22: Haemoglobin values of the patients after treatment with 
Hepatogard forte Tablet.  
Sr. no 
of 
patients  
Age  Hb values after different week treatments 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 12.3 12.4 12.4 - - - 
2 34 13.6 13.7 13.7 13.7 - - 
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3 50 11 11.1 11.2 11.2 11.2 11.3 
4 39 11.2 11.2 11.3 11.4 11.4 11.4 
5 39 10.1 10.1 10.2 10.3 10.3 10.4 
6 60 11.2 11.2 11.3 11.3 11.3 11.4 
7 32 9.3 9.3 9.4 9.4 9.5 - 
8 49 11.8 12 12.1 12.1 12.1 - 
9 55 10.6 10.6 10.7 - - - 
10 60 11.4 11.5 11.5 - - - 
11 35 10.3 10.4 10.4 10.5 - - 
12 36 13.4 13.4 13.5 - - - 
13 58 12.1 12.2 12.2 12.2 12.3 12.3 
14 40 11.2 11.3 11.4 - - - 
15 50 12.1 12.2 12.3 - - - 
16 29 12.7 12.8 12.8 - - - 
17 38 12.7 12.7 12.8 - - - 
18 42 12.8 12.8 12.9 - - - 
19 59 11.9 12 12 - - - 
20 11 12.1 12.2 12.2 - - - 
21 32 10.4 10.5 10.5 10.6 10.6 - 
22 60 11.4 11.5 11.6 11.6 11.6 - 
23 35 12.3 12.4 12.4 - - - 
24 59 9.6 9.7 9.7 9.7 - - 
25 49 11.2 11.3 11.3 11.4 - - 
26 21 11.4 11.4 11.5 11.5 - - 
Chapter 5  RESULT AND DISCUSSION  
154 
 
27 60 9.8 9.9 9.9 - - - 
28 45 12.9 13 13 13 - - 
29 50 11.4 11.5 11.6 11.6 11.7 - 
30 55 10.2 10.3 10.3 10.4 - - 
31 51 11.2 11.4 11.4 11.5 - - 
32 23 10.2 10.4 10.5 10.5 10.6 - 
33 20 13.7 13.7 13.7 - - - 
34 22 8.1 8.2 - - - - 
35 48 5.4 2.8 1.1 - - - 
36 47 10.1 10.3 10.3 10.4 10.5 - 
37 41 11.7 11.8 11.9 12 - - 
38 32 11.3 11.4 11.5 11.5 11.5 - 
39 21 10.7 10.9 11 - - - 
40 21 14.5 14.5 14.5 14.6 - - 
41 22 9.8 10 - - - - 
42 50 11 11.1 - - - - 
43 42 13.1 13.2 - - - - 
44 30 12.4 12.4 12.4 - - - 
45 18 10.8 10.9 10.9 11 - - 
46 30 13.2 13.3 - - - - 
47 40 12.1 12.2 12.2 12.3 - - 
48 35 11.2 11.3 - - - - 
49 28 11.7 11.7 11.8 11.8 11.9 - 
50 37 12.2 12.2 12.3 12.4 12.4 12.5 
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51 49 9.9 10 10.3 - - - 
52 30 10.8 10.9 11 - - - 
53 29 11.2 11.4 - - - - 
54 41 8.9 9 9.1 9.2 - - 
55 42 8.4 8.7 8.9 - - - 
56 37 12.3 12.4 - - - - 
57 18 10.8 10.9 11 11 11.1 - 
58 13 10.3 10.5 - - - - 
59 23 11.6 11.8 11.9 11.9 12 12.1 
60 28 13.2 13.4 - - - - 
61 45 12 12.2 12.5 12.5 12.6 - 
62 15 11.6 11.8 11.9 12  - 
63 50 9.6 9.8 9.9 10 10.1 - 
64 32 9.3 9.4 - - - - 
65 43 8.3 8.5 8.6 8.7 8.8 8.8 
66 36 9.1 9.2 9.4 9.5 9.6 - 
67 38 10.2 10.3 - - - - 
68 35 10.1 10.2 10.3 - - - 
69 51 6.8 6.9 7 - - - 
70 55 11.1 11.2 11.3 11.3 11.4 - 
71 43 12.3 12.5 12.5 - - - 
72 46 12.1 12.3 12.3 - - - 
73 59 13.2 13.4 - - - - 
74 39 8.3 8.4 8.6 8.7 8.8 - 
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75 55 10.9 11 11.1 11.2 11.2 - 
76 35 8.2 8.4 8.5 8.5 - - 
77 51 12.1 12.2 - - - - 
78 45 12.2 12.3 12.4 12.4 - - 
79 40 8.9 8.9 9  - - 
80 17 7.3 7.5 7.6 7.7 7.8 7.8 
81 50 11.7 11.8 11.9 11.9 - - 
82 50 12.7 12.7 - - - - 
83 20 13.6 13.9 14 - - - 
84 51 11.4 11.6 11.7 - - - 
85 55 12.5 12.6 12.7 - - - 
86 50 10.9 11.1 11.1 11.3 - - 
87 39 13.7 13.9 14 - - - 
88 47 11.4 11.6 11.6 11.7 11.7 - 
89 37 12.4 12.5 12.6 - - - 
90 40 13.7 13.9 14 - - - 
91 51 12.6 12.8 12.8 12.9 - - 
92 47 10.7 10.9 11 11.1 11.1 11.1 
93 49 8 8.3 8.3 8.3 8.4 - 
94 39 9 9.3 9.3 - - - 
95 35 9.2 9.3 9.4 9.4 - - 
Average  11.0873 11.1778 11.1637 11.0645 10.8392 10.91 
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Table 5.23.a : P value of Hb after treatment with Hepatogard forte Tablet 
Group 
(week) 
Mean Standard 
Deviation 
Standard Error  
of Mean 
Median 
Initial 11.087 1.682 0.1699 11.2 
First 11.177 1.774 0.1801 11.4 
Second 11.163 1.900 0.2099 11.4 
Third 11.064 1.394 0.1972 11.3 
Fourth 10.839 1.245 0.2311 11.2 
Sixth 10.910 1.447 0.4362 11.3 
Table 5.23. b: Paired samples test of Hb after treatment with Hepatogard 
forte Tablet 
Pai
r  
Paired Differences 
t test df 
P value 
Significa
nt (2 
tailed) Mean 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
A 
B 
C 
D 
E 
-.0972 .2735 .0264 -.1496 -.0447 -3.676 106 .000* 
-.1409 .4891 .0521 -.2445 -.0372 -2.703 87 .008 
-.250 .1023 .0139 -.2779 -.2220 -17.953 53 .000* 
-.3225 .1257 .0225 -.3687 -.2764 -14.286 30 .000* 
-.3545 .1293 .0390 -.4414 -.2676 -9.092 10 .000* 
A=Initial-First week, B=Initial- Second week, C= Initial- Third week , D=Initial 
Fourth week, E= Initial-Sixth week  
Where * = The P value is < 0.001, considered significant. 
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Table 5.24:  Comparative average haemoglobin values for different week 
treatment using Eclipta prostrata, Livercare Churna and Hepatogard 
forte Tablet. 
Week 
Eclipta 
prostrata 
Livercare 
Churna 
Hepatogard forte 
Tablet 
Initial 10.7602 10.50645 11.08737 
First 10.86113 10.7086 11.17789 
Second 11.04302 10.73867 11.16375 
Third 11.21967 10.5 11.06458 
Fourth 10.97647 10.63 10.83929 
Sixth 11.13077 10.26 10.91 
 
 
 
Figure 5.4: Haemoglobin v/s Week. Column graph showing comparative 
values of haemoglobin for different week treatment using Eclipta 
prostrata, Livercare Churna and Hepatogard forte Tablet as 
hepatoprotective drugs. 
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For Eclipta prostrata the mean haemoglobin values of group on zero 
day is 10.76 gm%. In comparison with zero week, haemoglobin level increase 
on first, second and third week, on fourth and sixth week haemoglobin level 
decreases slightly but in comparison with zero week it is increased. The P 
value is insignificant for haemoglobin. 
For Livercare Churna the mean haemoglobin values of group on zero 
day is 10.50 gm%. In comparison with zero week, haemoglobin level increase 
on first, and second, on third and fourth week haemoglobin level decreases 
slightly but in comparison with zero week it is increased. On sixth week 
haemoglobin level decreased compared to zero week.  The P value is 
insignificant for haemoglobin. 
For Hepatogard forte Tablet the mean haemoglobin values of group on 
zero day is 11.087 gm%. In comparison with zero week, haemoglobin level 
increase on first and second week, on third, fourth and sixth week 
haemoglobin level decreases slightly but in comparison with zero week it is 
decreased. The P value is insignificant for haemoglobin. 
Actually there is an increasing heamoglobin values in each patients in each 
group of treatment. However there is decrease in average heamoglobin 
values in third fourth and sixth week of treatment because number of patients 
being treated for longer duration are having severe liver damage and less 
heamoglobin. Number of patients are also less in these long (4 to 6 week) 
treatments, so mean heamoglobin decreases in these later weeks    
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Table 5.25: Blood pressure values of the patients after treatment with 
Eclipta prostrata.  
Sr. no 
of 
patients 
Age Blood pressure after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 65 80-120 80-120 80-120 - - - 
2 30 80-120 80-120 80-120 - 80-120 - 
3 38 80-120 80-120 80-120 - - - 
4 38 80-120 80-120 80-120 - - - 
5 35 90-130 80-120 80-120 - - - 
6 40 80-120 80-120 80-120 80-120 80-120 - 
7 60 100-140 110-150 110-150 100-140 100-140 - 
8 4.5 80-120 80-120 80-120 80-120 - - 
9 50 130-170 120-160 110-150 110-150 - - 
10 50 90-130 80-120 80-120 - - - 
11 25 80-120 80-120 80-120 80-120 - - 
12 45 90-130 80-120 80-120 - - - 
13 30 80-120 80-120 - - - - 
14 24 80-120 80-120 80-120 - - - 
15 40 80-120 80-120 80-120 80-120 - - 
16 16 80-120 80-120 80-120 - - - 
17 50 140-180 100-140 100-140 - - - 
18 41 100-140 90-130 - - - - 
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19 35 80-120 80-120 80-120 80-120 80-120 - 
20 49 80-120 80-120 80-120 80-120 - - 
21 9 80-120 80-120 80-120 80-120 - - 
22 32 80-120 80-120 80-120 80-120 - - 
23 9 80-120 80-120 80-120 80-120 80-120 80-120 
24 47 100-140 90-130 90-130 - - - 
25 20 80-120 80-120 80-120 80-120 80-120 80-120 
26 40 80-120 80-120 80-120 80-120 - - 
27 29 80-120 80-120 80-120 80-120 80-120 80-120 
28 42 100-140 90-130 90-130 90-130 - - 
29 60 80-120 80-120 80-120 80-120 80-120 80-120 
30 47 80-120 80-120 80-120 80-120 80-120 - 
31 9 80-120 80-120 80-120 80-120 80-120 - 
32 40 80-120 80-120 80-120 - - - 
33 17 80-120 80-120 - - - - 
34 27 80-120 80-120 80-120 80-120 - - 
35 50 80-120 80-120 80-120 80-120 - - 
36 53 90-130 90-130 90-130 90-130 - - 
37 25 80-120 80-120 - - - - 
38 19 80-120 80-120 80-120 80-120 80-120 - 
39 18 80-120 80-120 80-120 80-120 80-120 - 
40 38 80-120 80-120 - - - - 
41 37 80-120 80-120 - - - - 
42 52 90-130 90-130 90-1130 90-130 90-130 90-130 
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43 50 90-130 90-130 90-1130 90-130 90-130 - 
44 60 90-130 90-130 90-130 90-120 - - 
45 22 80-120 80-120 80-120 80-120 - - 
46 9 80-120 80-120 80-120 80-120 80-120 - 
47 10 80-120 80-120 80-120 80-120 80-120 80-120 
48 40 90-130 90-130 90-130 90-130 - - 
49 19 80-120 80-120 80-120 80-120 - - 
50 38 80-120 80-120 80-120 80-120 80-120 - 
51 50 80-120 80-120 80-120 80-120 80-120 - 
52 39 80-120 80-120 80-120 - - - 
53 45 80-120 80-120 80-120 80-120 - - 
54 47 80-120 80-120 - - - - 
55 50 90-130 90-130 90-130 - - - 
56 57 100-140 80-120 80-120 80-120 80-120 80-120 
57 32 80-120 80-120 80-120 80-120 80-120 - 
58 50 80-120 80-120 80-120 80-120 80-120 80-120 
59 53 80-120 80-120 80-120 80-120 80-120 80-120 
60 40 80-120 80-120 80-120 80-120 80-120 80-120 
61 48 80-120 80-120 80-120 80-120 - - 
62 29 80-120 80-120 80-120 80-120 - - 
63 28 80-120 80-120 80-120 80-120 - - 
64 42 80-120 80-120 80-120 80-120 80-120 - 
65 29 80-120 80-120 80-120 80-120 80-120 - 
66 42 80-120 80-120 80-120 - - - 
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67 37 80-120 80-120 80-120 80-120 - - 
68 21 80-120 80-120 80-120 80-120 - - 
69 37 80-120 80-120 80-120 80-120 80-120 - 
70 22 80-120 80-120 80-120 - - - 
71 22 80-120 80-120 80-120 80-120 - - 
72 40 80-120 80-120 - - - - 
73 24 80-120 80-120 80-120 80-120 80-120 - 
74 10 80-120 80-120 80-120 80-120 80-120 - 
75 48 80-120 80-120 80-120 80-120 80-120 80-120 
76 27 80-120 80-120 80-120 80-120 - - 
77 16 80-120 80-120 80-120 80-120 - - 
78 12 80-120 80-120 80-120 80-120 80-120 80-120 
79 48 80-120 80-120 80-120 - - - 
80 28 80-120 80-120 - - - - 
81 46 80-120 80-120 - - - - 
82 65 80-120 80-120 80-120 - - - 
83 38 80-120 80-120 80-120 80-120 - - 
84 12 80-120 80-120 80-120 80-120 80-120 - 
85 8 80-120 80-120 80-120 80-120 80-120 - 
86 56 80-120 80-120 80-120 - - - 
87 42 80-120 80-120 80-120 80-120 80-120 80-120 
88 38 80-120 80-120 80-120 80-120 - - 
89 42 100-140 100-140 100-140 100-140 100-140 - 
90 28 80-120 80-120 80-120 80-120 - - 
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91 23 80-120 80-120 80-120 - - - 
92 35 80-120 80-120 80-120 - - - 
93 18 80-120 80-120 80-120 - - - 
94 11 80-120 80-120 80-120 - - - 
95 18 80-120 80-120 80-120 80-120 - - 
96 45 90-140 90-140 - - - - 
97 12 80-120 80-120 80-120 - - - 
98 20 80-120 80-120 - - - - 
 
Table 5.26: Blood pressure values of the patients after treatment with 
Livercare Churna.  
Sr. no 
of 
patients  
Age  Blood pressure after different weeks treatment 
Initial 
(zero 
week) First 
Secon
d Third Fourth Sixth 
1 17 80-120 80-120 80-120 - - - 
2 47 90-130 80-120 80-120 80-120 - - 
3 49 100-140 100-140 90-130 - - - 
4 51 80-120 80-120 80-120 80-120 80-120 80-120 
5 31 80-120 80-120 80-120 - - - 
6 53 80-120 80-120 80-120 80-120 - - 
7 47 90-130 90-130 80-120 80-120 - - 
8 40 80-120 80-120 80-120 80-120 80-120 80-120 
9 47 80-120 80-120 80-120 80-120 80-120 - 
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10 50 80-120 80-120 80-120 80-120 80-120 - 
11 44 80-120 80-120 80-120 - - - 
12 46 80-120 80-120 80-120 80-120 80-120 80-120 
13 35 80-120 80-120 80-120 80-120 - - 
14 55 90-130 80-120 80-120 - - - 
15 50 100-140 90-130 90-130 90-130 80-120 - 
16 60 80-120 80-120 80-120 80-120 80-120 80-120 
17 43 80-120 80-120 - - - - 
18 45 80-120 80-120 80-120 - - - 
19 40 80-120 80-120 80-120 80-120 80-120 80-120 
20 29 80-120 80-120 80-120 - - - 
21 44 80-120 80-120 80-120 80-120 80-120 - 
22 25 80-120 80-120 80-120 80-120 80-120 - 
23 17 80-120 80-120 80-120 80-120 80-120 - 
24 40 80-120 80-120 - - - - 
25 35 80-120 80-120 80-120 80-120 80-120 - 
26 25 80-120 80-120 80-120 80-120 80-120 - 
27 21 80-120 80-120 80-120 80-120 80-120 - 
28 52 80-120 80-120 80-120 - - - 
29 45 80-120 80-120 80-120 80-120 80-120 - 
30 62 80-120 80-120 80-120 80-120 80-120 80-120 
31 50 80-120 80-120 80-120 - - - 
32 45 90-130 90-130 80-120 80-120 - - 
33 50 80-120 80-120 80-120 80-120 80-120 - 
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34 30 80-120 80-120 80-120 80-120 80-120 - 
35 19 80-120 80-120 80-120 80-120 80-120 - 
36 45 80-120 80-120 80-120 - - - 
37 25 80-120 80-120 80-120 80-120 - - 
38 25 80-120 80-120 80-120 80-120 - - 
39 27 80-120 80-120 80-120 80-120 80-120 - 
40 17 80-120 80-120 80-120 80-120 - - 
41 57 80-120 80-120 80-120 80-120 - - 
42 45 80-120 80-120 80-120 - - - 
43 60 80-120 80-120 80-120 - - - 
44 49 80-120 80-120 80-120 - - - 
45 36 80-120 80-120 80-120 - - - 
46 49 90-130 90-130 90-130 90-130 90-130 90-130 
47 50 80-120 80-120 80-120 80-120 - - 
48 40 80-120 80-120 80-120 80-120 80-120 80-120 
49 40 90-130 90-130 90-130 90-130 90-130 - 
50 39 80-120 80-120 - - - - 
51 41 80-120 80-120 80-120 80-120 80-120 80-120 
52 45 80-120 80-120 80-120 - - - 
53 29 80-120 80-120 80-120 80-120 - - 
54 52 80-120 80-120 80-120 - - - 
55 50 80-120 80-120 80-120 80-120 - - 
56 49 100-140 80-120 80-120 80-120 80-120 - 
57 39 80-120 80-120 - - - - 
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58 11 80-120 80-120 80-120 - - - 
59 19 80-120 80-120 80-120 - - - 
60 52 80-120 80-120 80-120 80-120 - - 
61 21 80-120 80-120 80-120 80-120 80-120 - 
62 29 80-120 80-120 80-120 80-120 80-120 - 
63 40 80-120 80-120 80-120 - - - 
64 55 80-120 80-120 - - - - 
65 50 80-120 80-120 80-120 80-120 80-120 - 
66 39 80-120 80-120 80-120 - - - 
67 38 80-120 80-120 80-120 - - - 
68 19 80-120 80-120 80-120 80-120 - - 
69 35 80-120 80-120 80-120 80-120 80-120 - 
70 45 80-120 80-120 80-120 - - - 
71 31 80-120 80-120 80-120 80-120 - - 
72 49 80-120 80-120 - - - - 
73 45 80-120 80-120 - - - - 
74 53 90-130 90-130 80-120 - - - 
75 48 80-120 80-120 - - - - 
76 20 80-120 80-120 - - - - 
77 17 80-120 80-120 80-120 - - - 
78 27 80-120 80-120 80-120 80-120 80-120 80-120 
79 31 80-120 80-120 80-120 - - - 
80 50 90-130 80-120 - - - - 
81 35 80-120 80-120 80-120 80-120 80-120 - 
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82 39 80-120 80-120 - - - - 
83 29 80-120 80-120 - - - - 
84 41 80-120 80-120 - - - - 
85 22 80-120 80-120 - - - - 
86 31 80-120 80-120 80-120 80-120 - - 
87 47 80-120 80-120 - - - - 
88 28 80-120 80-120 80-120 - - - 
89 12 80-120 80-120 - - - - 
90 41 80-120 80-120 - - - - 
91 36 80-120 80-120 - - - - 
92 44 80-120 80-120 80-120 - - - 
93 39 80-120 80-120 80-120 - - - 
 
Table 5.27: Blood pressure values of the patients after treatment with 
Hepatogard forte Tablet  
Sr. no 
 of 
patients 
Age  Blood pressure after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 80-120 80-120 80-120 - - - 
2 34 80-120 80-120 80-120 80-120 - - 
3 50 100-140 100-140 100-140 90-130 90-130 90-130 
4 39 80-120 80-120 80-120 80-120 80-120 80-120 
5 39 80-120 80-120 80-120 80-120 80-120 80-120 
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6 60 80-120 80-120 80-120 80-120 80-120 80-120 
7 32 80-120 80-120 80-120 80-120 80-120 - 
8 49 100-140 100-140 100-140 90-130 90-130 - 
9 55 80-120 80-120 80-120 - - - 
10 60 90-130 90-130 80-120 - - - 
11 35 80-120 80-120 80-120 80-120 - - 
12 36 80-120 80-120 80-120 - - - 
13 58 90-130 90-130 90-130 90-130 90-130 90-130 
14 40 90-130 90-130 80-120 - - - 
15 50 90-130 90-130 80-120 - - - 
16 29 80-120 80-120 80-120 - - - 
17 38 80-120 80-120 80-120 - - - 
18 42 80-120 80-120 80-120 - - - 
19 59 90-130 90-130 90-130 - - - 
20 11 80-120 80-120 80-120 - - - 
21 32 80-120 80-120 80-120 80-120 80-120 - 
22 60 80-120 80-120 80-120 80-120 80-120 - 
23 35 80-120 80-120 80-120 - - - 
24 59 80-120 80-120 80-120 80-120 - - 
25 49 80-120 80-120 80-120 80-120 - - 
26 21 80-120 80-120 80-120 80-120 - - 
27 60 80-120 80-120 80-120 - - - 
28 45 80-120 80-120 80-120 80-120 - - 
29 50 80-120 80-120 80-120 80-120 80-120 - 
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30 55 80-120 80-120 80-120 80-120 - - 
31 51 80-120 80-120 80-120 80-120 - - 
32 23 80-120 80-120 80-120 80-120 80-120 - 
33 20 80-120 80-120 80-120 - - - 
34 22 80-120 80-120 - - - - 
35 48 80-120 80-120 80-120 - - - 
36 47 80-120 80-120 80-120 80-120 80-120 - 
37 41 80-120 80-120 80-120 80-120 - - 
38 32 80-120 80-120 80-120 80-120 80-120 - 
39 21 80-120 80-120 80-120 - - - 
40 21 80-120 80-120 80-120 80-120 - - 
41 22 80-120 80-120 - - - - 
42 50 80-120 80-120 - - - - 
43 42 80-120 80-120 - - - - 
44 30 80-120 80-120 80-120 - - - 
45 18 80-120 80-120 80-120 80-120 - - 
46 30 80-120 80-120 - - - - 
47 40 80-120 80-120 80-120 80-120 - - 
48 35 80-120 80-120 - - - - 
49 28 80-120 80-120 80-120 80-120 80-120 - 
50 37 80-120 80-120 80-120 80-120 80-120 80-120 
51 49 80-120 80-120 80-120 - - - 
52 30 80-120 80-120 80-120 - - - 
53 29 80-120 80-120 - - - - 
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54 41 90-130 90-130 80-120 80-120 - - 
55 42 80-120 80-120 80-120 - - - 
56 37 80-120 80-120 - - - - 
57 18 80-120 80-120 80-120 80-120 80-120 - 
58 13 80-120 80-120 - - - - 
59 23 80-120 80-120 80-120 80-120 80-120 80-120 
60 28 80-120 80-120 - - - - 
61 45 80-120 80-120 80-120 80-120 80-120 - 
62 15 80-120 80-120 80-120 80-120 - - 
63 50 90-130 90-130 80-120 80-120 80-120 - 
64 32 80-120 80-120 - - - - 
65 43 80-120 80-120 80-120 80-120 80-120 80-120 
66 36 80-120 80-120 80-120 80-120 80-120 - 
67 38 80-120 80-120 - - - - 
68 35 80-120 80-120 80-120 - - - 
69 51 80-120 80-120 80-120 - - - 
70 55 80-120 80-120 80-120 80-120 80-120 - 
71 43 80-120 80-120 80-120 - - - 
72 46 80-120 80-120 80-120 - - - 
73 59 80-120 80-120 - - - - 
74 39 80-120 80-120 80-120 80-120 80-120 - 
75 55 80-120 80-120 80-120 80-120 80-120 - 
76 35 80-120 80-120 80-120 80-120 - - 
77 51 80-120 80-120 - - - - 
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78 45 80-120 80-120 80-120 80-120 - - 
79 40 80-120 80-120 80-120 - - - 
80 17 80-120 80-120 80-120 80-120 80-120 80-120 
81 50 100-140 100-140 90-130 90-130 - - 
82 50 100-140 100-140 - - - - 
83 20 80-120 80-120 80-120 - - - 
84 51 80-120 80-120 80-120 - - - 
85 55 100-140 100-140 100-140 - - - 
86 50 80-120 80-120 80-120 80-120 - - 
87 39 80-120 80-120 80-120 - - - 
88 47 100-120 100-120 90-120 90-130 80-120 - 
89 37 80-120 80-120 80-120 - - - 
90 40 80-120 80-120 80-120 - - - 
91 51 100-140 90-120 90-120 90-130 - - 
92 47 80-120 80-120 80-120 80-120 80-120 80-120 
93 49 80-120 80-120 80-120 80-120 80-120 - 
94 39 80-120 80-120 80-120 - - - 
95 35 80-120 80-120 80-120 80-120 - - 
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Table 5.28: Comparative blood pressure values for different week 
treatment using Eclipta prostrata, Livercare Churna and Hepatogard 
forte Tablet.  
Sr 
no 
Drug Total 
num of 
patients 
No of 
patients 
having 
BP 
Normalized Reduced Remain 
unchanged 
1 Eclipta 
prostrata 
98 18 4 6 8 
2 Livercare 
Churna 
93 10 8 2 - 
3 Hepatogard 
forte Tablet 
95 14 6 4 4 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them 18 patients have hypertension. After 
treatment with Eclipta prostrata 4 patients were normalized, 6 patients slightly 
reduced hypertension and 8 patients remained unchanged. 93 patients of 
Livercare Churna group were found infected with jaundice among them 10 
patients have hypertension. After treatment with Livercare Churna 8 patients 
were normalized, 2 patients slightly reduced hypertension. 95 patients of 
Hepatogard forte Tablet group were found infected with jaundice among them 
14 patients have hypertension. After treatment with Hepatogard forte Tablet 6 
patients were normalized, 4 patients slightly reduced hypertension and 4 
patients remained unchanged. 
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Table 5.29: Urine sugar values of the patients after treatment with Eclipta 
prostrata  
Sr. no 
of 
patients  
Age  Urine sugar after different weeks treatment  
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 65 X X Normal - - - 
2 30 Normal Normal Normal Normal Normal - 
3 38 Normal Normal Normal - - - 
4 38 Normal Normal Normal - - - 
5 35 Normal Normal Normal - - - 
6 40 Normal Normal Normal Normal Normal - 
7 60 X X X X X - 
8 4.5 Normal Normal Normal Normal - - 
9 50 Normal Normal Normal Normal - - 
10 50 Normal Normal Normal  - - 
11 25 Normal Normal Normal Normal - - 
12 45 XX X X - - - 
13 30 Normal Normal  - - - 
14 24 Normal Normal Normal - - - 
15 40 Normal Normal Normal Normal - - 
16 16 Normal Normal Normal - - - 
17 50 Normal Normal Normal - - - 
18 41 Normal Normal - - - - 
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19 35 Normal Normal Normal Normal Normal - 
20 49 Normal Normal Normal Normal - - 
21 9 Normal Normal Normal Normal - - 
22 32 Normal Normal Normal Normal - - 
23 9 Normal Normal Normal Normal Normal Normal 
24 47 Normal Normal Normal - - - 
25 20 Normal Normal Normal Normal Normal Normal 
26 40 Normal Normal Normal Normal - - 
27 29 Normal Normal Normal Normal Normal Normal 
28 42 Normal Normal Normal Normal - - 
29 60 Normal Normal Normal Normal Normal Normal 
30 47 Normal Normal Normal Normal Normal - 
31 9 Normal Normal Normal Normal Normal - 
32 40 Normal Normal Normal - - - 
33 17 Normal Normal - - - - 
34 27 Normal Normal Normal Normal - - 
35 50 Normal Normal Normal Normal - - 
36 53 XX X X X - - 
37 25 Normal Normal - - - - 
38 19 Normal Normal Normal Normal Normal - 
39 18 Normal Normal Normal Normal Normal - 
40 38 Normal Normal - - - - 
41 37 Normal Normal - - - - 
42 52 X X X X X X 
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43 50 Normal Normal Normal Normal Normal - 
44 60 Normal Normal Normal Normal - - 
45 22 Normal Normal Normal Normal - - 
46 9 Normal Normal Normal Normal Normal - 
47 10 Normal Normal Normal Normal Normal Normal 
48 40 Normal Normal Normal Normal - - 
49 19 Normal Normal Normal Normal - - 
50 38 Normal Normal Normal Normal Normal - 
51 50 Normal Normal Normal Normal Normal - 
52 39 Normal Normal Normal - - - 
53 45 Normal Normal Normal Normal - - 
54 47 Normal Normal - - - - 
55 50 X X X - - - 
56 57 Normal Normal Normal Normal Normal Normal 
57 32 Normal Normal Normal Normal Normal - 
58 50 Normal Normal Normal Normal Normal Normal 
59 53 Normal Normal Normal Normal Normal Normal 
60 40 Normal Normal Normal Normal Normal Normal 
61 48 X X X X - - 
62 29 Normal Normal Normal Normal - - 
63 28 Normal Normal Normal Normal - - 
64 42 Normal Normal Normal Normal Normal - 
65 29 Normal Normal Normal Normal Normal - 
66 42 Normal Normal Normal - - - 
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67 37 Normal Normal Normal Normal - - 
68 21 Normal Normal Normal Normal - - 
69 37 Normal Normal Normal Normal Normal - 
70 22 Normal Normal Normal - - - 
71 22 Normal Normal Normal Normal - - 
72 40 Normal Normal - - - - 
73 24 Normal Normal Normal Normal Normal - 
74 10 Normal Normal Normal Normal Normal - 
75 48 Normal Normal Normal Normal Normal Normal 
76 27 Normal Normal Normal Normal - - 
77 16 Normal Normal Normal Normal - - 
78 12 Normal Normal Normal Normal Normal Normal 
79 48 Normal Normal Normal - - - 
80 28 Normal Normal - - - - 
81 46 Normal Normal - - - - 
82 65 X X X - - - 
83 38 Normal Normal Normal Normal - - 
84 12 Normal Normal Normal Normal Normal - 
85 8 Normal Normal Normal Normal Normal - 
86 56 Normal Normal Normal - - - 
87 42 Normal Normal Normal Normal Normal Normal 
88 38 Normal Normal Normal Normal - - 
89 42 Normal Normal Normal Normal Normal - 
90 28 Normal Normal Normal Normal - - 
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91 23 Normal Normal Normal - - - 
92 35 Normal Normal Normal - - - 
93 18 Normal Normal Normal - - - 
94 11 Normal Normal Normal - - - 
95 18 Normal Normal Normal Normal - - 
96 45 Normal Normal - - - - 
97 12 Normal Normal Normal - - - 
98 20 Normal Normal - - - - 
 
Table 5.30: Urine sugar values of the patients after treatment with 
Livercare Churna.  
Sr. no 
of 
patients  
Age  Urine sugar after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 17 Normal Normal Normal - - - 
2 47 Normal Normal Normal Normal - - 
3 49 Normal Normal Normal - - - 
4 51 X X X Normal Normal Normal 
5 31 Normal Normal Normal - - - 
6 53 Normal Normal Normal Normal - - 
7 47 Normal Normal Normal Normal - - 
8 40 Normal Normal Normal Normal Normal Normal 
9 47 Normal Normal Normal Normal Normal - 
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10 50 X X X Normal Normal - 
11 44 Normal Normal Normal - - - 
12 46 Normal Normal Normal Normal Normal Normal 
13 35 Normal Normal Normal Normal - - 
14 55 X Normal Normal - - - 
15 50 XX XX X X X - 
16 60 Normal Normal Normal Normal Normal Normal 
17 43 Normal Normal - - - - 
18 45 Normal Normal Normal - - - 
19 40 Normal Normal Normal Normal Normal Normal 
20 29 Normal Normal Normal - - - 
21 44 Normal Normal Normal Normal Normal - 
22 25 Normal Normal Normal Normal Normal - 
23 17 Normal Normal Normal Normal Normal - 
24 40 Normal Normal - - - - 
25 35 Normal Normal Normal Normal Normal - 
26 25 Normal Normal Normal Normal Normal - 
27 21 Normal Normal Normal Normal Normal - 
28 52 X X Normal   - 
29 45 Normal Normal Normal Normal Normal - 
30 62 Normal Normal Normal Normal Normal Normal 
31 50 Normal Normal Normal - - - 
32 45 Normal Normal Normal Normal - - 
33 50 Normal Normal Normal Normal Normal - 
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34 30 Normal Normal Normal Normal Normal - 
35 19 Normal Normal Normal Normal Normal - 
36 45 X X Normal - - - 
37 25 Normal Normal Normal Normal - - 
38 25 Normal Normal Normal Normal - - 
39 27 Normal Normal Normal Normal Normal - 
40 17 Normal Normal Normal Normal - - 
41 57 X X Normal Normal - - 
42 45 Normal Normal Normal - - - 
43 60 Normal Normal Normal - - - 
44 49 X X Normal - - - 
45 36 Normal Normal Normal - - - 
46 49 X X Normal Normal Normal Normal 
47 50 Normal Normal Normal Normal - - 
48 40 Normal Normal Normal Normal Normal Normal 
49 40 X X X Normal Normal - 
50 39 Normal Normal - - - - 
51 41 Normal Normal Normal Normal Normal Normal 
52 45 Normal Normal Normal - - - 
53 29 Normal Normal Normal Normal - - 
54 52 X X Normal - - - 
55 50 Normal Normal Normal Normal - - 
56 49 XX XX X X X - 
57 39 Normal Normal - - - - 
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58 11 Normal Normal Normal - - - 
59 19 Normal Normal Normal - - - 
60 52 Normal Normal Normal Normal - - 
61 21 Normal Normal Normal Normal Normal - 
62 29 Normal Normal Normal Normal Normal - 
63 40 Normal Normal Normal - - - 
64 55 Normal Normal - - - - 
65 50 Normal Normal Normal Normal Normal - 
66 39 Normal Normal Normal - - - 
67 38 Normal Normal Normal - - - 
68 19 Normal Normal Normal Normal - - 
69 35 Normal Normal Normal Normal Normal - 
70 45 Normal Normal Normal - - - 
71 31 Normal Normal Normal Normal - - 
72 49 Normal Normal - - - - 
73 45 Normal Normal - - - - 
74 53 Normal Normal Normal - - - 
75 48 Normal Normal - - - - 
76 20 Normal Normal - - - - 
77 17 Normal Normal Normal - - - 
78 27 Normal Normal Normal Normal Normal Normal 
79 31 Normal Normal Normal - - - 
80 50 Normal Normal - - - - 
81 35 Normal Normal Normal Normal Normal - 
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82 39 Normal Normal - - - - 
83 29 Normal Normal - - - - 
84 41 Normal Normal - - - - 
85 22 Normal Normal - - - - 
86 31 Normal Normal Normal Normal - - 
87 47 Normal Normal - - - - 
88 28 Normal Normal Normal - - - 
89 12 Normal Normal - - - - 
90 41 Normal Normal - - - - 
91 36 Normal Normal - - - - 
92 44 Normal Normal Normal - - - 
93 39 Normal Normal Normal - - - 
 
Table 5.31: Urine sugar values of the patients after treatment with 
Hepatogard forte Tablet  
Sr. no 
of 
patients  
Age  Urine sugar after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 Normal Normal Normal - - - 
2 34 Normal Normal Normal Normal - - 
3 50 X X X X X X 
4 39 Normal Normal Normal Normal Normal Normal 
5 39 Normal Normal Normal Normal Normal Normal 
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6 60 Normal Normal Normal Normal Normal Normal 
7 32 Normal Normal Normal Normal Normal - 
8 49 Normal Normal Normal Normal Normal - 
9 55 XX XX XX - - - 
10 60 X X X - - - 
11 35 Normal Normal Normal Normal - - 
12 36 Normal Normal Normal - - - 
13 58 XX XX XX XX X X 
14 40 Normal Normal Normal - - - 
15 50 Normal Normal Normal - - - 
16 29 Normal Normal Normal - - - 
17 38 Normal Normal Normal - - - 
18 42 Normal Normal Normal - - - 
19 59 XX XX XX - - - 
20 11 Normal Normal Normal - - - 
21 32 Normal Normal Normal Normal Normal - 
22 60 X X X X X - 
23 35 Normal Normal Normal - - - 
24 59 Normal Normal Normal Normal - - 
25 49 Normal Normal Normal Normal - - 
26 21 Normal Normal Normal Normal - - 
27 60 X X X - - - 
28 45 Normal Normal Normal Normal - - 
29 50 Normal Normal Normal Normal Normal - 
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30 55 Normal Normal Normal Normal - - 
31 51 X Normal Normal Normal - - 
32 23 Normal Normal Normal Normal Normal - 
33 20 Normal Normal Normal - - - 
34 22 Normal Normal - - - - 
35 48 Normal Normal Normal - - - 
36 47 Normal Normal Normal Normal Normal - 
37 41 Normal Normal Normal Normal - - 
38 32 Normal Normal Normal Normal Normal - 
39 21 Normal Normal Normal - - - 
40 21 Normal Normal Normal Normal - - 
41 22 Normal Normal - - - - 
42 50 Normal Normal - - - - 
43 42 Normal Normal - - - - 
44 30 Normal Normal Normal - - - 
45 18 Normal Normal Normal Normal - - 
46 30 Normal Normal - - - - 
47 40 Normal Normal Normal Normal - - 
48 35 Normal Normal - - - - 
49 28 Normal Normal Normal Normal Normal  
50 37 Normal Normal Normal Normal Normal Normal 
51 49 Normal Normal Normal - - - 
52 30 Normal Normal Normal - - - 
53 29 Normal Normal - - - - 
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54 41 X X X X - - 
55 42 Normal Normal Normal - - - 
56 37 Normal Normal - - - - 
57 18 Normal Normal Normal Normal Normal - 
58 13 Normal Normal - - - - 
59 23 Normal Normal Normal Normal Normal Normal 
60 28 Normal Normal - - - - 
61 45 X X X X X - 
62 15 Normal Normal Normal Normal - - 
63 50 Xx X X X X - 
64 32 Normal Normal - - - - 
65 43 Normal Normal Normal Normal Normal Normal 
66 36 Normal Normal Normal Normal Normal - 
67 38 Normal Normal - - - - 
68 35 Normal Normal Normal - - - 
69 51 X X Normal - - - 
70 55 Normal Normal Normal Normal Normal - 
71 43 Normal Normal Normal - - - 
72 46 Normal Normal Normal - - - 
73 59 Normal Normal - - - - 
74 39 Normal Normal Normal Normal Normal - 
75 55 X X X X X - 
76 35 Normal Normal Normal Normal - - 
77 51 Normal Normal -  - - 
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78 45 Normal Normal Normal Normal - - 
79 40 Normal Normal Normal - - - 
80 17 Normal Normal Normal Normal Normal Normal 
81 50 XX XX XX X - - 
82 50 XX XX - - - - 
83 20 Normal Normal Normal - - - 
84 51 Normal Normal Normal - - - 
85 55 Normal Normal Normal - - - 
86 50 X X X X - - 
87 39 Normal Normal Normal - - - 
88 47 XX XX XX XX X - 
89 37 Normal Normal Normal - - - 
90 40 Normal Normal Normal - - - 
91 51 XX XX XX XX - - 
92 47 Normal Normal Normal Normal Normal Normal 
93 49 Normal Normal Normal Normal Normal - 
94 39 Normal Normal Normal - - - 
95 35 Normal Normal Normal Normal - - 
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Table 5.32: Comparative urine sugar values of Eclipta prostrata, 
Livercare Churna and Hepatogard forte Tablet as hepatoprotective drug  
Sr. 
no 
Drug Total 
number 
of 
patients 
No of 
patients 
having 
urine sugar 
Normal
ized 
Reduc
ed 
Remain 
unchan
ged 
1 Eclipta 
prostrata 
98 8 1 2 5 
2 Livercare 
Churna 
93 12 10 2 - 
3 Hepatogard 
forte Tablet 
95 18 2 4 12 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them 8 patients have higher urine sugar 
level. After treatment with Eclipta prostrata 1 patients was normalized, 2 
patients reduced the sugar level and 5 patients remained unchanged. 93 
patients of Livercare Churna group were found infected with jaundice among 
them 12 patients have higher urine sugar level. After treatment with Livercare 
Churna 10 patients were normalized, 2 patients reduced urine sugar and no 
patients with unchanged urine sugar. 95 patients of Hepatogard forte Tablet 
group were found infected with jaundice among them 18 patients have higher 
urine sugar level. After treatment with Hepatogard forte Tablet 2 patients were 
normalized, 4 patients reduced the sugar level and 12 patients remained 
unchanged. 
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Table 5.33: Urine Creatinine levels of the patients after treatment with 
Eclipta prostrata.  
Sr. no 
of 
patients 
Age  Urine Creatinine after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 65 Positive Positive Normal - - - 
2 30 Positive Positive Positive - Normal - 
3 38 Positive Positive Normal - - - 
4 38 Positive Positive Normal - - - 
5 35 Positive Positive Normal - - - 
6 40 Positive Positive Positive Positive Normal - 
7 60 Positive Positive Positive Positive Normal - 
8 4.5 Positive Positive Positive Normal - - 
9 50 Positive Positive Positive Normal - - 
10 50 Positive Positive Normal - - - 
11 25 Positive Positive Normal Normal - - 
12 45 Positive Positive Normal - - - 
13 30 Positive Normal - - - - 
14 24 Positive Positive Normal - - - 
15 40 Positive Positive Positive Normal - - 
16 16 Positive Positive Normal - - - 
17 50 Positive Positive Normal - - - 
18 41 Positive Normal - - - - 
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19 35 Positive Positive Positive Positive Normal - 
20 49 Positive Positive Positive Normal - - 
21 9 Positive Positive Positive Normal - - 
22 32 Positive Positive Positive Normal - - 
23 9 Positive Positive Positive Positive Positive Normal 
24 47 Positive Positive Normal - - - 
25 20 Positive Positive Positive Positive Positive Normal 
26 40 Positive Positive Positive Normal - - 
27 29 Positive Positive Positive Positive Positive Normal 
28 42 Positive Positive Positive Normal - - 
29 60 Positive Positive Positive Positive Positive Normal 
30 47 Positive Positive Positive Positive Normal - 
31 9 Positive Positive Positive Positive Normal - 
32 40 Positive Positive Normal - - - 
33 17 Positive Normal - - - - 
34 27 Positive Positive Positive Normal - - 
35 50 Positive Positive Positive Normal - - 
36 53 Positive Positive Positive Normal - - 
37 25 Positive Positive - - - - 
38 19 Positive Positive Positive Positive Normal - 
39 18 Positive Positive Positive Positive Normal - 
40 38 Positive Normal - - - - 
41 37 Positive Normal - - - - 
42 52 Positive Positive Positive Positive Positive Normal 
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43 50 Positive Positive Positive Positive Normal - 
44 60 Positive Positive Positive Normal - - 
45 22 Positive Positive Positive Normal - - 
46 9 Positive Positive Positive Positive Normal - 
47 10 Positive Positive Positive Positive Positive Normal 
48 40 Positive Positive Positive Normal - - 
49 19 Positive Positive Positive Normal - - 
50 38 Positive Positive Positive Positive Normal - 
51 50 Positive Normal Positive Positive Normal - 
52 39 Positive Positive Normal - - - 
53 45 Positive Positive Positive Normal - - 
54 47 Positive Normal - - - - 
55 50 Positive Positive Normal - - - 
56 57 Positive Positive Positive Positive Positive Normal 
57 32 Positive Positive Positive Positive Positive - 
58 50 Positive Positive Positive Positive Positive Normal 
59 53 Positive Positive Positive Positive Positive Normal 
60 40 Positive Positive Positive Positive Positive Normal 
61 48 Positive Positive Positive Positive - - 
62 29 Positive Positive Positive Positive - - 
63 28 Positive Positive Positive Positive - - 
64 42 Positive Positive Positive Positive Normal - 
65 29 Positive Positive Positive Positive Normal - 
66 42 Positive Positive Normal - - - 
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67 37 Positive Positive Positive Normal - - 
68 21 Positive Positive Positive Normal - - 
69 37 Positive Positive Positive Positive Normal - 
70 22 Positive Positive Normal - - - 
71 22 Positive Positive Positive Normal - - 
72 40 Positive Normal - - - - 
73 24 Positive Positive Positive Positive Normal - 
74 10 Positive Positive Positive Positive Normal - 
75 48 Positive Positive Positive Positive Positive Normal 
76 27 Positive Positive Positive Normal - - 
77 16 Positive Positive Positive Normal - - 
78 12 Positive Positive Positive Positive Positive Normal 
79 48 Positive Positive Normal - - - 
80 28 Positive Normal - - - - 
81 46 Positive Normal - - - - 
82 65 Positive Positive Normal - - - 
83 38 Positive Positive Positive Normal - - 
84 12 Positive Positive Positive Positive Normal - 
85 8 Positive Positive Positive Positive Normal - 
86 56 Positive Positive Normal - - - 
87 42 Positive Positive Positive Positive Positive Normal 
88 38 Positive Positive Positive Normal - - 
89 42 Positive Positive Positive Positive Normal - 
90 28 Positive Positive Positive Positive - - 
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91 23 Positive Positive Normal - - - 
92 35 Positive Positive Normal - - - 
93 18 Positive Positive Normal - - - 
94 11 Positive Positive Normal - - - 
95 18 Positive Positive Positive Normal - - 
96 45 Positive Normal - - - - 
97 12 Positive Positive Normal - - - 
98 20 Positive Normal - - - - 
 
Table 5.34: Urine Creatinine levels of the patients after treatment with 
Livercare Churna.  
Sr. no 
of 
patients 
Age  Urine Creatinine after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 17 Positive Positive Normal - - - 
2 47 Positive Positive Positive Normal - - 
3 49 Positive Positive Normal - - - 
4 51 Positive Positive Positive Positive Positive Normal 
5 31 Positive Positive Normal - - - 
6 53 Positive Positive Positive Normal - - 
7 47 Positive Positive Positive Normal - - 
8 40 Positive Positive Positive Positive Positive Normal 
9 47 Positive Positive Positive Positive Positive - 
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10 50 Positive Positive Positive Positive Normal - 
11 44 Positive Positive Positive - - - 
12 46 Positive Positive Positive Positive Positive Normal 
13 35 Positive Positive Positive Normal - - 
14 55 Positive Positive Normal - - - 
15 50 Positive Positive Positive Positive Normal - 
16 60 Positive Positive Positive Positive Positive Normal 
17 43 Positive Normal - - - - 
18 45 Positive Positive Normal - - - 
19 40 Positive Positive Positive Positive Positive Normal 
20 29 Positive Positive Normal - - - 
21 44 Positive Positive Positive Positive Positive - 
22 25 Positive Positive Positive Positive Normal - 
23 17 Positive Positive Positive Positive Normal - 
24 40 Positive Normal - - - - 
25 35 Positive Positive Positive Positive Normal - 
26 25 Positive Positive Positive Positive Normal - 
27 21 Positive Positive Positive Positive Normal - 
28 52 Positive Positive Normal - - - 
29 45 Positive Positive Positive Positive Normal - 
30 62 Positive Positive Positive Positive Positive Normal 
31 50 Positive Positive Normal - - - 
32 45 Positive Positive Positive Positive - - 
33 50 Positive Positive Positive Positive Normal - 
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34 30 Positive Positive Positive Positive Positive - 
35 19 Positive Positive Positive Positive Normal - 
36 45 Positive Positive Positive - - - 
37 25 Positive Positive Positive Normal - - 
38 25 Positive Positive Positive Normal - - 
39 27 Positive Positive Positive Positive Normal - 
40 17 Positive Positive Positive Normal - - 
41 57 Positive Positive Positive Normal - - 
42 45 Positive Positive Normal - - - 
43 60 Positive Positive Normal - - - 
44 49 Positive Positive Normal - - - 
45 36 Positive Positive Normal - - - 
46 49 Positive Positive Positive Positive Positive Normal 
47 50 Positive Positive Positive Normal - - 
48 40 Positive Positive Positive Positive Positive Normal 
49 40 Positive Positive Positive Positive Normal - 
50 39 Positive Normal - - - - 
51 41 Positive Positive Positive Positive Positive Normal 
52 45 Positive Positive Normal - - - 
53 29 Positive Positive Positive Normal - - 
54 52 Positive Positive Normal - - - 
55 50 Positive Positive Positive Normal - - 
56 49 Positive Positive Positive Positive Normal - 
57 39 Positive Normal - - - - 
Chapter 5  RESULT AND DISCUSSION  
195 
 
58 11 Positive Positive Normal - - - 
59 19 Positive Positive Normal - - - 
60 52 Positive Positive Positive Normal - - 
61 21 Positive Positive Positive Positive Normal - 
62 29 Positive Positive Positive Positive Normal - 
63 40 Positive Normal Normal - - - 
64 55 Positive Normal - - - - 
65 50 Positive Positive Positive Positive Normal - 
66 39 Positive Positive Normal - - - 
67 38 Positive Positive Normal - - - 
68 19 Positive Positive Positive Normal - - 
69 35 Positive Positive Positive Positive Normal - 
70 45 Positive Positive Normal - - - 
71 31 Positive Positive Positive Normal - - 
72 49 Positive Normal - - - - 
73 45 Positive Normal - - - - 
74 53 Positive Positive Normal - - - 
75 48 Positive Normal - - - - 
76 20 Positive Normal - - - - 
77 17 Positive Positive Normal - - - 
78 27 Positive Positive Positive Positive Positive Normal 
79 31 Positive Positive Normal - - - 
80 50 Positive Positive - - - - 
81 35 Positive Positive Positive Positive Normal - 
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82 39 Positive Normal - - - - 
83 29 Positive Normal - - - - 
84 41 Positive Normal - - - - 
85 22 Positive Normal - - - - 
86 31 Positive Positive Positive Normal - - 
87 47 Positive Normal - - - - 
88 28 Positive Positive Normal - - - 
89 12 Positive Normal - - - - 
90 41 Positive Normal - - - - 
91 36 Positive Normal - - - - 
92 44 Positive Positive Normal - - - 
93 39 Positive Positive Normal - - - 
 
Table 5.35: Urine Creatinine levels of the patients after treatment with 
Hepatogard forte Tablet.  
Sr. no 
of 
patients  
Age  Urine Creatinine after different weeks treatment   
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 32 Positive Positive Normal - - - 
2 34 Positive Positive Positive Normal - - 
3 50 Positive Positive Positive Positive Positive Normal 
4 39 Positive Positive Positive Positive Positive Positive 
5 39 Positive Positive Positive Positive Positive Positive 
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6 60 Positive Positive Positive Positive Positive Normal 
7 32 Positive Positive Positive Positive Normal - 
8 49 Positive Positive Positive Positive Normal - 
9 55 Positive Positive Normal - - - 
10 60 Positive Positive Normal - - - 
11 35 Positive Positive Positive Normal - - 
12 36 Positive Positive Normal - - - 
13 58 Positive Positive Positive Positive Positive Normal 
14 40 Positive Positive Normal - - - 
15 50 Positive Positive Normal - - - 
16 29 Positive Positive Normal - - - 
17 38 Positive Positive Normal - - - 
18 42 Positive Positive Normal - - - 
19 59 Positive Positive Normal - - - 
20 11 Positive Positive Normal - - - 
21 32 Positive Positive Positive Positive Normal - 
22 60 Positive Positive Positive Positive Normal - 
23 35 Positive Positive Normal - - - 
24 59 Positive Positive Positive Normal - - 
25 49 Positive Positive Positive Normal - - 
26 21 Positive Positive Positive Normal - - 
27 60 Positive Positive Normal - - - 
28 45 Positive Positive Positive Normal - - 
29 50 Positive Positive Positive Positive Normal - 
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30 55 Positive Positive Positive Normal - - 
31 51 Positive Positive Positive Normal - - 
32 23 Positive Positive Positive Positive Normal - 
33 20 Positive Positive Normal - - - 
34 22 Positive Normal - - - - 
35 48 Positive Positive Normal - - - 
36 47 Positive Positive Positive Positive Normal - 
37 41 Positive Positive Positive Normal - - 
38 32 Positive Positive Positive Positive Normal - 
39 21 Positive Positive Normal - - - 
40 21 Positive Positive Positive Normal - - 
41 22 Positive Normal - - - - 
42 50 Positive Normal - - - - 
43 42 Positive Normal - - - - 
44 30 Positive Positive Positive - - - 
45 18 Positive Positive Positive Normal - - 
46 30 Positive Normal - - - - 
47 40 Positive Positive Positive Normal - - 
48 35 Positive Normal - - - - 
49 28 Positive Positive Positive Normal Normal - 
50 37 Positive Positive Positive Positive Positive Normal 
51 49 Positive Positive Normal - - - 
52 30 Positive Positive Normal - - - 
53 29 Positive Normal - - - - 
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54 41 Positive Positive Positive Normal - - 
55 42 Positive Positive Normal - - - 
56 37 Positive Normal - - - - 
57 18 Positive Positive Positive Positive Normal - 
58 13 Positive Normal - - - - 
59 23 Positive Positive Positive Positive Positive Normal 
60 28 Positive Normal - - - - 
61 45 Positive Positive Positive Positive Normal - 
62 15 Positive Positive Positive Normal - - 
63 50 Positive Positive Positive Positive Normal - 
64 32 Positive Normal - - - - 
65 43 Positive Positive Positive Positive Positive Normal 
66 36 Positive Positive Positive Positive Normal - 
67 38 Positive Normal - - - - 
68 35 Positive Positive Normal - - - 
69 51 Positive Positive Normal - - - 
70 55 Positive Positive Positive Positive Normal - 
71 43 Positive Positive Normal - - - 
72 46 Positive Positive Normal - - - 
73 59 Positive Normal - - - - 
74 39 Positive Positive Positive Positive Normal - 
75 55 Positive Positive Positive Positive Normal - 
76 35 Positive Positive Positive Normal - - 
77 51 Positive Normal - - - - 
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78 45 Positive Positive Positive Normal - - 
79 40 Positive Positive Normal - - - 
80 17 Positive Positive Positive Positive Positive Normal 
81 50 Positive Positive Positive Normal - - 
82 50 Positive Normal - - - - 
83 20 Positive Positive Normal - - - 
84 51 Positive Positive Normal - - - 
85 55 Positive Positive Normal - - - 
86 50 Positive Positive Positive Normal - - 
87 39 Positive Positive Normal - - - 
88 47 Positive Positive Positive Positive Normal - 
89 37 Positive Positive Normal - - - 
90 40 Positive Positive Normal - - - 
91 51 Positive Positive Positive Normal - - 
92 47 Positive Positive Positive Positive Positive Normal 
93 49 Positive Positive Positive Positive Normal - 
94 39 Positive Positive Normal - - - 
95 35 Positive Positive Positive Normal - - 
 
Chapter 5  RESULT AND DISCUSSION  
201 
 
Table 5.36: Comparative urine Creatinine levels for different weeks 
treatment with Eclipta prostrata, Livercare Churna and Hepatogard forte 
Tablet  
Sr. 
no 
Drug Total 
number 
of 
patients 
No of 
patients 
having 
Jaundice 
Normalized Reduced Remain 
unchanged 
1 Eclipta 
prostrata 
98 98 98 - - 
2 Livercare 
Churna 
93 93 93 - - 
3 Hepatogard 
forte Tablet 
95 95 93 02 - 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them 98 patients were urine Creatinine 
positive. After treatment with Eclipta prostrata all 98 patients were normalized. 
93 patients of Livercare Churna group were found infected with jaundice 
among them 93 patients were urine Creatinine positive. After treatment with 
Livercare Churna all 93 patients were normalized. 95 patients of Hepatogard 
forte Tablet group were found infected with jaundice among them 95 patients 
were urine Creatinine positive. After treatment with Hepatogard forte Tablet all 
93 patients were normalized and 2 patients decreases the urine Creatinine 
level. 
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Table 5.37: HBsAg values of the patients after treatment with Eclipta 
prostrata  
Sr. no 
of 
patients 
Age  HBsAg after different weeks treatment 
Initial 
(zero 
week) First Second Third Fourth Sixth 
1 65 Negative Negative Negative - - - 
2 30 Negative Negative Negative - Negative - 
3 38 Negative Negative Negative - - - 
4 38 Negative Negative Negative - - - 
5 35 Negative Negative Negative - - - 
6 40 Positive Negative Negative Negative Negative - 
7 60 Positive Negative Negative Negative Negative - 
8 4.5 Positive Negative Negative Negative - - 
9 50 Negative Negative Negative Negative - - 
10 50 Negative Negative Negative - - - 
11 25 Positive Negative Negative Negative - - 
12 45 Negative Negative Negative - - - 
13 30 Negative Negative - - - - 
14 24 Negative Negative Negative - - - 
15 40 Positive Negative Negative Negative - - 
16 16 Negative Negative Negative - - - 
17 50 Positive Negative Negative - - - 
18 41 Negative Negative - - - - 
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19 35 Negative Negative Negative Negative Negative - 
20 49 Negative Negative Negative Negative - - 
21 9 Negative Negative Negative Negative - - 
22 32 Negative Negative Negative Negative - - 
23 9 Negative Negative Negative Negative Negative Negative 
24 47 Negative Negative Negative - - - 
25 20 Negative Negative Negative Negative Negative Negative 
26 40 Positive Negative Negative Negative - - 
27 29 Negative Negative Negative Negative Negative Negative 
28 42 Negative Negative Negative Negative - - 
29 60 Positive Negative Negative Negative Negative Negative 
30 47 Positive Negative Negative Negative Negative - 
31 9 Negative Negative Negative Negative Negative - 
32 40 Negative Negative Negative - - - 
33 17 Negative Negative - - - - 
34 27 Negative Negative Negative Negative - - 
35 50 Positive Negative Negative Negative - - 
36 53 Positive Negative Negative Negative - - 
37 25 Negative Negative - - - - 
38 19 Negative Negative Negative Negative Negative - 
39 18 Negative Negative Negative Negative Negative - 
40 38 Negative Negative - - - - 
41 37 Negative Negative - - - - 
42 52 Negative Negative Negative Negative Negative Negative 
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43 50 Negative Negative Negative Negative Negative - 
44 60 Positive Negative Negative Negative - - 
45 22 Negative Negative Negative Negative - - 
46 9 Negative Negative Negative Negative Negative - 
47 10 Negative Negative Negative Negative Negative Negative 
48 40 Positive Negative Negative Negative - - 
49 19 Negative Negative Negative Negative - - 
50 38 Negative Negative Negative Negative Negative - 
51 50 Positive Negative Negative Negative Negative - 
52 39 Negative Negative Negative - - - 
53 45 Positive Negative Negative Negative - - 
54 47 Negative Negative - - - - 
55 50 Negative Negative Negative - - - 
56 57 Positive Negative Negative Negative Negative Negative 
57 32 Negative Negative Negative Negative Negative - 
58 50 Negative Negative Negative Negative Negative Negative 
59 53 Negative Negative Negative Negative Negative Negative 
60 40 Positive Negative Negative Negative Negative Negative 
61 48 Negative Negative Negative Negative - - 
62 29 Negative Negative Negative Negative - - 
63 28 Negative Negative Negative Negative - - 
64 42 Negative Negative Negative Negative Negative - 
65 29 Negative Negative Negative Negative Negative - 
66 42 Negative Negative Negative - - - 
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67 37 Positive Negative Negative Negative - - 
68 21 Negative Negative Negative Negative - - 
69 37 Negative Negative Negative Negative Negative - 
70 22 Negative Negative Negative - - - 
71 22 Negative Negative Negative Negative - - 
72 40 Negative Negative - - - - 
73 24 Negative Negative Negative Negative Negative - 
74 10 Positive Negative Negative Negative Negative - 
75 48 Positive Negative Negative Negative Negative Negative 
76 27 Negative Negative Negative Negative - - 
77 16 Negative Negative Negative Negative - - 
78 12 Positive Negative Negative Negative Negative Negative 
79 48 Negative Negative Negative - - - 
80 28 Negative Negative - - - - 
81 46 Negative Negative - - - - 
82 65 Negative Negative Negative - - - 
83 38 Negative Negative Negative Negative - - 
84 12 Negative Negative Negative Negative Negative - 
85 8 Positive Negative Negative Negative Negative - 
86 56 Negative Negative Negative - - - 
87 42 Positive Negative Negative Negative Negative Negative 
88 38 Negative Negative Negative Negative - - 
89 42 Negative Negative Negative Negative Negative - 
90 28 Negative Negative Negative Negative - - 
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91 23 Negative Negative Negative - - - 
92 35 Negative Negative Negative - - - 
93 18 Negative Negative Negative - - - 
94 11 Negative Negative Negative - - - 
95 18 Negative Negative Negative Negative - - 
96 45 Negative Negative - - - - 
97 12 Negative Negative Negative - - - 
98 20 Negative Negative - - - - 
 
Table 5.38: HBsAg values of the patients after treatment with Livercare 
Churna  
Sr. no 
of 
patients 
Age 
HBsAg after different weeks  treatment 
Initial 
(zero 
week) 
First Second Third Fourth Sixth 
1 17 Negative Negative - - - - 
2 47 Negative Negative Negative - - - 
3 49 Negative Negative - - - - 
4 51 Positive Negative Negative Negative Negative Negative 
5 31 Negative Negative - - - - 
6 53 Negative Negative Negative - - - 
7 47 Positive Negative Negative - - - 
8 40 Positive Negative Negative Negative Negative Negative 
9 47 Positive Negative Negative Negative - - 
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10 50 Negative Negative Negative Negative - - 
11 44 Negative Negative - - - - 
12 46 Positive Negative Negative Negative Negative Negative 
13 35 Negative Negative Negative - - - 
14 55 Positive Negative - - - - 
15 50 Positive Negative Negative Negative - - 
16 60 Positive Negative Negative Negative Negative Negative 
17 43 Negative - - - - - 
18 45 Positive Negative - - - - 
19 40 Positive Negative Negative Negative Negative Negative 
20 29 Negative Negative - - - - 
21 44 Negative Negative Negative Negative - - 
22 25 Positive Negative Negative Negative - - 
23 17 Negative Negative Negative Negative - - 
24 40 Negative - - - - - 
25 35 Positive Negative Negative Negative - - 
26 25 Positive Negative Negative Negative - - 
27 21 Negative Negative Negative Negative - - 
28 52 Negative Negative - - - - 
29 45 Negative Negative Negative Negative - - 
30 62 Positive Negative Negative Negative Negative Negative 
31 50 Negative Negative - - - - 
32 45 Negative Negative Negative - - - 
33 50 Positive Negative Negative Negative - - 
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34 30 Negative Negative Negative Negative - - 
35 19 Positive Negative Negative Negative - - 
36 45 Negative Negative - - - - 
37 25 Negative Negative Negative - - - 
38 25 Positive Negative Negative - - - 
39 27 Negative Negative Negative Negative - - 
40 17 Negative Negative Negative - - - 
41 57 Negative Negative Negative - - - 
42 45 Negative Negative - - - - 
43 60 Negative Negative - - - - 
44 49 Negative Negative - - - - 
45 36 Negative Negative - - - - 
46 49 Positive Negative Negative Negative Negative Negative 
47 50 Negative Negative Negative - - - 
48 40 Positive Negative Negative Negative Negative Negative 
49 40 Negative Negative Negative Negative - - 
50 39 Negative - - - - - 
51 41 Positive Negative Negative Negative Negative Negative 
52 45 Negative Negative - - - - 
53 29 Negative Negative Negative - - - 
54 52 Negative Negative - - - - 
55 50 Negative Negative Negative - - - 
56 49 Positive Negative Negative Negative - - 
57 39 Negative - - - - - 
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58 11 Negative Negative - - - - 
59 19 Negative Negative - - - - 
60 52 Negative Negative Negative - - - 
61 21 Positive Negative Negative Negative - - 
62 29 Negative Negative Negative Negative - - 
63 40 Negative Negative - - - - 
64 55 Negative - - - - - 
65 50 Positive Negative Negative Negative - - 
66 39 Negative Negative - - - - 
67 38 Negative Negative - - - - 
68 19 Negative Negative Negative - - - 
69 35 Positive Negative Negative Negative - - 
70 45 Negative Negative - - - - 
71 31 Negative Negative Negative - - - 
72 49 Negative - - - - - 
73 45 Negative - - - - - 
74 53 Negative Negative - - - - 
75 48 Negative - - - - - 
76 20 Negative - - - - - 
77 17 Negative Negative - - - - 
78 27 Positive Negative Negative Negative Negative Negative 
79 31 Negative Negative - - - - 
80 50 Positive Negative - - - - 
81 35 Positive Negative Negative Negative - - 
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82 39 Negative - - - - - 
83 29 Negative - - - - - 
84 41 Negative - - - - - 
85 22 Positive - - - - - 
86 31 Positive Negative Negative - - - 
87 47 Negative - - - - - 
88 28 Negative Negative - - - - 
89 12 Negative - - - - - 
90 41 Negative - - - - - 
91 36 Negative - - - - - 
92 44 Negative Negative - - - - 
93 39 Positive Negative - - - - 
 
Table 5.39: HBsAg values of the patients after treatment with 
Hepatogard forte Tablet.  
Sr. no 
of 
patients 
Age 
HBsAg after different weeks treatment 
Initial 
(zero 
week) 
First Second Third Fourth Sixth 
1 32 Negative Negative Negative - - - 
2 34 Negative Negative Negative Negative - - 
3 50 Negative Negative Negative Negative Negative Negative 
4 39 Positive Negative Negative Negative Negative Negative 
5 39 Positive Negative Negative Negative Negative Negative 
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6 60 Positive Negative Negative Negative Negative Negative 
7 32 Negative Negative Negative Negative Negative - 
8 49 Negative Negative Negative Negative Negative - 
9 55 Negative Negative Negative - - - 
10 60 Negative Negative Negative - - - 
11 35 Negative Negative Negative Negative - - 
12 36 Negative Negative Negative - - - 
13 58 Positive Negative Negative Negative Negative Negative 
14 40 Positive Negative Negative - - - 
15 50 Negative Negative Negative - - - 
16 29 Negative Negative Negative - - - 
17 38 Negative Negative Negative - - - 
18 42 Positive Negative Negative - - - 
19 59 Negative Negative Negative - - - 
20 11 Negative Negative Negative - - - 
21 32 Negative Negative Negative Negative Negative - 
22 60 Positive Negative Negative Negative Negative - 
23 35 Negative Negative Negative - - - 
24 59 Negative Negative Negative Negative - - 
25 49 Negative Negative Negative Negative - - 
26 21 Positive Negative Negative Negative - - 
27 60 Negative Negative Negative - - - 
28 45 Negative Negative Negative Negative - - 
29 50 Negative Negative Negative Negative Negative - 
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30 55 Positive Negative Negative Negative - - 
31 51 Negative Negative Negative Negative - - 
32 23 Negative Negative Negative Negative Negative - 
33 20 Negative Negative Negative - - - 
34 22 Negative Negative - - - - 
35 48 Negative Negative Negative - - - 
36 47 Negative Negative Negative Negative Negative - 
37 41 Negative Negative Negative Negative - - 
38 32 Negative Negative Negative Negative Negative - 
39 21 Negative Negative Negative - - - 
40 21 Negative Negative Negative Negative - - 
41 22 Negative Negative - - - - 
42 50 Negative Negative - - - - 
43 42 Negative Negative - - - - 
44 30 Negative Negative Negative - - - 
45 18 Positive Negative Negative Negative - - 
46 30 Negative Negative - - - - 
47 40 Negative Negative Negative Negative - - 
48 35 Negative Negative - - - - 
49 28 Positive Negative Negative Negative Negative - 
50 37 Positive Negative Negative Negative Negative Negative 
51 49 Negative Negative Negative - - - 
52 30 Positive Negative Negative - - - 
53 29 Negative Negative - - - - 
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54 41 Negative Negative Negative Negative - - 
55 42 Negative Negative Negative - - - 
56 37 Negative Negative - - - - 
57 18 Positive Negative Negative Negative Negative - 
58 13 Negative Negative - - - - 
59 23 Positive Negative Negative Negative Negative Negative 
60 28 Negative Negative - - - - 
61 45 Negative Negative Negative Negative Negative - 
62 15 Negative Negative Negative Negative - - 
63 50 Positive Negative Negative Negative Negative - 
64 32 Negative Negative - - - - 
65 43 Negative Negative Negative Negative Negative Negative 
66 36 Positive Negative Negative Negative Negative - 
67 38 Negative Negative - - - - 
68 35 Negative Negative Negative - - - 
69 51 Negative Negative Negative - - - 
70 55 Positive Negative Negative Negative Negative - 
71 43 Negative Negative Negative - - - 
72 46 Negative Negative Negative - - - 
73 59 Negative Negative - - - - 
74 39 Negative Negative Negative Negative Negative - 
75 55 Positive Negative Negative Negative Negative - 
76 35 Negative Negative Negative Negative - - 
77 51 Negative Negative - - - - 
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78 45 Negative Negative Negative Negative - - 
79 40 Negative Negative Negative - - - 
80 17 Positive Negative Negative Negative Negative Negative 
81 50 Positive Negative Negative Negative - - 
82 50 Negative Negative - - - - 
83 20 Negative Negative Negative - - - 
84 51 Negative Negative Negative - - - 
85 55 Negative Negative Negative - - - 
86 50 Negative Negative Negative Negative - - 
87 39 Positive Negative Negative - - - 
88 47 Negative Negative Negative Negative Negative - 
89 37 Positive Negative Negative - - - 
90 40 Negative Negative Negative - - - 
91 51 Negative Negative Negative Negative - - 
92 47 Positive Negative Negative Negative Negative Negative 
93 49 Positive Negative Negative Negative Negative - 
94 39 Positive Negative Negative - - - 
95 35 Positive Negative Negative Negative - - 
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Table 5.40: Comparative HBsAg values for different week treatment with 
Eclipta prostrata, Livercare Churna and Hepatogard forte Tablet  
Sr 
no 
Drug Total 
no of 
patients 
No of 
patients 
having 
Hepatitis 
B 
Normali
zed 
Reduc
ed 
Remain 
unchanged 
1 Eclipta 
prostrata 
98 23 23 - - 
2 Livercare 
Churna 
93 30 30 - - 
3 Hepatogard 
forte Tablet 
95 27 27 - - 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them 23 patients were Hepatitis B 
positive. After treatment with Eclipta prostrata all 23 patients were normalized. 
93 patients of Livercare Churna group were found infected with jaundice 
among them 30 patients were Hepatitis B positive. After treatment with 
Livercare Churna all 30 patients were normalized. 95 patients of Hepatogard 
forte Tablet group were found infected with jaundice among them 27 patients 
were Hepatitis B positive. After treatment with Hepatogard forte Tablet all 27 
patients were normalized. 
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Table 5.41: Comparative asthma values for different weeks treatment 
with Eclipta prostrata, Livercare Churna and Hepatogard forte Tablet.  
Sr. 
no 
 
Drug 
Total no. 
of 
patients 
No of 
patients 
having 
Asthma 
No. of 
patients  
Normaliz
ed from 
asthma 
Reduction 
in severity 
of asthma 
No of 
patients 
remain 
unchang
ed 
1 Eclipta 
prostrata 
98 3 - 3 - 
2 Livercare 
Churna 
93 2 - 2 - 
3 Hepatogard 
forte Tablet 
95 2 - 1 1 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found to be infected with jaundice among them 3 patients had problem of 
asthma. After treatment with Eclipta prostrata, there was reduction in 
asthmatic severity in all the three patients. 93 patients of Livercare Churna 
group were found infected with jaundice among them 2 patients had a 
problem of asthma. After treatment with Livercare Churna, there was 
reduction in asthmatic severity in all the two patients. 95 patients of 
Hepatogard forte Tablet group were found infected with jaundice among them 
2 patients had a problem of asthma. After treatment with Hepatogard forte 
Tablet there was improvement in the condition of asthmatic one patient while 
there was no improvement in another patient in asthma. 
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Table 5.42: Comparative hair growth values for different weeks 
treatment with Eclipta prostrata, Livercare Churna and Hepatogard forte 
Tablet.  
Sr. no Drug Total no. of 
patients 
Increase in 
hair growth 
in number of 
patients 
Remain 
unchanged 
in number of 
patients 
1 Eclipta prostrata 98 66 32 
2 Livercare 
Churna 
93 18 75 
3 Hepatogard 
forte Tablet 
95 13 82 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them patient’s hair growth was observed. 
After treatment with Eclipta prostrata 66 patients have shown about 1-2 cm 
growth of hair. 32 patients remained unchanged. 93 patients of Livercare 
Churna group were found infected with jaundice among them patient’s hair 
growth was observed. After treatment with Livercare Churna 18 patients have 
shown about 1-1.5 cm growth of hair and 75 patients remained unchanged. 
95 patients of Hepatogard forte Tablet group were found infected with 
jaundice among them patient’s hair growth was observed. After treatment with 
Hepatogard forte Tablet 13 patients have shown about 1 cm growth of hair 
and 82 patients remained unchanged. 
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Table 5.43: Comparative kidney stone study for different weeks 
treatment with Eclipta prostrata, Livercare Churna and Hepatogard forte 
Tablet  
Sr 
no 
Drug Total 
no. of 
patients 
No of 
patients 
having 
Kidney 
stone 
Patient 
number/stone size 
/ place 
Stone 
size after 
treatment 
1 Eclipta 
prostrata 
98 2 57/5mm/right kidney 
6/4mm/left kidney 
3mm 
4mm 
2 Livercare 
Churna 
93 1 66/ 6mm / left 
kidney 
4mm 
3 Hepatogard 
forte Tablet 
95 - - 
 
- 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them 2 patients have complain of pain of 
kidney stone. Pain and Sonography report showed presence of stone. After 
the treatment with Eclipta prostrata there was reduction in the stone size from 
5mm to 3mm and in one patient there was no change in the stone size. 93 
patients of Livercare Churna group were found infected with jaundice among 
them 1 patient showed presence of kidney stone in Sonography report. After 
the treatment with Livercare Churna the size of stone was reduced from 6mm 
to 4mm.   
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Table 5.44: Comparative pimples values for different weeks treatment 
with Eclipta prostrata, Livercare Churna and Hepatogard forte Tablet  
Sr 
no 
Drug Total 
no. of 
patients 
No of 
patients 
having 
Pimples 
Normalized Reduced Remain 
unchanged 
1 Eclipta 
prostrata 
98 3 - 1 2 
2 Livercare 
Churna 
93 7 - 5 2 
3 Hepatogard 
forte Tablet 
95 4 - 2 2 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them 3 patients have pimple. After the 
treatment with Eclipta prostrata there was reduction in size in 1 patient and in 
2 patients it remained unchanged. 93 patients of Livercare Churna group were 
found infected with jaundice among them 7 patients have pimples. After 
treatment with Livercare Churna no patients was normalized but there was 
reduction in pimples size in 5 patients and it remained unchanged in 2 
patients. 95 patients of Hepatogard forte Tablet group were found infected 
with jaundice among them 4 patients have pimples. After treatment with 
Hepatogard forte Tablet there was reduction pimple size in 2 patients and no 
change in remaining 2 patients. 
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Table 5.45: Comparative cough values for different weeks treatment 
Eclipta prostrata, Livercare Churna and Hepatogard forte Tablet  
Sr. 
no 
Drug Total 
no of 
patients 
No of 
patients 
having 
Cough 
Normalized Reduced Remain 
unchanged 
1 Eclipta 
prostrata 
98 3 - 2 1 
2 Livercare 
Churna 
93 2 - 1 1 
3 Hepatogard 
forte Tablet 
95 2 - 1 1 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them 3 patients have problem of cough. 
After the treatment with Eclipta prostrata there was relief in cough in 2 
patients and 1 patient remained unchanged. 93 patients of Livercare Churna 
group were found infected with jaundice among them 2 patients have problem 
of cough. After the treatment with Livercare Churna there was relief in cough 
of one patient and 1 patient remained unchanged. 95 patients of Hepatogard 
forte Tablet group were found infected with jaundice among them 2 patients 
have problem of cough. After the treatment with Hepatogard forte Tablet there 
was relief in cough of 1 patient and 1 patient remained unchanged. 
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Table 5.46: Comparative study of arthritis condition for different weeks 
treatment with Eclipta prostrata, Livercare Churna and Hepatogard forte 
Tablet  
Sr. 
no 
Drug Total 
no of 
patients 
No of 
patients 
having 
Arthritis 
Normalized Reduced Remain 
unchanged 
1 Eclipta 
prostrata 
98 3 - - 3 
2 Livercare 
Churna 
93 2 - 1 1 
3 Hepatogard 
forte Tablet 
95 1 - - 1 
 
During clinical study selected 98 patients of Eclipta prostrata group were 
found infected with jaundice among them 3 patients have a problem of 
arthritis. After the treatment with Eclipta prostrata there was no improvement 
in arthritis of above three patients. 93 patients of Livercare Churna group were 
found infected with jaundice among them 2 patients have a problem of 
arthritis. After the treatment with Livercare Churna there was relief in pain of 
arthritis in 1 patient and 1 patient remained unchanged. 95 patients of 
Hepatogard forte Tablet group were found infected with jaundice among them 
1 patient has a problem of arthritis. After the treatment with Hepatogard forte 
Tablet there was no improvement in the pain of above arthritic patient. 
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SUMMARY 
Liver is a versatile organ in the body concerned with regulation 
of internal chemical environment.  Therefore, damage to the liver 
inflicted by hepatotoxic agents is of grave consequence.  There is an 
ever increasing need for an agent which could protect liver damage 
especially of one which facilitates regeneration by the proliferation of 
parenchymal cells after damage and arrests growth of fibrous tissue.  
In the present study of hepatoprotective activity was observed in the 
patients having liver damage. 
 In the present study, fresh herb of Eclipta prostrata was collected, 
authentified  and shade dried.  The dried material was reduced to a 
powder of required particle size. 
 Study of physicochemical parameters of fresh powdered material of 
Eclipta prostrata was carried out which comply with the parameters 
given in Ayurvedic Pharmacopoeia of India and Indian herbal 
Pharmacopoeia.  
 Marketed hepatoprotective formulations (Hepatogaurd forte Tablet and 
Livercare Churna) were collected from the local market. On TLC study 
the alcoholic extract of above two formulations and the collected 
Eclipta prostrata herb showed presence of wedelolactone an active 
constituent of Eclipta prostrata. 
 Evaluation of parameters such as SGPT, Billirubin, Hb, Creatinine, 
HBsAg, urine sugar were carried out in the patients of jaundice after 
forming an Ethical committee and taking the written consent of the 
patients.  
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 Treatment with Eclipta prostrata powder, Livercare Churna and 
Hepatogard forte Tablets orally for the period of 1 to 3weeks, to 4 and 
6weeks was carried out as per severity of the condition and recovery of 
the patients.  
 Evaluation parameters such as SGPT, Billirubin showed significant P 
value <0.001 on treatment with Eclipta prostrata herb powder, 
Livercare Churna and Hepatogard forte Tablets.  
 Drug Eclipta prostrata, and marketed formulation Livercare Churna 
showed better hepatoprotective effects than marketed formulation 
Hepatogaurd forte Tablet. 
 There was also improvement in Hb, reduction in blood pressure, urine 
sugar, removal of HBsAg, reduction in kidney stone size, reduction in 
asthmatic discomfort, reduction in pimples, increase in hair growth. 
 The multiple claims described for a single herb in Ayurveda or 
traditional system of medicines seems to be true. Eclipta prostrata and 
its formulations have hepatoprotective activity and also tonic (increase 
Hb %), Hair tonic (increasing hair length), reduce blood pressure, 
dissolve kidney stone, useful in asthma, cough, etc.    
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   ANNEXURE  
Annexure I 
 
Eclipta Prostrata is utilized as Hepatoprotective drug 
 
1) Patients name: 
2) Address: 
 
3) Contact number: 
4) Patients age: 
5) Patients sex: 
6) Patients weight: 
7) Patients diagnosis: Hepatitis A/ Hepatitis B/ Hepatitis C 
 
8) Drug is given: 
(a) Eclipta Prostrata 
(b) Hepatogard forte 
(c) Liver care 
 
9) Dose of drug: OD/BD/TD 
 
10) Duration of illness:1) One day 2)2-3 days 3)Week 
4) Fort night 5) Month 6) Chronic 
 
11) Patient habituated like: 
 House wife   yes/no 
 Farmer    yes/no 
 Business   yes/no 
 Smoking   yes/no 
 Tobacco consumption  yes/no 
 Alcohol consumption  yes/no 
 Narcotic consumption  yes/no 
 Pregnancy   yes/no 
 Feeding   yes/no 
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12) Laboratory tests 
 
 
 
 
 
13) Patient improvement in other disease 
 
 
 
SR 
no 
SGPT  
Liver 
problem 
HB 
(tonicity) 
Urine 
(Creatinine) 
Billirubin Urine 
Sugar 
(Diabetes) 
HBsAg 
1
st
       
2
nd
       
3
rd
       
4
th
       
6
th
       
SR no Blood 
pressure 
Kidney 
stone 
Hair 
growth/ 
dandruff 
Pimples Arthritis Asthma Cough 
 
1
st
        
2
nd
        
3
rd
        
4
th
        
6
th
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